|
G |
A2m |
alpha-2-macroglobulin |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of A2M mRNA |
CTD |
PMID:34480604 |
|
NCBI chr 4:154,897,770...154,947,787
Ensembl chr 4:154,897,877...154,947,786
|
|
G |
Aars1 |
alanyl-tRNA synthetase 1 |
decreases expression |
ISO |
Ascorbic Acid results in decreased expression of AARS1 mRNA |
CTD |
PMID:19197388 |
|
NCBI chr19:38,999,130...39,021,152
Ensembl chr19:38,999,163...39,021,147
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of ABCA1 mRNA; [Bexarotene co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 protein; [diazepinylbenzoic acid co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in decreased expression of ABCA1 mRNA; [LG 100268 co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 mRNA; [Quercetin co-treated with Ascorbic Acid] results in decreased expression of ABCA1 mRNA; [Rosiglitazone co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 protein; [T0901317 co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 mRNA; [tributyltin co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 mRNA; [tributyltin co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 protein; diazepinylbenzoic acid inhibits the reaction [[LG 100268 co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 mRNA]; diazepinylbenzoic acid inhibits the reaction [[tributyltin co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 mRNA] |
CTD |
PMID:17639512 PMID:25932594 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions |
ISO EXP |
Ascorbic Acid inhibits the reaction [3',4',7-trihydroxyisoflavone results in decreased expression of ABCB1 mRNA] [Ascorbic Acid co-treated with Sesame Oil] inhibits the reaction [abamectin results in increased expression of ABCB1A mRNA]; Ascorbic Acid inhibits the reaction [abamectin results in increased expression of ABCB1A mRNA] |
CTD |
PMID:22914566 PMID:31739238 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ABCC1 mRNA; Ascorbic Acid inhibits the reaction [3',4',7-trihydroxyisoflavone results in decreased expression of ABCC1 mRNA] |
CTD |
PMID:22914566 PMID:34480604 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions |
ISO EXP |
Ascorbic Acid inhibits the reaction [3',4',7-trihydroxyisoflavone results in decreased expression of ABCC2 mRNA]; Ascorbic Acid inhibits the reaction [4-hydroxy-2-nonenal inhibits the reaction [ABCC2 protein results in increased transport of 5(6)-carboxy-2',7'-dichlorofluorescein]]; Ascorbic Acid promotes the reaction [ABCC2 protein results in increased transport of 5(6)-carboxy-2',7'-dichlorofluorescein] Ascorbic Acid inhibits the reaction [Fructose results in decreased expression of ABCC2 mRNA]; Ascorbic Acid inhibits the reaction [Fructose results in decreased expression of ABCC2 protein] |
CTD |
PMID:19326901 PMID:22914566 PMID:31005848 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Acan |
aggrecan |
multiple interactions |
ISO |
[TGFB3 protein co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of ACAN mRNA; IL1B protein inhibits the reaction [[TGFB3 protein co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of ACAN mRNA]; Resveratrol inhibits the reaction [IL1B protein inhibits the reaction [[TGFB3 protein co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of ACAN mRNA]] |
CTD |
PMID:26526931 |
|
NCBI chr 1:132,981,582...133,044,416
Ensembl chr 1:132,981,582...133,043,627
|
|
G |
Ace |
angiotensin I converting enzyme |
multiple interactions |
ISO |
Ascorbic Acid inhibits the reaction [epigallocatechin gallate results in decreased activity of ACE protein] |
CTD |
PMID:28544013 |
|
NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
|
|
G |
Ace2 |
angiotensin converting enzyme 2 |
multiple interactions |
ISO |
[Quercetin co-treated with Ascorbic Acid] results in decreased expression of ACE2 mRNA |
CTD |
PMID:17639512 |
|
NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977
|
|
G |
Ache |
acetylcholinesterase |
decreases activity multiple interactions increases activity |
ISO EXP |
Ascorbic Acid results in decreased activity of ACHE protein [Resveratrol co-treated with Ascorbic Acid co-treated with Thioctic Acid co-treated with Vitamin E] results in increased activity of ACHE protein; Hexachlorocyclohexane inhibits the reaction [[Resveratrol co-treated with Ascorbic Acid co-treated with Thioctic Acid co-treated with Vitamin E] results in increased activity of ACHE protein] Ascorbic Acid results in increased activity of ACHE protein Ascorbic Acid inhibits the reaction [Glucose results in decreased activity of ACHE protein] [Dexamethasone co-treated with Ascorbic Acid] results in increased expression of ACHE mRNA; [Dexamethasone co-treated with Ascorbic Acid] results in increased expression of and results in increased activity of ACHE protein; [Zinc co-treated with Vitamin E co-treated with Ascorbic Acid] inhibits the reaction [sodium arsenite results in increased activity of ACHE protein]; Ascorbic Acid inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased activity of ACHE protein]; Ascorbic Acid inhibits the reaction [Scopolamine results in decreased activity of ACHE protein]; Ascorbic Acid inhibits the reaction [Sodium Benzoate results in increased activity of ACHE protein] |
CTD |
PMID:11814146 PMID:16248992 PMID:16822217 PMID:19703495 PMID:20663516 PMID:23619517 PMID:26163454 PMID:27019979 PMID:35187746 More...
|
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Acsl4 |
acyl-CoA synthetase long-chain family member 4 |
decreases expression |
EXP |
Ascorbic Acid results in decreased expression of ACSL4 mRNA |
CTD |
PMID:15372504 |
|
NCBI chr X:105,942,794...106,006,573
Ensembl chr X:105,942,799...106,006,427
|
|
G |
Acsl5 |
acyl-CoA synthetase long-chain family member 5 |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ACSL5 mRNA |
CTD |
PMID:34480604 |
|
NCBI chr 1:254,289,513...254,336,608
Ensembl chr 1:254,292,521...254,336,607
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
EXP ISO |
[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of ACTA2 protein [Ascorbic Acid co-treated with TGFB1 protein] results in increased expression of ACTA2 mRNA; [Ascorbic Acid co-treated with TGFB1 protein] results in increased expression of ACTA2 protein; [Mercaptoethanol co-treated with Ascorbic Acid] results in increased expression of ACTA2 protein; Ascorbic Acid promotes the reaction [Quartz results in increased expression of ACTA2 mRNA] |
CTD |
PMID:7593635 PMID:17053324 PMID:18607632 PMID:27381660 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Actn2 |
actinin alpha 2 |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ACTN2 mRNA |
CTD |
PMID:34480604 |
|
NCBI chr17:58,143,334...58,210,622
Ensembl chr17:58,142,625...58,210,622
|
|
G |
Adcy6 |
adenylate cyclase 6 |
decreases expression |
ISO |
Ascorbic Acid results in decreased expression of ADCY6 mRNA |
CTD |
PMID:17303424 |
|
NCBI chr 7:129,742,827...129,763,922
Ensembl chr 7:129,742,838...129,763,754
|
|
G |
Adgrl1 |
adhesion G protein-coupled receptor L1 |
decreases expression |
EXP |
Ascorbic Acid results in decreased expression of ADGRL1 mRNA |
CTD |
PMID:15372504 |
|
NCBI chr19:24,202,405...24,244,137
Ensembl chr19:24,204,360...24,244,139
|
|
G |
Afp |
alpha-fetoprotein |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of AFP mRNA |
CTD |
PMID:34480604 |
|
NCBI chr14:17,573,412...17,591,476
Ensembl chr14:17,573,412...17,591,480
|
|
G |
Ago2 |
argonaute RISC catalytic component 2 |
decreases expression |
EXP |
Ascorbic Acid results in decreased expression of AGO2 mRNA |
CTD |
PMID:15372504 |
|
NCBI chr 7:105,018,202...105,105,118
Ensembl chr 7:105,029,120...105,104,974
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
EXP ISO |
Ascorbic Acid inhibits the reaction [AGT protein modified form results in decreased hydroxylation of HIF1A protein]; Ascorbic Acid inhibits the reaction [AGT protein modified form results in increased expression of TIMP1 protein] [Ascorbic Acid co-treated with Copper Sulfate] promotes the reaction [AGT protein modified form results in increased chemical synthesis of [4-hydroxy-2-nonenal binds to AGT protein modified form]]; [Ascorbic Acid co-treated with Copper Sulfate] promotes the reaction [AGT protein modified form results in increased chemical synthesis of [pyruvamide binds to AGT protein modified form]]; Ascorbic Acid promotes the reaction [linoleic acid hydroperoxide results in increased lipidation of AGT protein modified form]; Losartan inhibits the reaction [[AGT protein modified form co-treated with Ascorbic Acid co-treated with Copper Sulfate] results in increased chemical synthesis of [4-hydroxy-2-nonenal binds to AGT protein modified form]]; Losartan inhibits the reaction [[AGT protein modified form co-treated with Ascorbic Acid co-treated with Copper Sulfate] results in increased chemical synthesis of [pyruvamide binds to AGT protein modified form]] |
CTD |
PMID:20881940 PMID:26111765 PMID:31144504 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Ak4 |
adenylate kinase 4 |
decreases expression |
ISO |
Ascorbic Acid results in decreased expression of AK4 mRNA |
CTD |
PMID:15305145 |
|
NCBI chr 5:116,039,222...116,099,064
Ensembl chr 5:116,039,616...116,098,618
|
|
G |
Akr1a1 |
aldo-keto reductase family 1 member A1 |
decreases abundance multiple interactions |
ISO |
AKR1A1 gene mutant form results in decreased abundance of Ascorbic Acid [AKR1A1 gene mutant form results in increased susceptibility to Diethylnitrosamine] which results in decreased abundance of Ascorbic Acid; AKR1A1 gene mutant form promotes the reaction [Diethylnitrosamine results in decreased abundance of Ascorbic Acid] |
CTD |
PMID:32805337 |
|
NCBI chr 5:130,092,945...130,130,277
Ensembl chr 5:130,092,732...130,113,674
|
|
G |
Akr1b1 |
aldo-keto reductase family 1 member B1 |
increases reduction |
ISO |
Ascorbic Acid results in increased reduction of AKR1B1 protein modified form |
CTD |
PMID:19061876 |
|
NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:62,932,031...62,946,157
|
|
G |
Akr1b10 |
aldo-keto reductase family 1 member B10 |
increases expression |
ISO |
Ascorbic Acid results in increased expression of AKR1B10 mRNA |
CTD |
PMID:26198647 |
|
NCBI chr 4:63,038,459...63,060,336
Ensembl chr 4:63,040,169...63,053,852
|
|
G |
Akr1c2 |
aldo-keto reductase family 1, member C2 |
increases expression |
ISO |
Ascorbic Acid results in increased expression of AKR1C2 mRNA |
CTD |
PMID:26198647 |
|
NCBI chr17:65,759,778...65,808,013
Ensembl chr17:65,759,788...65,775,764
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
[Ascorbic Acid co-treated with Vitamin E] inhibits the reaction [Diethylhexyl Phthalate results in decreased phosphorylation of AKT1 protein]; Ascorbic Acid inhibits the reaction [Potassium Dichromate results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:21262251 PMID:21911000 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Akt2 |
AKT serine/threonine kinase 2 |
affects expression |
ISO |
Ascorbic Acid affects the expression of AKT2 mRNA |
CTD |
PMID:30597948 |
|
NCBI chr 1:82,877,228...82,933,828
Ensembl chr 1:82,883,547...82,933,817
|
|
G |
Alas1 |
5'-aminolevulinate synthase 1 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid] inhibits the reaction [Griseofulvin results in increased activity of ALAS1 protein]; Ascorbic Acid inhibits the reaction [Griseofulvin results in increased activity of ALAS1 protein] |
CTD |
PMID:24523661 |
|
NCBI chr 8:106,876,514...106,889,917
Ensembl chr 8:106,876,514...106,889,917
|
|
G |
Alb |
albumin |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ALB mRNA |
CTD |
PMID:34480604 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2 family member |
multiple interactions |
ISO |
ALDH2 protein affects the reaction [Ascorbic Acid deficiency results in decreased susceptibility to Nitroglycerin] |
CTD |
PMID:23194305 |
|
NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521
|
|
G |
Aldoa |
aldolase, fructose-bisphosphate A |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ALDOA mRNA |
CTD |
PMID:34480604 |
|
NCBI chr 1:181,402,275...181,407,476
Ensembl chr 1:181,402,275...181,406,182
|
|
G |
Alpi |
alkaline phosphatase, intestinal |
multiple interactions |
ISO |
[Quercetin co-treated with Ascorbic Acid] results in decreased expression of ALPI mRNA |
CTD |
PMID:17639512 |
|
NCBI chr 9:87,773,411...87,776,877
Ensembl chr 9:87,773,411...87,776,877
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
multiple interactions increases expression |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of ALPL mRNA; EZH2 protein inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of ALPL mRNA] Ascorbic Acid results in increased expression of ALPL mRNA [Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of ALPL mRNA; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of ALPL mRNA] |
CTD |
PMID:26424790 PMID:26492236 PMID:28105418 |
|
NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
|
|
G |
Amhr2 |
anti-Mullerian hormone receptor type 2 |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of AMHR2 mRNA |
CTD |
PMID:34480604 |
|
NCBI chr 7:133,579,152...133,588,874
Ensembl chr 7:133,579,393...133,588,258
|
|
G |
Anpep |
alanyl aminopeptidase, membrane |
multiple interactions |
ISO |
[Quercetin co-treated with Ascorbic Acid] results in decreased expression of ANPEP mRNA |
CTD |
PMID:17639512 |
|
NCBI chr 1:133,767,332...133,810,137
Ensembl chr 1:133,767,332...133,785,789
|
|
G |
Anxa1 |
annexin A1 |
multiple interactions increases expression |
ISO EXP |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ANXA1 mRNA; [Quercetin co-treated with Ascorbic Acid] results in increased expression of ANXA1 mRNA Ascorbic Acid results in increased expression of ANXA1 mRNA |
CTD |
PMID:15372504 PMID:17639512 PMID:34480604 |
|
NCBI chr 1:217,861,175...217,877,205
Ensembl chr 1:217,861,175...217,877,343
|
|
G |
Anxa5 |
annexin A5 |
multiple interactions increases expression |
ISO EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of ANXA5 mRNA Ascorbic Acid results in increased expression of ANXA5 protein Ascorbic Acid results in increased expression of ANXA5 mRNA |
CTD |
PMID:15372504 PMID:17917374 PMID:19224539 |
|
NCBI chr 2:119,314,007...119,344,703
Ensembl chr 2:119,314,007...119,353,369
|
|
G |
Apoa1 |
apolipoprotein A1 |
decreases expression decreases activity multiple interactions |
ISO EXP |
Ascorbic Acid results in decreased expression of APOA1 mRNA; Ascorbic Acid results in decreased expression of APOA1 protein Ascorbic Acid results in decreased activity of APOA1 promoter [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of APOA1 mRNA |
CTD |
PMID:16423621 PMID:34480604 |
|
NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
|
|
G |
Apob |
apolipoprotein B |
multiple interactions |
ISO |
[Quercetin co-treated with Ascorbic Acid] results in decreased expression of APOB mRNA; Ascorbic Acid promotes the reaction [Flavonoids inhibits the reaction [Copper results in increased oxidation of APOB protein]]; Ascorbic Acid promotes the reaction [Quercetin inhibits the reaction [Copper results in increased oxidation of APOB protein]] |
CTD |
PMID:17475462 PMID:17639512 |
|
NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497
|
|
G |
Apoe |
apolipoprotein E |
increases expression |
EXP |
Ascorbic Acid results in increased expression of APOE mRNA |
CTD |
PMID:15372504 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
Apom |
apolipoprotein M |
multiple interactions |
ISO |
[Quercetin co-treated with Ascorbic Acid] results in decreased expression of APOM mRNA |
CTD |
PMID:17639512 |
|
NCBI chr20:3,690,950...3,693,550
Ensembl chr20:3,688,413...3,693,550
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions increases oxidation decreases abundance |
EXP ISO |
Ascorbic Acid inhibits the reaction [APP protein modified form results in increased abundance of Reactive Oxygen Species]; resveratrol inhibits the reaction [APP protein modified form results in decreased abundance of Ascorbic Acid] [[[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of phosphatidylcholine hydroperoxide] which results in increased chemical synthesis of 4-hydroxy-2-nonenal; [[[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of Phosphatidylcholines] which results in increased chemical synthesis of phosphatidylcholine hydroperoxide; [[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of phosphatidylcholine hydroperoxide; [[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of Phosphatidylcholines; [APP protein modified form binds to Copper] which results in increased oxidation of Ascorbic Acid; [APP protein modified form inhibits the reaction [[Copper co-treated with Ascorbic Acid] results in increased oxidation of phosphatidylcholine hydroperoxide]] which results in increased chemical synthesis of 4-hydroxy-2-nonenal; APP protein inhibits the reaction [Copper results in increased oxidation of Ascorbic Acid]; APP protein modified form inhibits the reaction [[Copper co-treated with Ascorbic Acid] results in increased oxidation of phosphatidylcholine hydroperoxide]; Copper promotes the reaction [APP protein modified form results in increased oxidation of Ascorbic Acid]; Deferoxamine inhibits the reaction [[[[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of phosphatidylcholine hydroperoxide] which results in increased chemical synthesis of 4-hydroxy-2-nonenal]; Edetic Acid inhibits the reaction [[[[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of phosphatidylcholine hydroperoxide] which results in increased chemical synthesis of 4-hydroxy-2-nonenal]; Edetic Acid inhibits the reaction [[[[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of Phosphatidylcholines] which results in increased chemical synthesis of phosphatidylcholine hydroperoxide]; Penicillamine inhibits the reaction [[[[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of Phosphatidylcholines] which results in increased chemical synthesis of phosphatidylcholine hydroperoxide]; Trientine inhibits the reaction [[[[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of phosphatidylcholine hydroperoxide] which results in increased chemical synthesis of 4-hydroxy-2-nonenal]; Trientine inhibits the reaction [[[[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of Phosphatidylcholines] which results in increased chemical synthesis of phosphatidylcholine hydroperoxide] |
CTD |
PMID:15030205 PMID:17964426 PMID:24276282 PMID:25654502 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Aqp3 |
aquaporin 3 (Gill blood group) |
multiple interactions |
ISO |
[Quercetin co-treated with Ascorbic Acid] results in decreased expression of AQP3 mRNA |
CTD |
PMID:17639512 |
|
NCBI chr 5:56,239,200...56,244,718
Ensembl chr 5:56,239,201...56,244,720
|
|
G |
Arhgdia |
Rho GDP dissociation inhibitor alpha |
increases expression |
ISO |
Ascorbic Acid results in increased expression of ARHGDIA mRNA |
CTD |
PMID:22139585 |
|
NCBI chr10:105,854,526...105,858,020
Ensembl chr10:105,854,533...105,858,023
|
|
G |
Arhgdib |
Rho GDP dissociation inhibitor beta |
multiple interactions increases expression |
ISO |
[Quercetin co-treated with Ascorbic Acid] results in increased expression of ARHGDIB mRNA Ascorbic Acid results in increased expression of ARHGDIB protein |
CTD |
PMID:17639512 PMID:22139585 |
|
NCBI chr 4:169,822,951...169,841,884
Ensembl chr 4:169,822,952...169,841,658
|
|
G |
Arpc5 |
actin related protein 2/3 complex, subunit 5 |
increases expression |
ISO |
Ascorbic Acid results in increased expression of ARPC5 mRNA; Ascorbic Acid results in increased expression of ARPC5 protein |
CTD |
PMID:22139585 |
|
NCBI chr13:64,904,504...64,913,413
Ensembl chr13:64,887,136...64,913,410
|
|
G |
Ascl1 |
achaete-scute family bHLH transcription factor 1 |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ASCL1 mRNA |
CTD |
PMID:34480604 |
|
NCBI chr 7:21,903,136...21,906,003
Ensembl chr 7:21,903,126...21,905,993
|
|
G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
decreases expression |
ISO |
Ascorbic Acid results in decreased expression of ASNS mRNA |
CTD |
PMID:19197388 |
|
NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423
|
|
G |
Atad2 |
ATPase family, AAA domain containing 2 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of ATAD2 mRNA |
CTD |
PMID:26424790 |
|
NCBI chr 7:89,634,123...89,676,738
Ensembl chr 7:89,634,123...89,676,738
|
|
G |
Atad2b |
ATPase family, AAA domain containing 2B |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of ATAD2B mRNA |
CTD |
PMID:26424790 |
|
NCBI chr 6:27,914,546...28,070,103
Ensembl chr 6:27,912,862...28,067,047
|
|
G |
Atf3 |
activating transcription factor 3 |
multiple interactions |
ISO |
[Quercetin co-treated with Ascorbic Acid] results in increased expression of ATF3 mRNA |
CTD |
PMID:17639512 |
|
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Atm |
ATM serine/threonine kinase |
multiple interactions |
ISO |
[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of ATM mRNA Ascorbic Acid inhibits the reaction [potassium chromate(VI) results in increased expression of ATM protein modified form] |
CTD |
PMID:17917374 PMID:25977998 |
|
NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437
|
|
G |
Atp5f1b |
ATP synthase F1 subunit beta |
increases expression |
ISO |
Ascorbic Acid results in increased expression of ATP5F1B protein |
CTD |
PMID:22139585 |
|
NCBI chr 7:515,454...521,858
Ensembl chr 7:515,460...567,273
|
|
G |
Atp6v1a |
ATPase H+ transporting V1 subunit A |
increases expression |
ISO |
Ascorbic Acid results in increased expression of ATP6V1A mRNA |
CTD |
PMID:22139585 |
|
NCBI chr11:56,561,444...56,614,694
Ensembl chr11:56,560,974...56,614,694
|
|
G |
Aurkb |
aurora kinase B |
multiple interactions |
ISO |
[Quercetin co-treated with Ascorbic Acid] results in increased expression of AURKB mRNA |
CTD |
PMID:17639512 |
|
NCBI chr10:53,744,290...53,750,831
Ensembl chr10:53,745,142...53,750,837
|
|
G |
Auts2 |
activator of transcription and developmental regulator AUTS2 |
increases expression |
ISO |
Ascorbic Acid results in increased expression of AUTS2 mRNA |
CTD |
PMID:25555879 |
|
NCBI chr12:24,104,187...25,194,123
Ensembl chr12:24,104,192...25,194,416
|
|
G |
B2m |
beta-2 microglobulin |
increases expression |
EXP |
Ascorbic Acid results in increased expression of B2M mRNA |
CTD |
PMID:15372504 |
|
NCBI chr 3:109,095,740...109,101,764
Ensembl chr 3:109,095,729...109,101,766
|
|
G |
Bach1 |
BTB domain and CNC homolog 1 |
multiple interactions |
ISO |
Ascorbic Acid inhibits the reaction [Hydrogen Peroxide results in decreased expression of BACH1 protein] |
CTD |
PMID:28285367 |
|
NCBI chr11:26,939,429...26,974,876
Ensembl chr11:26,939,480...26,972,447
|
|
G |
Bad |
BCL2-associated agonist of cell death |
multiple interactions |
EXP ISO |
Ascorbic Acid inhibits the reaction [Potassium Dichromate affects the localization of BAD protein]; Ascorbic Acid inhibits the reaction [Potassium Dichromate results in decreased phosphorylation of BAD protein]; Ascorbic Acid inhibits the reaction [Potassium Dichromate results in increased expression of BAD protein] [juglone co-treated with Ascorbic Acid] results in increased expression of BAD protein |
CTD |
PMID:21262251 PMID:29992683 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bak1 |
BCL2-antagonist/killer 1 |
multiple interactions |
ISO |
[arsenic trioxide co-treated with Ascorbic Acid co-treated with Disulfiram] results in decreased expression of BAK1 protein |
CTD |
PMID:24126434 |
|
NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO EXP |
[Arsenic Trioxide co-treated with Ascorbic Acid co-treated with Disulfiram] results in increased expression of BAX protein; [Arsenic Trioxide results in increased susceptibility to Ascorbic Acid] which results in increased expression of BAX protein; [juglone co-treated with Ascorbic Acid] results in increased expression of BAX protein; Ascorbic Acid inhibits the reaction [deoxynivalenol results in increased expression of BAX protein]; Ascorbic Acid inhibits the reaction [Silicon Dioxide results in increased expression of BAX mRNA]; Ascorbic Acid inhibits the reaction [Silicon Dioxide results in increased expression of BAX protein] Ascorbic Acid inhibits the reaction [Humic Substances results in increased expression of BAX protein]; Ascorbic Acid inhibits the reaction [lead acetate results in increased expression of BAX protein]; Ascorbic Acid inhibits the reaction [Potassium Dichromate affects the localization of BAX protein]; Ascorbic Acid inhibits the reaction [Potassium Dichromate results in increased expression of BAX protein]; Ascorbic Acid inhibits the reaction [Streptozocin results in increased expression of BAX protein] Ascorbic Acid inhibits the reaction [glycidamide results in increased expression of BAX mRNA] |
CTD |
PMID:17166419 PMID:17959157 PMID:18683188 PMID:18758938 PMID:21262251 PMID:22245848 PMID:24126434 PMID:29992683 PMID:32632975 PMID:38160894 More...
|
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of BBC3 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of BBC3 protein] |
CTD |
PMID:20530418 |
|
NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509
|
|
G |
Bche |
butyrylcholinesterase |
multiple interactions |
ISO |
[Resveratrol co-treated with Ascorbic Acid co-treated with Thioctic Acid co-treated with Vitamin E] results in increased activity of BCHE protein; Hexachlorocyclohexane inhibits the reaction [[Resveratrol co-treated with Ascorbic Acid co-treated with Thioctic Acid co-treated with Vitamin E] results in increased activity of BCHE protein] |
CTD |
PMID:20663516 |
|
NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression increases abundance multiple interactions |
ISO EXP |
Ascorbic Acid results in decreased expression of BCL2 mRNA BCL2 protein results in increased abundance of Ascorbic Acid [alpha-Tocopherol co-treated with Ascorbic Acid] inhibits the reaction [Arsenic Trioxide results in decreased expression of BCL2 mRNA]; Ascorbic Acid inhibits the reaction [Humic Substances results in decreased expression of BCL2 protein]; Ascorbic Acid inhibits the reaction [Potassium Dichromate results in decreased expression of BCL2 protein]; Ascorbic Acid inhibits the reaction [Streptozocin results in decreased expression of BCL2 protein]; Ascorbic Acid promotes the reaction [lead acetate results in increased expression of BCL2 protein] [arsenic trioxide co-treated with Ascorbic Acid co-treated with Disulfiram] results in decreased expression of BCL2 protein; [Ascorbic Acid co-treated with Quartz] results in increased expression of BCL2 mRNA; Ascorbic Acid inhibits the reaction [deoxynivalenol results in decreased expression of BCL2 protein]; Ascorbic Acid inhibits the reaction [Silicon Dioxide results in decreased expression of BCL2 mRNA]; Ascorbic Acid inhibits the reaction [Silicon Dioxide results in decreased expression of BCL2 protein] Ascorbic Acid inhibits the reaction [glycidamide results in decreased expression of BCL2 mRNA] |
CTD |
PMID:15449323 PMID:17166419 PMID:17959157 PMID:18683188 PMID:18758938 PMID:21262251 PMID:21919647 PMID:22245848 PMID:24126434 PMID:27381660 PMID:29297235 PMID:32632975 More...
|
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions |
EXP |
Ascorbic Acid inhibits the reaction [Potassium Dichromate results in decreased expression of BCL2L1 protein]; Ascorbic Acid inhibits the reaction [Streptozocin results in decreased expression of BCL2L1 protein] |
CTD |
PMID:18758938 PMID:21262251 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Bcl2l14 |
Bcl2-like 14 |
multiple interactions |
ISO |
[Quercetin co-treated with Ascorbic Acid] results in decreased expression of BCL2L14 mRNA |
CTD |
PMID:17639512 |
|
NCBI chr 4:167,217,561...167,258,723
Ensembl chr 4:167,219,871...167,258,086
|
|
G |
Bcl2l2 |
Bcl2-like 2 |
multiple interactions |
ISO |
[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of BCL2L2 mRNA |
CTD |
PMID:17917374 |
|
NCBI chr15:28,346,449...28,361,627
Ensembl chr15:28,356,807...28,361,624
|
|
G |
Bco1 |
beta-carotene oxygenase 1 |
multiple interactions |
EXP |
Ascorbic Acid inhibits the reaction [Oxidants inhibits the reaction [BCO1 protein results in increased oxidation of beta Carotene]] |
CTD |
PMID:9526112 |
|
NCBI chr19:45,149,250...45,186,102
Ensembl chr19:45,149,265...45,186,101
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
increases expression multiple interactions |
ISO |
Ascorbic Acid results in increased expression of BDNF mRNA [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of E2F2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FOXM1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FZD10 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of GLI1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HES3 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HOXB1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of INHBE mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of LEF1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of TERT mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of CNTN1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of DLG4 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GABRA2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GFAP mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIA2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2A mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2B mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of MAP2 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SCN2A mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A6 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A7 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SYN mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SYN protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of TUBB3 protein |
CTD |
PMID:15305145 PMID:33713149 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
multiple interactions affects binding |
ISO EXP |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA; [Ascorbic Acid co-treated with Copper] affects the cleavage of BGLAP3 protein; [Ascorbic Acid co-treated with Dexamethasone] results in increased expression of BGLAP mRNA; [Cholecalciferol co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] results in increased expression of BGLAP protein; Bexarotene inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; Rosiglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; tributyltin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA] [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of BGLAP mRNA; Hydrogen Peroxide affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of BGLAP mRNA]; Quercetin affects the reaction [Hydrogen Peroxide affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of BGLAP mRNA]] 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] co-treated with fasudil] results in increased expression of BGLAP mRNA]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] co-treated with fasudil] results in increased expression of BGLAP protein]; [[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] co-treated with fasudil] results in increased expression of BGLAP mRNA; [[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] co-treated with fasudil] results in increased expression of BGLAP protein; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA; [Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP mRNA; [Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP protein; Allethrins inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; d,d-T80-prallethrin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP mRNA]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP protein]; Pioglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; quinoxyfen inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; Rosiglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; Tretinoin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; triphenyltin hydroxide inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA] BGLAP3 protein binds to Ascorbic Acid |
CTD |
PMID:11396734 PMID:12510807 PMID:17692823 PMID:25932594 PMID:26492236 PMID:27028516 PMID:31935364 PMID:32473317 More...
|
|
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Bid |
BH3 interacting domain death agonist |
multiple interactions |
ISO |
[juglone co-treated with Ascorbic Acid] affects the expression of BID protein |
CTD |
PMID:29992683 |
|
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
multiple interactions |
ISO |
[Quercetin co-treated with Ascorbic Acid] results in increased expression of BIRC3 mRNA |
CTD |
PMID:17639512 |
|
NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
decreases expression |
ISO |
Ascorbic Acid results in decreased expression of BIRC5 mRNA |
CTD |
PMID:21919647 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Bmp1 |
bone morphogenetic protein 1 |
multiple interactions |
EXP |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMP1 mRNA |
CTD |
PMID:15994055 |
|
NCBI chr15:45,551,603...45,595,862
Ensembl chr15:45,551,603...45,595,776
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
multiple interactions |
EXP ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 protein; Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 protein]; ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 protein]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 protein]]] [Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 mRNA; [Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 protein; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 mRNA]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 protein] |
CTD |
PMID:15994055 PMID:26492236 PMID:27387537 |
|
NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397
|
|
G |
Bmp3 |
bone morphogenetic protein 3 |
multiple interactions |
EXP |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMP3 mRNA |
CTD |
PMID:15994055 |
|
NCBI chr14:10,712,489...10,737,153
Ensembl chr14:10,712,489...10,737,153
|
|
G |
Bmp4 |
bone morphogenetic protein 4 |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ABCC1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ACTN2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ALDOA mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ASCL1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of CDC20 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of CYP24A1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of DCX mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ECSCR mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ELAVL3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ELAVL4 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of EMX2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ESRG mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FAH mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FLT1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FOXD3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FOXG1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of GSTP1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of H2BC14 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of HES5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of KEAP1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of LCK mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of MAFG mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of OLIG2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of OTX2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of POU5F1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SFRP2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SH3BP5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SOX1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SOX2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SPTSSB mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SRXN1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of STMN2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of A2M mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ACSL5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of AFP mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ALB mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of AMHR2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ANXA1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of APOA1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of BMP5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CDH10 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CEACAM6 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CIDEC mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of COL3A1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CRYAB mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CYP26B1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CYP3A5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DCC mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DCN mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DHRS9 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DNAJB1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of EBF3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of EGLN3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FABP1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FBXO32 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FGB mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FGF7 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FGG mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FLRT3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GADD45A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GATA6 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GCLM mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GPR183 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GPX2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GRIA2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GRIA3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GSTA1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GSTA2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GSTO1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GUCY1A1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HAND2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HAVCR1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HMGCS2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXA2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXB3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXD4 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXD8 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HSD3B1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of IGFBP7 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of IGHV3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of IL1R1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ISL1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of KRT6A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of LEF1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of LUM mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MLIP mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MMP1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MPZL1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MYL4 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of NQO1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of NR2F1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of NR2F2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of PDE1A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of PLN mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of RBM20 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of RRAD mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SCARB1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SCN2A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SEMA3C mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SERPINA1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SLCO2B1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SQSTM1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TBX2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TF mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TFAP2A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TM4SF4 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TTR mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TXNRD1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of UGT2A3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of VCAM1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of VGLL1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of VTN mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ZFAND2A mRNA |
CTD |
PMID:34480604 |
|
NCBI chr15:19,618,538...19,633,494
Ensembl chr15:19,618,542...19,623,306
|
|
G |
Bmp5 |
bone morphogenetic protein 5 |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of BMP5 mRNA |
CTD |
PMID:34480604 |
|
NCBI chr 8:76,517,164...76,639,925
Ensembl chr 8:76,517,164...76,639,925
|
|
G |
Bmp7 |
bone morphogenetic protein 7 |
multiple interactions |
EXP |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMP7 mRNA |
CTD |
PMID:15994055 |
|
NCBI chr 3:161,639,915...161,716,938
Ensembl chr 3:161,516,462...161,716,788
|
|
G |
Bmpr1a |
bone morphogenetic protein receptor type 1A |
multiple interactions |
EXP |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMPR1A protein; Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMPR1A protein]; ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMPR1A protein]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMPR1A protein]]] |
CTD |
PMID:27387537 |
|
NCBI chr16:9,736,390...9,829,825
Ensembl chr16:9,736,630...9,780,616
|
|
G |
Bmpr1b |
bone morphogenetic protein receptor type 1B |
increases expression |
ISO |
Ascorbic Acid results in increased expression of BMPR1B mRNA |
CTD |
PMID:15305145 |
|
NCBI chr 2:230,538,252...230,871,077
Ensembl chr 2:230,541,558...230,871,368
|
|
G |
Bub1 |
BUB1 mitotic checkpoint serine/threonine kinase |
multiple interactions |
ISO |
[Quercetin co-treated with Ascorbic Acid] results in increased expression of BUB1 mRNA |
CTD |
PMID:17639512 |
|
NCBI chr 3:115,020,254...115,051,650
Ensembl chr 3:115,020,254...115,051,650
|
|
G |
C3 |
complement C3 |
increases expression |
EXP |
Ascorbic Acid results in increased expression of C3 mRNA |
CTD |
PMID:15372504 |
|
NCBI chr 9:2,087,437...2,114,366
Ensembl chr 9:2,087,437...2,114,429
|
|
G |
C5 |
complement C5 |
multiple interactions |
ISO |
Ascorbic Acid inhibits the reaction [Asbestos, Crocidolite results in increased cleavage of C5 protein]; Ascorbic Acid inhibits the reaction [Asbestos, Serpentine results in increased cleavage of C5 protein] |
CTD |
PMID:10777245 |
|
NCBI chr 3:18,270,696...18,361,994
Ensembl chr 3:18,270,696...18,361,994
|
|
G |
C8h11orf54 |
similar to human chromosome 11 open reading frame 54 |
decreases expression multiple interactions |
ISO |
Ascorbic Acid results in decreased expression of C11ORF54 mRNA [arsenic trioxide co-treated with Ascorbic Acid] results in decreased expression of C11ORF54 mRNA |
CTD |
PMID:25555879 |
|
NCBI chr 8:12,123,839...12,146,412
Ensembl chr 8:12,123,823...12,146,473
|
|
G |
Cacna1h |
calcium voltage-gated channel subunit alpha1 H |
decreases activity multiple interactions |
ISO |
Ascorbic Acid results in decreased activity of CACNA1H protein Ascorbic Acid inhibits the reaction [Vincristine results in increased expression of CACNA1H mRNA]; Ascorbic Acid inhibits the reaction [Vincristine results in increased expression of CACNA1H protein] |
CTD |
PMID:34286406 |
|
NCBI chr10:14,390,104...14,448,204
Ensembl chr10:14,390,113...14,448,376
|
|
G |
Calb2 |
calbindin 2 |
multiple interactions |
EXP |
Ascorbic Acid inhibits the reaction [[lead acetate results in increased abundance of Lead] which results in decreased expression of CALB2 protein] |
CTD |
PMID:31708536 |
|
NCBI chr19:38,114,435...38,141,438
Ensembl chr19:38,114,424...38,141,438
|
|
G |
Car2 |
carbonic anhydrase 2 |
increases expression |
ISO |
Ascorbic Acid results in increased expression of CAR2 mRNA |
CTD |
PMID:15730627 |
|
NCBI chr 2:86,741,625...86,756,766
Ensembl chr 2:86,741,626...86,756,818
|
|
G |
Car9 |
carbonic anhydrase 9 |
multiple interactions |
ISO |
Ascorbic Acid inhibits the reaction [nickel sulfate results in increased expression of CA9 protein] |
CTD |
PMID:16288478 |
|
NCBI chr 5:57,763,234...57,769,838
Ensembl chr 5:57,763,206...57,769,838
|
|
G |
Casp2 |
caspase 2 |
multiple interactions |
EXP |
Ascorbic Acid inhibits the reaction [Norepinephrine results in increased activity of CASP2 protein] |
CTD |
PMID:15158148 |
|
NCBI chr 4:71,149,632...71,167,388
Ensembl chr 4:71,149,669...71,167,379
|
|
G |
Casp3 |
caspase 3 |
multiple interactions decreases activity increases expression |
ISO EXP |
[Arsenic Trioxide results in increased susceptibility to Ascorbic Acid] which results in increased cleavage of CASP3 protein; [Ascorbic Acid co-treated with Eosine I Bluish] results in increased activity of CASP3 protein; [Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of CASP3 protein; [Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of CASP3 mRNA; [Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of CASP3 protein]; [Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of CASP3 mRNA]; [juglone co-treated with Ascorbic Acid] results in decreased expression of CASP3 protein; Ascorbic Acid inhibits the reaction [[chromium hexavalent ion co-treated with Antimycin A] results in increased activity of CASP3 protein]; Ascorbic Acid inhibits the reaction [[chromium hexavalent ion co-treated with Rotenone] results in increased activity of CASP3 protein]; Ascorbic Acid inhibits the reaction [Antimycin A results in increased activity of CASP3 protein]; Ascorbic Acid inhibits the reaction [chromium hexavalent ion results in increased activity of CASP3 protein]; Ascorbic Acid inhibits the reaction [deoxynivalenol results in increased expression of CASP3 protein]; Ascorbic Acid inhibits the reaction [Fenretinide results in increased activity of CASP3 protein]; Ascorbic Acid inhibits the reaction [hydroxyethyl methacrylate results in increased activity of CASP3 protein]; Ascorbic Acid inhibits the reaction [Oleanolic Acid results in increased cleavage of CASP3 protein]; Ascorbic Acid inhibits the reaction [Paraquat results in increased activity of CASP3 protein]; Ascorbic Acid inhibits the reaction [Reactive Oxygen Species results in increased activity of CASP3 protein]; Ascorbic Acid inhibits the reaction [Rotenone results in increased activity of CASP3 protein]; Ascorbic Acid inhibits the reaction [Silicon Dioxide results in decreased expression of CASP3 mRNA]; Ascorbic Acid inhibits the reaction [Silicon Dioxide results in increased activity of CASP3 protein]; Ascorbic Acid inhibits the reaction [TNFSF10 protein results in increased activity of CASP3 protein]; Ascorbic Acid inhibits the reaction [triethylene glycol dimethacrylate results in increased activity of CASP3 protein]; Ascorbic Acid promotes the reaction [Arsenic Trioxide results in increased activity of CASP3 protein]; Ascorbic Acid promotes the reaction [Arsenic Trioxide results in increased cleavage of and results in increased activity of CASP3 protein]; Ascorbic Acid promotes the reaction [chromium hexavalent ion results in increased cleavage of CASP3 protein]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with Eosine I Bluish] results in increased activity of CASP3 protein] Ascorbic Acid results in decreased activity of CASP3 protein [Ascorbic Acid co-treated with Sesame Oil] inhibits the reaction [abamectin results in increased expression of CASP3 protein]; [Vitamin E co-treated with Ascorbic Acid] inhibits the reaction [Dichlorvos results in increased activity of CASP3 protein]; Ascorbic Acid inhibits the reaction [[sodium bisulfite co-treated with sodium sulfite] results in increased cleavage of CASP3 protein]; Ascorbic Acid inhibits the reaction [abamectin results in increased expression of CASP3 protein]; Ascorbic Acid inhibits the reaction [Arsenic results in increased activity of CASP3 protein]; Ascorbic Acid inhibits the reaction [Arsenic Trioxide results in increased activity of CASP3 protein]; Ascorbic Acid inhibits the reaction [Norepinephrine results in increased activity of CASP3 protein]; Ascorbic Acid inhibits the reaction [Potassium Dichromate results in increased cleavage of CASP3 protein]; Ascorbic Acid inhibits the reaction [Sodium Benzoate results in increased expression of CASP3 protein]; Ascorbic Acid inhibits the reaction [Streptozocin results in increased activity of CASP3 protein] Ascorbic Acid results in increased expression of CASP3 mRNA Ascorbic Acid inhibits the reaction [glycidamide results in increased expression of CASP3 mRNA] |
CTD |
PMID:12750841 PMID:15158148 PMID:16124896 PMID:16407847 PMID:16867262 PMID:16973328 PMID:17166419 PMID:17301063 PMID:17618090 PMID:17879260 PMID:18758938 PMID:20356860 PMID:21262251 PMID:21873648 PMID:22245848 PMID:22678527 PMID:23711929 PMID:24295472 PMID:24488945 PMID:24732427 PMID:29992683 PMID:30597948 PMID:31739238 PMID:32632975 PMID:33248029 PMID:33592258 PMID:35187746 PMID:38160894 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp4 |
caspase 4 |
multiple interactions |
EXP |
Ascorbic Acid inhibits the reaction [[kojic acid co-treated with Diethylnitrosamine] results in increased expression of CASP4 mRNA] |
CTD |
PMID:18544905 |
|
NCBI chr 8:2,599,017...2,635,097
Ensembl chr 8:2,598,876...2,635,092
|
|
G |
Casp6 |
caspase 6 |
multiple interactions |
EXP |
Ascorbic Acid inhibits the reaction [Norepinephrine results in increased activity of CASP6 protein] |
CTD |
PMID:15158148 |
|
NCBI chr 2:218,466,063...218,478,503
Ensembl chr 2:218,466,076...218,478,502
|
|
G |
Casp7 |
caspase 7 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of CASP7 protein; [Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of CASP7 mRNA; [Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of CASP7 protein]; [Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of CASP7 mRNA]; Ascorbic Acid promotes the reaction [chromium hexavalent ion results in increased cleavage of CASP7 protein] |
CTD |
PMID:17301063 PMID:17879260 |
|
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp8 |
caspase 8 |
multiple interactions increases expression |
EXP ISO |
[Ascorbic Acid co-treated with INS1 protein] results in increased expression of CASP8 mRNA; [Ascorbic Acid co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of CASP8 mRNA Ascorbic Acid inhibits the reaction [TNFSF10 protein results in increased activity of CASP8 protein] Ascorbic Acid results in increased expression of CASP8 mRNA |
CTD |
PMID:18544905 PMID:20400526 PMID:23711929 PMID:30597948 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
EXP ISO |
[Vitamin E co-treated with Ascorbic Acid] inhibits the reaction [Dichlorvos results in increased activity of CASP9 protein]; Ascorbic Acid inhibits the reaction [Norepinephrine results in increased activity of CASP9 protein] Ascorbic Acid inhibits the reaction [TNFSF10 protein results in increased activity of CASP9 protein] |
CTD |
PMID:15158148 PMID:16973328 PMID:23711929 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cast |
calpastatin |
increases expression |
EXP |
Ascorbic Acid results in increased expression of CAST mRNA |
CTD |
PMID:15372504 |
|
NCBI chr 2:3,973,112...4,082,658
Ensembl chr 2:3,973,112...4,082,659
|
|
G |
Cat |
catalase |
affects expression decreases response to substance multiple interactions increases expression increases activity decreases activity |
ISO EXP |
Ascorbic Acid affects the expression of CAT protein CAT protein results in decreased susceptibility to Ascorbic Acid [Ascorbic Acid co-treated with CAT protein] inhibits the reaction [Zinc deficiency results in increased expression of IREB2 protein]; [Ascorbic Acid co-treated with CAT protein] inhibits the reaction [Zinc deficiency results in increased expression of TFRC protein]; Ascorbic Acid inhibits the reaction [Arsenic Trioxide results in decreased activity of CAT protein]; Ascorbic Acid inhibits the reaction [Cadmium Chloride results in decreased activity of CAT protein]; Ascorbic Acid inhibits the reaction [fipronil results in decreased activity of CAT protein]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of [NFKB1 protein binds to RELA protein]]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased degradation of Hyaluronic Acid]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of CD44 mRNA]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of CD44 protein]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of IL1B mRNA]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of IL1B protein]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of MMP13 mRNA]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of MMP13 protein]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of NOS2 mRNA]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of NOS2 protein]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TLR2 mRNA]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TLR2 protein]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TLR4 mRNA]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TLR4 protein]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TNF mRNA]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TNF protein]; CAT protein inhibits the reaction [Ascorbic Acid promotes the reaction [Quartz results in increased secretion of TNF protein]] Ascorbic Acid results in increased expression of CAT protein [Ascorbic Acid co-treated with Vitamin E] inhibits the reaction [Air Pollutants, Occupational affects the expression of CAT protein]; [Ascorbic Acid co-treated with Vitamin E] inhibits the reaction [Malathion results in increased activity of CAT protein]; [Ascorbic Acid co-treated with Vitamin E] results in increased expression of CAT mRNA; [juglone co-treated with Ascorbic Acid] results in decreased activity of CAT protein; Ascorbic Acid inhibits the reaction [[lead acetate results in increased abundance of Lead] which results in decreased activity of CAT protein]; Ascorbic Acid inhibits the reaction [[lead acetate results in increased abundance of Lead] which results in decreased expression of CAT mRNA]; Ascorbic Acid inhibits the reaction [Dimethoate results in increased activity of CAT protein]; Ascorbic Acid inhibits the reaction [hydroxyethyl methacrylate results in increased degradation of CAT mRNA]; Ascorbic Acid inhibits the reaction [Malathion results in increased activity of CAT protein]; Ascorbic Acid inhibits the reaction [triethylene glycol dimethacrylate results in increased degradation of CAT mRNA]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with Eosine I Bluish] results in increased activity of CASP3 protein]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with Eosine I Bluish] results in increased phosphorylation of MAPK8 protein]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with Eosine I Bluish] results in increased phosphorylation of MAPK9 protein]; CAT protein inhibits the reaction [Copper promotes the reaction [Ascorbic Acid results in decreased activity of PON1 protein]]; CAT protein results in decreased susceptibility to [Arsenic Trioxide co-treated with Ascorbic Acid]; CAT results in decreased susceptibility to [Vitamin K 3 co-treated with Ascorbic Acid] Ascorbic Acid results in increased activity of CAT protein [[Sodium Selenite results in increased abundance of Selenium] which co-treated with Ascorbic Acid] inhibits the reaction [barium chloride results in decreased activity of CAT protein]; [Ascorbic Acid co-treated with beta Carotene co-treated with alpha-Tocopherol co-treated with Sodium Selenite] inhibits the reaction [Galactosamine results in increased activity of CAT protein]; [Ascorbic Acid co-treated with Lead] results in increased expression of CAT protein; [Ascorbic Acid co-treated with Sesame Oil] inhibits the reaction [abamectin results in increased activity of CAT protein]; [Ascorbic Acid co-treated with sodium arsenite] results in increased activity of CAT protein; [Zinc co-treated with Vitamin E co-treated with Ascorbic Acid co-treated with sodium arsenite] results in increased activity of CAT protein; Ascorbic Acid inhibits the reaction [abamectin results in increased activity of CAT protein]; Ascorbic Acid inhibits the reaction [Arsenic results in decreased activity of CAT protein]; Ascorbic Acid inhibits the reaction [barium chloride results in decreased activity of CAT protein]; Ascorbic Acid inhibits the reaction [bisphenol A results in decreased activity of CAT protein]; Ascorbic Acid inhibits the reaction [Cadmium results in decreased activity of CAT protein]; Ascorbic Acid inhibits the reaction [Carbon Tetrachloride results in decreased activity of CAT protein]; Ascorbic Acid inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased activity of CAT protein]; Ascorbic Acid inhibits the reaction [chromium hexavalent ion results in decreased activity of CAT protein]; Ascorbic Acid inhibits the reaction [Cisplatin results in decreased activity of CAT protein]; Ascorbic Acid inhibits the reaction [Cyclosporine results in decreased activity of CAT protein]; Ascorbic Acid inhibits the reaction [Food Additives affects the activity of CAT protein]; Ascorbic Acid inhibits the reaction [Indomethacin results in increased activity of CAT protein]; Ascorbic Acid inhibits the reaction [Potassium Dichromate results in decreased activity of CAT protein]; Ascorbic Acid inhibits the reaction [Potassium Dichromate results in decreased expression of CAT mRNA]; Ascorbic Acid inhibits the reaction [sodium arsenite results in decreased activity of CAT protein]; Ascorbic Acid inhibits the reaction [sodium arsenite results in decreased expression of CAT protein]; Ascorbic Acid inhibits the reaction [sodium arsenite results in increased activity of CAT protein]; Ascorbic Acid inhibits the reaction [Sodium Benzoate results in decreased activity of CAT protein]; Ascorbic Acid inhibits the reaction [Sodium Fluoride results in decreased activity of CAT protein] Ascorbic Acid results in decreased activity of CAT protein Ascorbic Acid results in increased expression of CAT mRNA |
CTD |
PMID:10772068 PMID:12540038 PMID:12767684 PMID:14698046 PMID:15104111 PMID:16248992 PMID:16298753 PMID:16758767 PMID:17512118 PMID:17822687 PMID:18073202 PMID:18096215 PMID:18548748 PMID:18655177 PMID:18715643 PMID:18726076 PMID:19298665 PMID:19391111 PMID:19429265 PMID:20028703 PMID:20077558 PMID:20122981 PMID:20171736 PMID:20535553 PMID:20876158 PMID:21310208 PMID:21689642 PMID:22008531 PMID:22056337 PMID:22207723 PMID:23194016 PMID:23470461 PMID:23619517 PMID:23692848 PMID:24295472 PMID:24488945 PMID:25721553 PMID:27941167 PMID:29572072 PMID:29992683 PMID:30676168 PMID:31005848 PMID:31022331 PMID:31576639 PMID:31610155 PMID:31739238 PMID:32913121 PMID:33248029 PMID:34089294 PMID:35187746 More...
|
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cav1 |
caveolin 1 |
multiple interactions |
ISO |
Ascorbic Acid inhibits the reaction [2,3,5-trichloro-6-phenyl-(1,4)benzoquinone results in increased phosphorylation of CAV1 protein] |
CTD |
PMID:35349355 |
|
NCBI chr 4:45,640,624...45,673,708
Ensembl chr 4:45,634,918...45,673,705
|
|
G |
Cbs |
cystathionine beta synthase |
decreases expression |
ISO |
Ascorbic Acid results in decreased expression of CBS mRNA |
CTD |
PMID:19197388 |
|
NCBI chr20:9,708,089...9,732,623
Ensembl chr20:9,708,090...9,732,764
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
affects expression decreases expression |
ISO |
Ascorbic Acid affects the expression of CCL2 mRNA; Ascorbic Acid deficiency affects the expression of CCL2 mRNA Ascorbic Acid results in decreased expression of CCL2 mRNA |
CTD |
PMID:19932582 PMID:21796779 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl21 |
C-C motif chemokine ligand 21 |
multiple interactions |
ISO |
[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of CCL21A mRNA |
CTD |
PMID:17917374 |
|
NCBI chr 5:56,980,557...56,981,661
Ensembl chr 5:56,980,558...56,981,686
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions |
ISO |
[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of CCL3 mRNA |
CTD |
PMID:17917374 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccna1 |
cyclin A1 |
multiple interactions |
EXP |
Ascorbic Acid inhibits the reaction [chromium hexavalent ion results in decreased expression of CCNA1 protein] |
CTD |
PMID:21621607 |
|
NCBI chr 2:139,231,738...139,278,066
Ensembl chr 2:139,201,074...139,243,157
|
|
G |
Ccnb1 |
cyclin B1 |
multiple interactions |
EXP |
Ascorbic Acid inhibits the reaction [chromium hexavalent ion results in decreased expression of CCNB1 protein] |
CTD |
PMID:21621607 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnc |
cyclin C |
multiple interactions |
ISO |
[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of CCNC mRNA |
CTD |
PMID:17917374 |
|
NCBI chr 5:35,266,828...35,284,943
Ensembl chr 5:35,266,823...35,296,584
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions decreases expression |
ISO EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of CCND1 mRNA; Ascorbic Acid inhibits the reaction [phenylhydrazine results in decreased expression of CCND1 mRNA] Ascorbic Acid results in decreased expression of CCND1 mRNA Ascorbic Acid inhibits the reaction [chromium hexavalent ion results in decreased expression of CCND1 protein] |
CTD |
PMID:17917374 PMID:21621607 PMID:21919647 PMID:30140404 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccnd2 |
cyclin D2 |
multiple interactions |
ISO EXP |
[Quercetin co-treated with Ascorbic Acid] results in increased expression of CCND2 mRNA Ascorbic Acid inhibits the reaction [chromium hexavalent ion results in decreased expression of CCND2 protein] |
CTD |
PMID:17639512 PMID:21621607 |
|
NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495
|
|
G |
Ccnd3 |
cyclin D3 |
multiple interactions |
EXP ISO |
Ascorbic Acid inhibits the reaction [chromium hexavalent ion results in decreased expression of CCND3 protein] Ascorbic Acid promotes the reaction [juglone results in decreased expression of CCND3 protein] |
CTD |
PMID:21621607 PMID:29992683 |
|
NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371
|
|
G |
Ccne2 |
cyclin E2 |
multiple interactions |
EXP |
Ascorbic Acid inhibits the reaction [chromium hexavalent ion results in decreased expression of CCNE2 protein] |
CTD |
PMID:21621607 |
|
NCBI chr 5:24,285,078...24,298,258
Ensembl chr 5:24,284,922...24,297,632
|
|
G |
Ccng1 |
cyclin G1 |
multiple interactions |
ISO EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of CCNG1 mRNA [Ascorbic Acid co-treated with kojic acid co-treated with Diethylnitrosamine] results in increased expression of CCNG1 mRNA |
CTD |
PMID:17917374 PMID:18544905 |
|
NCBI chr10:25,176,231...25,182,604
Ensembl chr10:25,176,234...25,181,641
|
|
G |
Cd24 |
CD24 molecule |
multiple interactions |
ISO |
[Quercetin co-treated with Ascorbic Acid] results in increased expression of CD24 mRNA |
CTD |
PMID:17639512 |
|
NCBI chr20:47,074,353...47,079,662
Ensembl chr20:47,073,512...47,079,662
|
|
G |
Cd34 |
CD34 molecule |
multiple interactions |
ISO |
[Tretinoin co-treated with Ascorbic Acid] results in decreased expression of CD34 mRNA |
CTD |
PMID:16443354 |
|
NCBI chr13:106,480,313...106,500,844
Ensembl chr13:106,480,043...106,499,832
|
|
G |
Cd40 |
CD40 molecule |
multiple interactions |
ISO |
[Tretinoin co-treated with Ascorbic Acid] results in decreased expression of CD40 mRNA |
CTD |
PMID:16443354 |
|
NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534
|
|
G |
Cd44 |
CD44 molecule |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of CD44 mRNA; [Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of CD44 protein; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of CD44 mRNA]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of CD44 protein]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of CD44 mRNA]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of CD44 protein] |
CTD |
PMID:23692848 |
|
NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620
|
|
G |
Cd48 |
Cd48 molecule |
increases expression |
EXP |
Ascorbic Acid results in increased expression of CD48 mRNA |
CTD |
PMID:15372504 |
|
NCBI chr13:84,184,884...84,209,144
Ensembl chr13:84,185,532...84,209,142
|
|
G |
Cd69 |
Cd69 molecule |
decreases expression |
ISO |
Ascorbic Acid deficiency results in decreased expression of CD69 protein |
CTD |
PMID:22306178 |
|
NCBI chr 4:162,725,446...162,733,364
Ensembl chr 4:162,725,446...162,733,542
|
|
G |
Cd82 |
Cd82 molecule |
increases expression |
EXP |
Ascorbic Acid results in increased expression of CD82 mRNA |
CTD |
PMID:15372504 |
|
NCBI chr 3:79,387,361...79,431,847
Ensembl chr 3:79,385,887...79,431,809
|
|
G |
Cdc20 |
cell division cycle 20 |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of CDC20 mRNA |
CTD |
PMID:34480604 |
|
NCBI chr 5:131,966,203...131,970,406
Ensembl chr 5:131,966,215...131,970,512
|
|
G |
Cdc6 |
cell division cycle 6 |
multiple interactions |
ISO |
[Quercetin co-treated with Ascorbic Acid] results in increased expression of CDC6 mRNA |
CTD |
PMID:17639512 |
|
NCBI chr10:83,864,189...83,878,011
Ensembl chr10:83,864,638...83,878,011
|
|
G |
Cdh10 |
cadherin 10 |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CDH10 mRNA |
CTD |
PMID:34480604 |
|
NCBI chr 2:68,628,623...68,850,995
Ensembl chr 2:68,628,780...68,850,995
|
|
G |
Cdh13 |
cadherin 13 |
increases expression |
ISO |
Ascorbic Acid results in increased expression of CDH13 mRNA |
CTD |
PMID:15305145 |
|
NCBI chr19:46,349,562...47,387,462
Ensembl chr19:46,349,430...47,387,459
|
|
G |
Cdh2 |
cadherin 2 |
multiple interactions |
EXP |
[Ascorbic Acid co-treated with Vitamin E] inhibits the reaction [mono-(2-ethylhexyl)phthalate affects the localization of CDH2 protein] |
CTD |
PMID:29940330 |
|
NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167
|
|
G |
Cdh22 |
cadherin 22 |
increases expression |
EXP |
Ascorbic Acid results in increased expression of CDH22 mRNA |
CTD |
PMID:15372504 |
|
NCBI chr 3:153,845,563...153,970,630
Ensembl chr 3:153,845,787...153,970,588
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
multiple interactions |
EXP |
Ascorbic Acid inhibits the reaction [chromium hexavalent ion results in decreased expression of CDK1 protein] |
CTD |
PMID:21621607 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
multiple interactions |
EXP |
Ascorbic Acid inhibits the reaction [chromium hexavalent ion results in decreased expression of CDK2 protein] |
CTD |
PMID:21621607 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
multiple interactions |
EXP ISO |
Ascorbic Acid inhibits the reaction [chromium hexavalent ion results in decreased expression of CDK4 protein] [juglone co-treated with Ascorbic Acid] results in decreased expression of CDK4 protein |
CTD |
PMID:21621607 PMID:29992683 |
|
NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdk6 |
cyclin-dependent kinase 6 |
multiple interactions |
EXP |
Ascorbic Acid inhibits the reaction [chromium hexavalent ion results in decreased expression of CDK6 protein] |
CTD |
PMID:21621607 |
|
NCBI chr 4:30,637,650...30,829,688
Ensembl chr 4:30,646,460...30,829,634
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions increases expression |
ISO EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of CDKN1A mRNA [Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of CDKN1A mRNA; Ascorbic Acid inhibits the reaction [potassium bromate results in increased expression of CDKN1A protein]; nutlin 3 inhibits the reaction [[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of CDKN1A mRNA] [INS1 protein co-treated with Ascorbic Acid] results in increased expression of CDKN1A mRNA; Ascorbic Acid inhibits the reaction [potassium bromate results in increased expression of CDKN1A protein] Ascorbic Acid results in increased expression of CDKN1A mRNA |
CTD |
PMID:17917374 PMID:20067818 PMID:20400526 PMID:20530418 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
multiple interactions |
EXP |
[Ascorbic Acid co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of CDKN1B mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
multiple interactions |
EXP |
Ascorbic Acid inhibits the reaction [chromium hexavalent ion results in increased expression of CDKN2A protein] |
CTD |
PMID:21621607 |
|
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Ceacam6 |
CEA cell adhesion molecule 6 |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CEACAM6 mRNA |
CTD |
PMID:34480604 |
|
NCBI chr 1:80,416,531...80,434,668
Ensembl chr 1:80,416,531...80,434,668
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of CEBPA protein [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of CEBPA mRNA |
CTD |
PMID:14505802 PMID:25932594 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
increases expression |
EXP |
Ascorbic Acid results in increased expression of CEBPB mRNA |
CTD |
PMID:15372504 |
|
NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
|
|
G |
Cfb |
complement factor B |
multiple interactions |
ISO |
[Quercetin co-treated with Ascorbic Acid] results in decreased expression of CFB mRNA |
CTD |
PMID:17639512 |
|
NCBI chr20:3,970,643...3,976,510
Ensembl chr20:3,951,474...3,976,505
|
|
G |
Cftr |
CF transmembrane conductance regulator |
multiple interactions increases activity |
ISO |
[Bicarbonates co-treated with Glutathione co-treated with Ascorbic Acid] results in increased activity of CFTR protein; Ascorbic Acid inhibits the reaction [Vehicle Emissions results in decreased activity of CFTR protein]; Ascorbic Acid promotes the reaction [CFTR protein results in increased secretion of Chlorides] Ascorbic Acid results in increased activity of CFTR protein |
CTD |
PMID:14993613 PMID:32374624 PMID:34601066 |
|
NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756
|
|
G |
Chaf1b |
chromatin assembly factor 1 subunit B |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of CHAF1B mRNA |
CTD |
PMID:26424790 |
|
NCBI chr11:33,200,894...33,221,076
Ensembl chr11:33,200,981...33,221,070
|
|
G |
Chat |
choline O-acetyltransferase |
multiple interactions |
EXP |
[Ascorbic Acid co-treated with alpha-Tocopherol co-treated with Acetylcysteine] results in increased expression of CHAT protein; Tobacco Smoke Pollution inhibits the reaction [[Ascorbic Acid co-treated with alpha-Tocopherol co-treated with Acetylcysteine] results in increased expression of CHAT protein] |
CTD |
PMID:25891525 |
|
NCBI chr16:7,657,362...7,717,093
Ensembl chr16:7,657,362...7,717,093
|
|
G |
Chek2 |
checkpoint kinase 2 |
multiple interactions |
EXP ISO |
Ascorbic Acid inhibits the reaction [[kojic acid co-treated with Diethylnitrosamine] results in increased expression of CHEK2 mRNA] Ascorbic Acid inhibits the reaction [chromium hexavalent ion results in increased phosphorylation of CHEK2 protein]; Ascorbic Acid inhibits the reaction [potassium chromate(VI) results in increased expression of CHEK2 protein modified form]; Ascorbic Acid inhibits the reaction [potassium chromate(VI) results in increased phosphorylation of CHEK2 protein] |
CTD |
PMID:18544905 PMID:25977998 PMID:31388677 |
|
NCBI chr12:45,788,823...45,821,382
Ensembl chr12:45,788,827...45,821,286
|
|
G |
Cidec |
cell death-inducing DFFA-like effector c |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CIDEC mRNA |
CTD |
PMID:34480604 |
|
NCBI chr 4:146,569,288...146,582,173
Ensembl chr 4:146,569,289...146,582,173
|
|
G |
Cit |
citron rho-interacting serine/threonine kinase |
multiple interactions |
ISO |
[Quercetin co-treated with Ascorbic Acid] results in increased expression of CIT mRNA |
CTD |
PMID:17639512 |
|
NCBI chr12:40,603,073...40,764,846
Ensembl chr12:40,605,563...40,763,860
|
|
G |
Cited1 |
Cbp/p300-interacting transactivator with Glu/Asp-rich carboxy-terminal domain 1 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of CITED1 mRNA; cadmium sulfate inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of CITED1 mRNA] |
CTD |
PMID:28189605 |
|
NCBI chr X:67,350,376...67,355,072
Ensembl chr X:67,350,373...67,355,162
|
|
G |
Clu |
clusterin |
increases expression |
EXP |
Ascorbic Acid results in increased expression of CLU mRNA |
CTD |
PMID:15372504 |
|
NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315
|
|
G |
Cmip |
c-Maf-inducing protein |
increases expression multiple interactions |
ISO |
Ascorbic Acid results in increased expression of CMIP mRNA [arsenic trioxide co-treated with Ascorbic Acid] results in increased expression of CMIP mRNA |
CTD |
PMID:25555879 |
|
NCBI chr19:45,304,597...45,510,653
Ensembl chr19:45,304,031...45,508,709
|
|
G |
Cnn1 |
calponin 1 |
multiple interactions increases expression |
ISO EXP |
[Ascorbic Acid co-treated with TGFB1 protein] results in increased expression of CNN1 mRNA; [Ascorbic Acid co-treated with TGFB1 protein] results in increased expression of CNN1 protein Ascorbic Acid results in increased expression of CNN1 protein |
CTD |
PMID:14639096 PMID:18607632 |
|
NCBI chr 8:20,632,434...20,641,097
Ensembl chr 8:20,632,338...20,641,098
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
multiple interactions |
ISO |
Ascorbic Acid inhibits the reaction [Hydrogen Peroxide results in increased expression of CNR1 protein] |
CTD |
PMID:28285367 |
|
NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099
|
|
G |
Cnr2 |
cannabinoid receptor 2 |
multiple interactions |
ISO |
Ascorbic Acid inhibits the reaction [Hydrogen Peroxide results in increased expression of CNR2 protein] |
CTD |
PMID:28285367 |
|
NCBI chr 5:148,125,222...148,151,548
Ensembl chr 5:148,125,604...148,151,548
|
|
G |
Cntf |
ciliary neurotrophic factor |
multiple interactions |
ISO |
Ascorbic Acid inhibits the reaction [Mercuric Chloride inhibits the reaction [CNTF protein results in increased phosphorylation of STAT1 protein]]; Ascorbic Acid inhibits the reaction [Mercuric Chloride inhibits the reaction [CNTF protein results in increased phosphorylation of STAT3 protein]] |
CTD |
PMID:16896058 |
|
NCBI chr 1:209,887,854...209,889,877
Ensembl chr 1:209,887,854...209,889,877
|
|
G |
Cntn1 |
contactin 1 |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of CNTN1 mRNA |
CTD |
PMID:33713149 |
|
NCBI chr 7:123,263,146...123,560,896
Ensembl chr 7:123,372,792...123,558,541
|
|
G |
Cntnap1 |
contactin associated protein 1 |
multiple interactions |
ISO |
[arsenic trioxide co-treated with Ascorbic Acid] results in increased expression of CNTNAP1 mRNA |
CTD |
PMID:25555879 |
|
NCBI chr10:86,109,850...86,125,612
Ensembl chr10:86,111,643...86,125,611
|
|
G |
Col10a1 |
collagen type X alpha 1 chain |
increases expression multiple interactions |
ISO |
Ascorbic Acid results in increased expression of COL10A1 mRNA U 0126 inhibits the reaction [Ascorbic Acid results in increased expression of COL10A1 mRNA] |
CTD |
PMID:20530736 |
|
NCBI chr20:38,183,103...38,189,488
Ensembl chr20:38,182,494...38,189,494
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
increases expression multiple interactions |
ISO |
Ascorbic Acid results in increased expression of COL1A1 mRNA 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] co-treated with fasudil] results in increased expression of COL1A1 mRNA]; [[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] co-treated with fasudil] results in increased expression of COL1A1 mRNA |
CTD |
PMID:12510807 PMID:14566779 PMID:28105418 PMID:31935364 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col1a2 |
collagen type I alpha 2 chain |
increases expression multiple interactions |
EXP ISO |
Ascorbic Acid results in increased expression of COL1A2 mRNA [arsenic trioxide co-treated with Ascorbic Acid] results in increased expression of COL1A2 mRNA |
CTD |
PMID:15372504 PMID:25555879 |
|
NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867
|
|
G |
Col2a1 |
collagen type II alpha 1 chain |
increases expression multiple interactions |
EXP ISO |
Ascorbic Acid results in increased expression of COL2A1 mRNA [TGFB3 protein co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of COL2A1 mRNA; IL1B protein inhibits the reaction [[TGFB3 protein co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of COL2A1 mRNA]; resveratrol inhibits the reaction [IL1B protein inhibits the reaction [[TGFB3 protein co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of COL2A1 mRNA]] |
CTD |
PMID:15372504 PMID:26526931 |
|
NCBI chr 7:129,098,489...129,127,560
Ensembl chr 7:129,098,786...129,127,546
|
|
G |
Col3a1 |
collagen type III alpha 1 chain |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of COL3A1 mRNA |
CTD |
PMID:34480604 |
|
NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547
|
|
G |
Cr2 |
complement C3d receptor 2 |
multiple interactions |
ISO |
[Tretinoin co-treated with Ascorbic Acid] results in decreased expression of CR2 mRNA |
CTD |
PMID:16443354 |
|
NCBI chr13:106,678,579...106,716,595
Ensembl chr13:106,685,413...106,716,235
|
|
G |
Crip2 |
cysteine-rich protein 2 |
increases expression |
EXP |
Ascorbic Acid results in increased expression of CRIP2 mRNA |
CTD |
PMID:15372504 |
|
NCBI chr 6:132,221,120...132,226,066
Ensembl chr 6:132,221,082...132,226,065
|
|
G |
Crp |
C-reactive protein |
multiple interactions |
ISO |
[Vitamin E co-treated with Ascorbic Acid co-treated with Folic Acid co-treated with Riboflavin co-treated with Vitamin B 6 co-treated with Vitamin B 12] results in decreased expression of CRP protein; [Vitamin E co-treated with Ascorbic Acid] results in decreased expression of CRP protein |
CTD |
PMID:16517955 |
|
NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178
|
|
G |
Cryab |
crystallin, alpha B |
increases expression multiple interactions |
EXP ISO |
Ascorbic Acid results in increased expression of CRYAB mRNA [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CRYAB mRNA |
CTD |
PMID:15372504 PMID:34480604 |
|
NCBI chr 8:51,093,441...51,099,161
Ensembl chr 8:51,093,441...51,099,157
|
|
G |
Cs |
citrate synthase |
multiple interactions |
ISO |
Ascorbic Acid inhibits the reaction [FMR1 5' UTR mutant form results in decreased activity of CS protein] |
CTD |
PMID:27385396 |
|
NCBI chr 7:758,074...791,421
Ensembl chr 7:758,345...791,421
|
|
G |
Cspg5 |
chondroitin sulfate proteoglycan 5 |
increases expression |
ISO |
Ascorbic Acid results in increased expression of CSPG5 mRNA |
CTD |
PMID:15305145 |
|
NCBI chr 8:110,220,506...110,234,766
Ensembl chr 8:110,220,653...110,234,758
|
|
G |
Csrp1 |
cysteine and glycine-rich protein 1 |
increases expression |
EXP |
Ascorbic Acid results in increased expression of CSRP1 mRNA |
CTD |
PMID:15372504 |
|
NCBI chr13:47,158,171...47,179,388
Ensembl chr13:47,167,789...47,179,384
|
|
G |
Cst6 |
cystatin E/M |
increases expression |
EXP |
Ascorbic Acid results in increased expression of CST6 mRNA |
CTD |
PMID:15372504 |
|
NCBI chr 1:202,655,322...202,657,030
Ensembl chr 1:202,655,322...202,657,030
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions |
EXP |
[Ascorbic Acid co-treated with Vitamin E] inhibits the reaction [Diethylhexyl Phthalate results in increased expression of and affects the localization of CTNNB1 protein]; [Ascorbic Acid co-treated with Vitamin E] inhibits the reaction [mono-(2-ethylhexyl)phthalate affects the localization of CTNNB1 protein] |
CTD |
PMID:29940330 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Ctps2 |
CTP synthase 2 |
multiple interactions |
ISO |
[arsenic trioxide co-treated with Ascorbic Acid] results in decreased expression of CTPS2 mRNA |
CTD |
PMID:25555879 |
|
NCBI chr X:31,645,873...31,786,733
Ensembl chr X:31,645,873...31,786,733
|
|
G |
Ctsd |
cathepsin D |
multiple interactions |
EXP |
[ferulic acid co-treated with Ascorbic Acid] inhibits the reaction [Isoproterenol results in increased activity of CTSD protein] |
CTD |
PMID:17045618 |
|
NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
|
|
G |
Ctsk |
cathepsin K |
increases expression |
ISO |
Ascorbic Acid results in increased expression of CTSK mRNA |
CTD |
PMID:15730627 |
|
NCBI chr 2:183,058,586...183,069,551
Ensembl chr 2:183,058,569...183,069,550
|
|
G |
Ctso |
cathepsin O |
multiple interactions |
ISO |
[Quercetin co-treated with Ascorbic Acid] results in decreased expression of CTSO mRNA |
CTD |
PMID:17639512 |
|
NCBI chr 2:167,230,407...167,254,761
Ensembl chr 2:167,230,330...167,253,702
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
increases expression |
EXP |
Ascorbic Acid deficiency results in increased expression of CXCL1 mRNA; Ascorbic Acid deficiency results in increased expression of CXCL1 protein |
CTD |
PMID:16637227 |
|
NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
decreases expression increases expression |
ISO |
Ascorbic Acid results in decreased expression of CXCL10 mRNA Ascorbic Acid deficiency results in increased expression of CXCL10 mRNA |
CTD |
PMID:19932582 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Cxcl6 |
C-X-C motif chemokine ligand 6 |
decreases expression increases expression |
ISO |
Ascorbic Acid results in decreased expression of CXCL6 mRNA Ascorbic Acid deficiency results in increased expression of CXCL6 mRNA |
CTD |
PMID:19932582 |
|
NCBI chr14:17,310,790...17,312,250
Ensembl chr14:17,310,426...17,313,093
|
|
G |
Cxcl9 |
C-X-C motif chemokine ligand 9 |
multiple interactions |
ISO |
[Tretinoin co-treated with Ascorbic Acid] results in increased expression of CXCL9 mRNA |
CTD |
PMID:16443354 |
|
NCBI chr14:15,722,868...15,727,779
Ensembl chr14:15,722,908...15,728,435
|
|
G |
Cxcr5 |
C-X-C motif chemokine receptor 5 |
multiple interactions |
ISO |
[Tretinoin co-treated with Ascorbic Acid] results in increased expression of CXCR5 mRNA |
CTD |
PMID:16443354 |
|
NCBI chr 8:44,842,098...44,858,425
Ensembl chr 8:44,843,413...44,857,893
|
|
G |
Cyba |
cytochrome b-245 alpha chain |
multiple interactions |
ISO |
Ascorbic Acid inhibits the reaction [Hydrogen Peroxide results in increased expression of CYBA mRNA]; Ascorbic Acid inhibits the reaction [Hydrogen Peroxide results in increased expression of CYBA protein] |
CTD |
PMID:25305479 |
|
NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721
|
|
G |
Cybb |
cytochrome b-245 beta chain |
increases expression |
ISO |
Ascorbic Acid results in increased expression of CYBB protein |
CTD |
PMID:21570463 |
|
NCBI chr X:13,358,101...13,392,570
Ensembl chr X:13,359,430...13,392,586
|
|
G |
Cybrd1 |
cytochrome b reductase 1 |
decreases expression increases expression |
ISO |
Ascorbic Acid results in decreased expression of CYBRD1 protein Ascorbic Acid results in increased expression of CYBRD1 protein |
CTD |
PMID:18815723 |
|
NCBI chr 3:55,934,874...55,962,132
Ensembl chr 3:55,934,874...55,962,108
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions |
ISO |
Ascorbic Acid inhibits the reaction [TNFSF10 protein affects the localization of CYCS protein] |
CTD |
PMID:23711929 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
multiple interactions increases expression |
EXP ISO |
Ascorbic Acid inhibits the reaction [Cadmium results in decreased expression of CYP11A1 mRNA]; Ascorbic Acid inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased activity of CYP11A1 protein]; Ascorbic Acid inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of CYP11A1 mRNA] Ascorbic Acid results in increased expression of CYP11A1 mRNA |
CTD |
PMID:15223132 PMID:16298753 PMID:17280759 PMID:17901237 |
|
NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
multiple interactions increases expression |
ISO |
[Tretinoin co-treated with Ascorbic Acid] results in decreased expression of CYP19A1 mRNA Ascorbic Acid results in increased expression of CYP19A1 mRNA |
CTD |
PMID:16443354 PMID:17901237 |
|
NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions decreases activity |
ISO |
[Quercetin co-treated with Ascorbic Acid] results in increased expression of CYP1A1 mRNA; Ascorbic Acid inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]; Ascorbic Acid inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; Ascorbic Acid inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein] Ascorbic Acid results in decreased activity of CYP1A1 protein Ascorbic Acid affects the reaction [andrographolide affects the reaction [beta-Naphthoflavone results in increased expression of CYP1A1 mRNA]]; Ascorbic Acid affects the reaction [beta-Naphthoflavone results in increased expression of CYP1A1 mRNA]; Ascorbic Acid inhibits the reaction [chromium hexavalent ion results in increased expression of CYP1A1 mRNA]; Ascorbic Acid inhibits the reaction [sodium arsenite results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:16517059 PMID:17512695 PMID:17639512 PMID:19268519 PMID:21094198 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
increases expression |
EXP |
Ascorbic Acid deficiency results in increased expression of CYP1A2 mRNA; Ascorbic Acid deficiency results in increased expression of CYP1A2 protein |
CTD |
PMID:8269614 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp24a1 |
cytochrome P450, family 24, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of CYP24A1 mRNA |
CTD |
PMID:34480604 |
|
NCBI chr 3:159,275,947...159,290,383
Ensembl chr 3:159,275,947...159,290,383
|
|
G |
Cyp26b1 |
cytochrome P450, family 26, subfamily b, polypeptide 1 |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CYP26B1 mRNA |
CTD |
PMID:34480604 |
|
NCBI chr 4:117,041,808...117,058,628
Ensembl chr 4:117,041,808...117,058,628
|
|
G |
Cyp2b2 |
cytochrome P450, family 2, subfamily b, polypeptide 2 |
decreases expression |
EXP |
Ascorbic Acid deficiency results in decreased expression of CYP2B2 protein |
CTD |
PMID:8269614 |
|
NCBI chr 1:81,594,534...81,608,567
Ensembl chr 1:81,594,555...81,608,566
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
multiple interactions |
ISO |
[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of CYP2B10 mRNA |
CTD |
PMID:17917374 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
decreases activity multiple interactions |
ISO EXP |
Ascorbic Acid results in decreased activity of CYP2E1 protein [Ascorbic Acid co-treated with Sesame Oil] inhibits the reaction [abamectin results in increased expression of CYP2E1 protein]; Ascorbic Acid inhibits the reaction [abamectin results in increased expression of CYP2E1 protein]; Ascorbic Acid inhibits the reaction [Ethylene Chlorohydrin results in increased expression of CYP2E1 mRNA]; Ascorbic Acid inhibits the reaction [Ethylene Chlorohydrin results in increased expression of CYP2E1 protein] |
CTD |
PMID:17512695 PMID:31585129 PMID:31739238 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CYP3A5 mRNA |
CTD |
PMID:34480604 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
multiple interactions |
ISO |
[Diethylnitrosamine co-treated with Ascorbic Acid] results in increased expression of CYP7A1 mRNA; [Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of CYP7A1 mRNA |
CTD |
PMID:17917374 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Dab2 |
DAB adaptor protein 2 |
decreases expression |
ISO |
Ascorbic Acid results in decreased expression of DAB2 mRNA |
CTD |
PMID:15305145 |
|
NCBI chr 2:55,514,692...55,567,476
Ensembl chr 2:55,514,700...55,567,476
|
|
G |
Dao |
D-amino-acid oxidase |
multiple interactions |
ISO |
Ascorbic Acid inhibits the reaction [Diquat results in increased activity of DAO protein] |
CTD |
PMID:33475796 |
|
NCBI chr12:42,592,342...42,613,046
Ensembl chr12:42,592,343...42,612,741
|
|
G |
Dcc |
DCC netrin 1 receptor |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DCC mRNA |
CTD |
PMID:34480604 |
|
NCBI chr18:64,868,987...65,972,783
Ensembl chr18:64,873,898...65,972,740
|
|
G |
Dclk1 |
doublecortin-like kinase 1 |
increases expression |
ISO |
Ascorbic Acid results in increased expression of DCLK1 mRNA |
CTD |
PMID:15305145 |
|
NCBI chr 2:139,417,234...139,710,956
Ensembl chr 2:139,417,163...139,710,956
|
|
G |
Dcn |
decorin |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DCN mRNA |
CTD |
PMID:34480604 |
|
NCBI chr 7:32,281,252...32,321,291
Ensembl chr 7:32,281,252...32,321,270
|
|
G |
Dcx |
doublecortin |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of DCX mRNA |
CTD |
PMID:34480604 |
|
NCBI chr X:107,430,767...107,573,612
Ensembl chr X:107,430,767...107,507,476
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
EXP |
[Ascorbic Acid co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of DDIT3 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Dhrs9 |
dehydrogenase/reductase 9 |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DHRS9 mRNA |
CTD |
PMID:34480604 |
|
NCBI chr 3:54,147,834...54,170,052
Ensembl chr 3:54,147,803...54,220,241
|
|
G |
Dkk1 |
dickkopf WNT signaling pathway inhibitor 1 |
decreases expression |
ISO |
Ascorbic Acid results in decreased expression of DKK1 mRNA |
CTD |
PMID:19197388 |
|
NCBI chr 1:228,381,521...228,385,202
Ensembl chr 1:228,381,521...228,385,202
|
|
G |
Dkk2 |
dickkopf WNT signaling pathway inhibitor 2 |
multiple interactions |
ISO |
Ascorbic Acid inhibits the reaction [Benzo(a)pyrene results in decreased expression of DKK2 mRNA]; Ascorbic Acid inhibits the reaction [Benzo(a)pyrene results in increased methylation of DKK2 promoter] |
CTD |
PMID:27901495 |
|
NCBI chr 2:220,568,338...220,660,225
Ensembl chr 2:220,568,338...220,660,225
|
|
G |
Dld |
dihydrolipoamide dehydrogenase |
multiple interactions |
ISO |
Ascorbic Acid inhibits the reaction [Cadmium Chloride results in decreased activity of and results in increased phosphorylation of DLD protein] |
CTD |
PMID:29158198 |
|
NCBI chr 6:47,904,153...47,924,814
Ensembl chr 6:47,903,914...47,924,795
|
|
G |
Dlg4 |
discs large MAGUK scaffold protein 4 |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of DLG4 mRNA Ascorbic Acid inhibits the reaction [Corticosterone results in decreased expression of DLG4 protein] |
CTD |
PMID:33713149 PMID:33872575 |
|
NCBI chr10:54,740,700...54,769,097
Ensembl chr10:54,739,470...54,767,153
|
|
G |
Dlgap5 |
DLG associated protein 5 |
multiple interactions |
ISO |
[Quercetin co-treated with Ascorbic Acid] results in increased expression of DLGAP5 mRNA |
CTD |
PMID:17639512 |
|
NCBI chr15:20,633,964...20,664,569
Ensembl chr15:20,633,966...20,664,518
|
|
G |
Dmp1 |
dentin matrix acidic phosphoprotein 1 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of DMP1 mRNA; bexarotene inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of DMP1 mRNA]; rosiglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of DMP1 mRNA]; tributyltin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of DMP1 mRNA] |
CTD |
PMID:25932594 |
|
NCBI chr14:5,528,441...5,542,078
Ensembl chr14:5,528,431...5,539,323
|
|
G |
Dnajb1 |
DnaJ heat shock protein family (Hsp40) member B1 |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DNAJB1 mRNA |
CTD |
PMID:34480604 |
|
NCBI chr19:24,522,731...24,526,419
Ensembl chr19:24,522,717...24,526,458
|
|
G |
Dnajc10 |
DnaJ heat shock protein family (Hsp40) member C10 |
multiple interactions |
ISO |
Ascorbic Acid inhibits the reaction [Fenretinide results in increased expression of DNAJC10 mRNA] |
CTD |
PMID:17353921 |
|
NCBI chr 3:65,232,031...65,272,732
Ensembl chr 3:65,232,697...65,272,719
|
|
G |
Dnase1 |
deoxyribonuclease 1 |
multiple interactions |
ISO |
[Quercetin co-treated with Ascorbic Acid] results in decreased expression of DNASE1 mRNA |
CTD |
PMID:17639512 |
|
NCBI chr10:11,498,930...11,505,151
Ensembl chr10:11,498,931...11,501,869
|
|
G |
Dpf1 |
double PHD fingers 1 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of DPF1 mRNA |
CTD |
PMID:26424790 |
|
NCBI chr 1:84,602,212...84,615,954
Ensembl chr 1:84,602,336...84,615,950
|
|
G |
Dpp4 |
dipeptidylpeptidase 4 |
multiple interactions |
ISO |
[Quercetin co-treated with Ascorbic Acid] results in decreased expression of DPP4 mRNA |
CTD |
PMID:17639512 |
|
NCBI chr 3:46,962,233...47,043,870
Ensembl chr 3:46,962,243...47,043,901
|
|
G |
Dppa2 |
developmental pluripotency-associated 2 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of DPPA2 mRNA |
CTD |
PMID:28189605 |
|
NCBI chr11:52,549,024...52,556,740
|
|
G |
Dppa5 |
developmental pluripotency associated 5 |
decreases expression |
ISO |
Ascorbic Acid results in decreased expression of DPPA5A mRNA |
CTD |
PMID:15305145 |
|
NCBI chr 8:79,215,341...79,217,282
Ensembl chr 8:79,215,362...79,216,570 Ensembl chr 7:79,215,362...79,216,570
|
|
G |
Dusp6 |
dual specificity phosphatase 6 |
decreases expression |
EXP |
Ascorbic Acid results in decreased expression of DUSP6 mRNA |
CTD |
PMID:15372504 |
|
NCBI chr 7:34,092,848...34,097,186
Ensembl chr 7:34,092,943...34,097,185
|
|
G |
E2f2 |
E2F transcription factor 2 |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of E2F2 mRNA |
CTD |
PMID:33713149 |
|
NCBI chr 5:148,399,193...148,422,595
Ensembl chr 5:148,399,642...148,421,217
|
|
G |
Ebf3 |
EBF transcription factor 3 |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of EBF3 mRNA |
CTD |
PMID:34480604 |
|
NCBI chr 1:191,996,726...192,114,593
Ensembl chr 1:191,996,730...192,114,359
|
|
G |
Ecscr |
endothelial cell surface expressed chemotaxis and apoptosis regulator |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ECSCR mRNA |
CTD |
PMID:34480604 |
|
NCBI chr18:27,309,711...27,319,106
Ensembl chr18:27,309,718...27,319,032
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions |
ISO |
[Tretinoin co-treated with Ascorbic Acid] results in increased expression of EDN1 mRNA |
CTD |
PMID:16443354 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Edn3 |
endothelin 3 |
multiple interactions |
ISO |
[Tretinoin co-treated with Ascorbic Acid] results in decreased expression of EDN3 mRNA |
CTD |
PMID:16443354 |
|
NCBI chr 3:163,562,307...163,586,636
Ensembl chr 3:163,562,520...163,585,093
|
|
G |
Ednrb |
endothelin receptor type B |
increases expression |
ISO |
Ascorbic Acid results in increased expression of EDNRB mRNA |
CTD |
PMID:15305145 |
|
NCBI chr15:80,640,839...80,672,115
Ensembl chr15:80,643,043...80,672,115
|
|
G |
Egfr |
epidermal growth factor receptor |
decreases expression |
ISO |
Ascorbic Acid results in decreased expression of EGFR mRNA |
CTD |
PMID:21919647 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Egln1 |
egl-9 family hypoxia-inducible factor 1 |
multiple interactions |
ISO |
EGLN1 mRNA affects the reaction [Ascorbic Acid results in increased expression of SP7 protein] |
CTD |
PMID:21467157 |
|
NCBI chr19:52,867,900...52,907,308
Ensembl chr19:52,869,486...52,907,777
|
|
G |
Egln3 |
egl-9 family hypoxia-inducible factor 3 |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of EGLN3 mRNA; [Quercetin co-treated with Ascorbic Acid] results in increased expression of EGLN3 mRNA |
CTD |
PMID:17639512 PMID:34480604 |
|
NCBI chr 6:71,650,297...71,675,766
Ensembl chr 6:71,650,297...71,675,766
|
|
G |
Eif2s2 |
eukaryotic translation initiation factor 2 subunit beta |
decreases expression |
ISO |
Ascorbic Acid results in decreased expression of EIF2S2 mRNA |
CTD |
PMID:19197388 |
|
NCBI chr 3:143,374,652...143,395,460
Ensembl chr 3:143,373,686...143,395,432
|
|
G |
Eif3a |
eukaryotic translation initiation factor 3, subunit A |
decreases expression |
ISO |
Ascorbic Acid results in decreased expression of EIF3A mRNA |
CTD |
PMID:19197388 |
|
NCBI chr 1:259,902,767...259,932,976
Ensembl chr 1:259,902,680...259,932,976
|
|
G |
Eif3c |
eukaryotic translation initiation factor 3, subunit C |
decreases expression |
ISO |
Ascorbic Acid results in decreased expression of EIF3C mRNA |
CTD |
PMID:19197388 |
|
NCBI chr 1:181,134,604...181,152,489
Ensembl chr 1:181,134,604...181,152,493
|
|
G |
Eif3i |
eukaryotic translation initiation factor 3, subunit I |
increases expression |
ISO |
Ascorbic Acid results in increased expression of EIF3I mRNA |
CTD |
PMID:22139585 |
|
NCBI chr 5:141,935,135...141,942,589
Ensembl chr 5:141,935,044...141,942,676
|
|
G |
Eif4a1 |
eukaryotic translation initiation factor 4A1 |
decreases expression |
ISO |
Ascorbic Acid results in decreased expression of EIF4A1 mRNA |
CTD |
PMID:19197388 |
|
NCBI chr10:54,384,345...54,389,855
Ensembl chr10:54,384,347...54,389,858
|
|
G |
Elavl3 |
ELAV like RNA binding protein 3 |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ELAVL3 mRNA |
CTD |
PMID:34480604 |
|
NCBI chr 8:20,547,108...20,583,369
Ensembl chr 8:20,550,201...20,583,641
|
|
G |
Elavl4 |
ELAV like RNA binding protein 4 |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ELAVL4 mRNA |
CTD |
PMID:34480604 |
|
NCBI chr 5:125,056,848...125,200,543
Ensembl chr 5:125,056,848...125,200,446
|
|
G |
Elp6 |
elongator acetyltransferase complex subunit 6 |
multiple interactions decreases expression |
ISO |
[arsenic trioxide co-treated with Ascorbic Acid] results in decreased expression of ELP6 mRNA Ascorbic Acid results in decreased expression of ELP6 mRNA |
CTD |
PMID:25555879 |
|
NCBI chr 8:110,280,059...110,295,070
Ensembl chr 8:110,279,979...110,295,067
|
|
G |
Emp1 |
epithelial membrane protein 1 |
multiple interactions |
ISO |
[Quercetin co-treated with Ascorbic Acid] results in increased expression of EMP1 mRNA |
CTD |
PMID:17639512 |
|
NCBI chr 4:168,212,901...168,233,039
Ensembl chr 4:168,212,861...168,232,904
|
|
G |
Emp3 |
epithelial membrane protein 3 |
multiple interactions |
ISO |
[Quercetin co-treated with Ascorbic Acid] results in increased expression of EMP3 mRNA |
CTD |
PMID:17639512 |
|
NCBI chr 1:96,388,651...96,391,946
Ensembl chr 1:96,388,652...96,391,988
|
|
G |
Emx2 |
empty spiracles homeobox 2 |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of EMX2 mRNA |
CTD |
PMID:34480604 |
|
NCBI chr 1:258,626,584...258,633,594
Ensembl chr 1:258,626,584...258,633,594
|
|
G |
En1 |
engrailed homeobox 1 |
multiple interactions |
ISO |
Ascorbic Acid inhibits the reaction [Benzo(a)pyrene results in decreased expression of EN1 mRNA]; Ascorbic Acid inhibits the reaction [Benzo(a)pyrene results in increased methylation of EN1 promoter] |
CTD |
PMID:27901495 |
|
NCBI chr13:31,750,892...31,756,477
Ensembl chr13:31,751,545...31,755,943
|
|
G |
Eno1 |
enolase 1 |
multiple interactions decreases expression |
ISO |
[Ascorbic Acid co-treated with Arsenic Trioxide] results in decreased expression of ENO1 protein; Arsenic Trioxide promotes the reaction [Ascorbic Acid results in decreased expression of ENO1 mRNA]; Arsenic Trioxide promotes the reaction [Ascorbic Acid results in decreased expression of ENO1 protein]; Ascorbic Acid promotes the reaction [Arsenic Trioxide results in decreased expression of ENO1 mRNA]; Ascorbic Acid promotes the reaction [Arsenic Trioxide results in decreased expression of ENO1 protein] Ascorbic Acid results in decreased expression of ENO1 mRNA; Ascorbic Acid results in decreased expression of ENO1 protein |
CTD |
PMID:38160894 |
|
NCBI chr 5:160,719,951...160,731,337
Ensembl chr 5:160,719,951...160,731,336
|
|
G |
Epas1 |
endothelial PAS domain protein 1 |
multiple interactions |
ISO |
Ascorbic Acid inhibits the reaction [nickel sulfate results in increased expression of EPAS1 protein] |
CTD |
PMID:16288478 |
|
NCBI chr 6:7,790,236...7,871,717
Ensembl chr 6:7,790,647...7,871,228
|
|
G |
Ephx1 |
epoxide hydrolase 1 |
multiple interactions |
ISO |
[Quercetin co-treated with Ascorbic Acid] results in decreased expression of EPHX1 mRNA |
CTD |
PMID:17639512 |
|
NCBI chr13:92,714,315...92,744,105
Ensembl chr13:92,714,315...92,790,235
|
|
G |
Ephx2 |
epoxide hydrolase 2 |
multiple interactions |
ISO |
[Quercetin co-treated with Ascorbic Acid] results in decreased expression of EPHX2 mRNA |
CTD |
PMID:17639512 |
|
NCBI chr15:40,289,901...40,327,632
Ensembl chr15:40,289,902...40,327,615
|
|
G |
Eprs1 |
glutamyl-prolyl-tRNA synthetase 1 |
decreases expression |
ISO |
Ascorbic Acid results in decreased expression of EPRS1 mRNA |
CTD |
PMID:19197388 |
|
NCBI chr13:96,901,548...96,971,966
Ensembl chr13:96,901,575...96,971,966
|
|
G |
Ercc2 |
ERCC excision repair 2, TFIIH core complex helicase subunit |
multiple interactions |
ISO |
[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of ERCC2 mRNA |
CTD |
PMID:17917374 |
|
NCBI chr 1:79,033,342...79,047,102
Ensembl chr 1:79,033,326...79,047,102
|
|
G |
Ercc4 |
ERCC excision repair 4, endonuclease catalytic subunit |
multiple interactions |
ISO |
[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of ERCC4 mRNA |
CTD |
PMID:17917374 |
|
NCBI chr10:2,416,259...2,448,364
Ensembl chr10:2,419,038...2,448,369
|
|
G |
Ercc5 |
ERCC excision repair 5, endonuclease |
multiple interactions |
ISO |
[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of ERCC5 mRNA |
CTD |
PMID:17917374 |
|
NCBI chr 9:46,309,477...46,354,478
Ensembl chr 9:46,309,389...46,354,472
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
EXP |
Ascorbic Acid inhibits the reaction [chromium hexavalent ion results in decreased expression of ESR1 mRNA] |
CTD |
PMID:18602937 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
EXP |
Ascorbic Acid inhibits the reaction [chromium hexavalent ion results in decreased expression of ESR2 mRNA] |
CTD |
PMID:18602937 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Ezh1 |
enhancer of zeste 1 polycomb repressive complex 2 subunit |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of EZH1 mRNA |
CTD |
PMID:26424790 |
|
NCBI chr10:86,126,023...86,162,001
Ensembl chr10:86,126,015...86,161,921
|
|
G |
Ezh2 |
enhancer of zeste 2 polycomb repressive complex 2 subunit |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of EZH2 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of EZH2 protein; EZH2 protein inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of ALPL mRNA]; EZH2 protein inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of RUNX2 mRNA]; EZH2 protein inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of SATB2 mRNA]; EZH2 protein inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of TNFRSF11B mRNA] |
CTD |
PMID:26424790 |
|
NCBI chr 4:76,624,399...76,687,362
Ensembl chr 4:76,624,399...76,687,362
|
|
G |
F3 |
coagulation factor III, tissue factor |
multiple interactions |
ISO |
Ascorbic Acid inhibits the reaction [Norepinephrine results in increased expression of F3 mRNA] |
CTD |
PMID:23114885 |
|
NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
|
|
G |
Fabp1 |
fatty acid binding protein 1 |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FABP1 mRNA |
CTD |
PMID:34480604 |
|
NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with Firemaster 550] results in increased expression of FABP4 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with triphenyl phosphate] results in increased expression of FABP4 mRNA; d,d-T80-prallethrin promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA]; Pioglitazone promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA]; Rosiglitazone promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA]; tetrabromobisphenol A promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA]; triphenyltin hydroxide promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA] |
CTD |
PMID:25062436 PMID:25932594 PMID:32473317 |
|
NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Fabp6 |
fatty acid binding protein 6 |
multiple interactions |
ISO |
[Quercetin co-treated with Ascorbic Acid] results in decreased expression of FABP6 mRNA |
CTD |
PMID:17639512 |
|
NCBI chr10:28,063,603...28,068,276
Ensembl chr10:28,063,603...28,068,282
|
|
G |
Fah |
fumarylacetoacetate hydrolase |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FAH mRNA |
CTD |
PMID:34480604 |
|
NCBI chr 1:138,548,830...138,571,599
Ensembl chr 1:138,548,834...138,571,505
|
|
G |
Fancl |
FA complementation group L |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of FANCL mRNA |
CTD |
PMID:26424790 |
|
NCBI chr14:100,249,733...100,317,958
Ensembl chr14:100,248,875...100,314,255
|
|
G |
Fat1 |
FAT atypical cadherin 1 |
multiple interactions increases expression |
ISO |
[arsenic trioxide co-treated with Ascorbic Acid] results in increased expression of FAT1 mRNA Ascorbic Acid results in increased expression of FAT1 mRNA |
CTD |
PMID:25555879 |
|
NCBI chr16:47,177,253...47,296,261
Ensembl chr16:47,177,248...47,296,107
|
|
G |
Fbln1 |
fibulin 1 |
increases expression multiple interactions |
ISO |
Ascorbic Acid results in increased expression of FBLN1 mRNA [arsenic trioxide co-treated with Ascorbic Acid] results in increased expression of FBLN1 mRNA |
CTD |
PMID:25555879 |
|
NCBI chr 7:116,310,582...116,390,075
Ensembl chr 7:116,310,582...116,390,075
|
|
G |
Fbp1 |
fructose-bisphosphatase 1 |
affects expression |
ISO |
Ascorbic Acid affects the expression of FBP1 protein |
CTD |
PMID:19224539 |
|
NCBI chr17:2,207,271...2,230,076
Ensembl chr17:2,208,031...2,230,071
|
|
G |
Fbxo32 |
F-box protein 32 |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FBXO32 mRNA |
CTD |
PMID:34480604 |
|
NCBI chr 7:89,731,428...89,764,997
Ensembl chr 7:89,730,232...89,765,436
|
|
G |
Fdxr |
ferredoxin reductase |
increases expression |
EXP |
Ascorbic Acid results in increased expression of FDXR mRNA |
CTD |
PMID:15372504 |
|
NCBI chr10:100,507,863...100,516,649
Ensembl chr10:100,507,865...100,516,658
|
|
G |
Fgb |
fibrinogen beta chain |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FGB mRNA |
CTD |
PMID:34480604 |
|
NCBI chr 2:168,394,901...168,402,863
Ensembl chr 2:168,394,916...168,405,979
|
|
G |
Fgf1 |
fibroblast growth factor 1 |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ABCC1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ACTN2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ALDOA mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ASCL1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of CDC20 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of CYP24A1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of DCX mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ECSCR mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ELAVL3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ELAVL4 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of EMX2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ESRG mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FAH mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FLT1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FOXD3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FOXG1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of GSTP1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of H2BC14 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of HES5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of KEAP1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of LCK mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of MAFG mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of OLIG2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of OTX2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of POU5F1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SFRP2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SH3BP5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SOX1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SOX2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SPTSSB mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SRXN1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of STMN2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of A2M mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ACSL5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of AFP mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ALB mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of AMHR2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ANXA1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of APOA1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of BMP5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CDH10 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CEACAM6 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CIDEC mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of COL3A1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CRYAB mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CYP26B1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CYP3A5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DCC mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DCN mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DHRS9 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DNAJB1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of EBF3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of EGLN3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FABP1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FBXO32 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FGB mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FGF7 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FGG mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FLRT3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GADD45A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GATA6 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GCLM mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GPR183 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GPX2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GRIA2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GRIA3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GSTA1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GSTA2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GSTO1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GUCY1A1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HAND2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HAVCR1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HMGCS2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXA2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXB3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXD4 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXD8 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HSD3B1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of IGFBP7 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of IGHV3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of IL1R1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ISL1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of KRT6A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of LEF1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of LUM mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MLIP mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MMP1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MPZL1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MYL4 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of NQO1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of NR2F1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of NR2F2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of PDE1A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of PLN mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of RBM20 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of RRAD mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SCARB1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SCN2A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SEMA3C mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SERPINA1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SLCO2B1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SQSTM1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TBX2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TF mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TFAP2A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TM4SF4 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TTR mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TXNRD1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of UGT2A3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of VCAM1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of VGLL1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of VTN mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ZFAND2A mRNA |
CTD |
PMID:34480604 |
|
NCBI chr18:30,686,555...30,772,667
Ensembl chr18:30,686,581...30,772,357
|
|
G |
Fgf7 |
fibroblast growth factor 7 |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FGF7 mRNA |
CTD |
PMID:34480604 |
|
NCBI chr 3:113,280,448...113,333,279
Ensembl chr 3:113,281,283...113,332,929
|
|
G |
Fgg |
fibrinogen gamma chain |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FGG mRNA |
CTD |
PMID:34480604 |
|
NCBI chr 2:168,354,880...168,362,325
Ensembl chr 2:168,355,013...168,362,322
|
|
G |
Flrt3 |
fibronectin leucine rich transmembrane protein 3 |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FLRT3 mRNA |
CTD |
PMID:34480604 |
|
NCBI chr 3:127,994,491...128,008,137
Ensembl chr 3:127,994,226...128,007,841
|
|
G |
Flt1 |
Fms related receptor tyrosine kinase 1 |
decreases expression multiple interactions |
ISO |
Ascorbic Acid results in decreased expression of FLT1 mRNA [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FLT1 mRNA |
CTD |
PMID:21919647 PMID:34480604 |
|
NCBI chr12:7,296,899...7,468,626
Ensembl chr12:7,297,292...7,468,626
|
|
G |
Fmo1 |
flavin containing dimethylaniline monoxygenase 1 |
multiple interactions |
ISO |
[Quercetin co-treated with Ascorbic Acid] results in decreased expression of FMO1 mRNA |
CTD |
PMID:17639512 |
|
NCBI chr13:75,182,184...75,214,439
Ensembl chr13:75,182,176...75,214,647
|
|
G |
Fmo5 |
flavin containing dimethylaniline monoxygenase 5 |
multiple interactions |
ISO |
[Quercetin co-treated with Ascorbic Acid] results in decreased expression of FMO5 mRNA |
CTD |
PMID:17639512 |
|
NCBI chr 2:185,197,184...185,249,699
Ensembl chr 2:185,222,204...185,249,693
|
|
G |
Fmr1 |
fragile X messenger ribonucleoprotein 1 |
multiple interactions |
ISO |
Ascorbic Acid inhibits the reaction [FMR1 5' UTR mutant form results in decreased activity of CS protein] |
CTD |
PMID:27385396 |
|
NCBI chr X:147,240,239...147,278,057
Ensembl chr X:147,240,301...147,278,050
|
|
G |
Fn1 |
fibronectin 1 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with Quartz] results in increased expression of FN1 mRNA; [Tretinoin co-treated with Ascorbic Acid] results in increased expression of FN1 mRNA |
CTD |
PMID:16443354 PMID:27381660 |
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Fn3krp |
fructosamine-3-kinase-related protein |
increases expression |
ISO |
Ascorbic Acid results in increased expression of FN3KRP mRNA |
CTD |
PMID:25555879 |
|
NCBI chr10:106,688,413...106,697,137
Ensembl chr10:106,688,439...106,697,134
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
Ascorbic Acid results in increased expression of FOS mRNA |
CTD |
PMID:15305145 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Foxa2 |
forkhead box A2 |
multiple interactions |
EXP |
Ascorbic Acid inhibits the reaction [nitrofen results in decreased expression of FOXA2 protein] |
CTD |
PMID:16863852 |
|
NCBI chr 3:135,470,123...135,474,326
Ensembl chr 3:135,470,131...135,474,326
|
|
G |
Foxd3 |
forkhead box D3 |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FOXD3 mRNA |
CTD |
PMID:34480604 |
|
NCBI chr 5:114,335,084...114,337,450
Ensembl chr 5:114,335,408...114,336,817
|
|
G |
Foxg1 |
forkhead box G1 |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FOXG1 mRNA |
CTD |
PMID:34480604 |
|
NCBI chr 6:66,674,797...66,677,611
Ensembl chr 6:66,666,587...66,678,607
|
|
G |
Foxj1 |
forkhead box J1 |
multiple interactions increases expression |
ISO EXP |
[Tretinoin co-treated with Ascorbic Acid] results in increased expression of FOXJ1 mRNA Ascorbic Acid results in increased expression of FOXJ1 mRNA |
CTD |
PMID:15372504 PMID:16443354 |
|
NCBI chr10:101,566,299...101,570,370
Ensembl chr10:101,566,304...101,570,237
|
|
G |
Foxm1 |
forkhead box M1 |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FOXM1 mRNA |
CTD |
PMID:33713149 |
|
NCBI chr 4:161,639,538...161,652,012
Ensembl chr 4:161,638,816...161,650,684
|
|
G |
Foxo3 |
forkhead box O3 |
multiple interactions affects localization increases expression |
ISO |
Ascorbic Acid results in increased expression of and results in decreased phosphorylation of FOXO3 protein; FOXO3 protein affects the reaction [Ascorbic Acid results in decreased expression of PCSK9 protein]; FOXO3 protein affects the reaction [Ascorbic Acid results in increased expression of LDLR protein] Ascorbic Acid affects the localization of FOXO3 protein Ascorbic Acid results in increased expression of FOXO3 mRNA |
CTD |
PMID:32913121 |
|
NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
multiple interactions |
EXP |
Ascorbic Acid inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of FSHB protein]; Ascorbic Acid inhibits the reaction [chromium hexavalent ion results in increased expression of FSHB protein]; Ascorbic Acid inhibits the reaction [Potassium Dichromate results in increased expression of FSHB protein] |
CTD |
PMID:16248992 PMID:17280759 PMID:18602937 PMID:23470461 |
|
NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370
|
|
G |
Fshr |
follicle stimulating hormone receptor |
multiple interactions |
EXP |
Ascorbic Acid inhibits the reaction [chromium hexavalent ion results in decreased expression of FSHR mRNA]; Ascorbic Acid inhibits the reaction [Potassium Dichromate results in decreased expression of FSHR mRNA]; Ascorbic Acid inhibits the reaction [Potassium Dichromate results in decreased expression of FSHR protein] |
CTD |
PMID:18602937 PMID:23470461 |
|
NCBI chr 6:5,198,825...5,406,785
Ensembl chr 6:5,198,825...5,406,785
|
|
G |
Fth1 |
ferritin heavy chain 1 |
increases expression |
EXP |
Ascorbic Acid results in increased expression of FTH1 mRNA |
CTD |
PMID:15372504 |
|
NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424
|
|
G |
Ftl1 |
ferritin light chain 1 |
affects expression |
ISO |
Ascorbic Acid affects the expression of FTL protein |
CTD |
PMID:19224539 |
|
NCBI chr 1:95,936,387...95,938,234
Ensembl chr 1:95,936,387...95,939,725 Ensembl chr10:95,936,387...95,939,725
|
|
G |
Fyn |
FYN proto-oncogene, Src family tyrosine kinase |
multiple interactions |
ISO |
Ascorbic Acid inhibits the reaction [bis(2-hydroxy-2-ethylbutanoato)oxochromate(V) results in increased phosphorylation of FYN protein]; Ascorbic Acid inhibits the reaction [Potassium Dichromate results in increased phosphorylation of FYN protein] |
CTD |
PMID:14572611 |
|
NCBI chr20:42,767,733...42,960,903
Ensembl chr20:42,766,369...42,959,911
|
|
G |
Fzd10 |
frizzled class receptor 10 |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FZD10 mRNA |
CTD |
PMID:33713149 |
|
NCBI chr12:28,098,371...28,101,566
Ensembl chr12:28,098,371...28,101,566
|
|
G |
Fzd2 |
frizzled class receptor 2 |
multiple interactions |
ISO |
[Quercetin co-treated with Ascorbic Acid] results in increased expression of FZD2 mRNA |
CTD |
PMID:17639512 |
|
NCBI chr10:87,561,866...87,563,776
Ensembl chr10:87,561,326...87,565,334
|
|
G |
G0s2 |
G0/G1switch 2 |
multiple interactions |
ISO |
[Quercetin co-treated with Ascorbic Acid] results in decreased expression of G0S2 mRNA |
CTD |
PMID:17639512 |
|
NCBI chr13:104,806,351...104,807,263
Ensembl chr13:104,806,156...104,807,451
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
multiple interactions |
ISO |
Ascorbic Acid inhibits the reaction [Cadmium Chloride results in decreased activity of G6PD protein] |
CTD |
PMID:18548748 |
|
NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801
|
|
G |
Gabarap |
GABA type A receptor-associated protein |
increases expression |
ISO |
Ascorbic Acid results in increased expression of GABARAP mRNA |
CTD |
PMID:15305145 |
|
NCBI chr10:54,714,777...54,718,099
Ensembl chr10:54,714,198...54,717,765
|
|
G |
Gabra2 |
gamma-aminobutyric acid type A receptor subunit alpha 2 |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GABRA2 mRNA |
CTD |
PMID:33713149 |
|
NCBI chr14:37,097,251...37,230,030
Ensembl chr14:37,097,279...37,228,944
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GADD45A mRNA |
CTD |
PMID:34480604 |
|
NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115
|
|
G |
Gadd45b |
growth arrest and DNA-damage-inducible, beta |
multiple interactions |
EXP |
[Ascorbic Acid co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of GADD45B mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 7:8,778,004...8,780,306
Ensembl chr 7:8,778,007...8,780,046
|
|
G |
Gak |
cyclin G associated kinase |
multiple interactions |
ISO |
[Tretinoin co-treated with Ascorbic Acid] results in decreased expression of GAK mRNA |
CTD |
PMID:16443354 |
|
NCBI chr14:1,089,853...1,164,098
Ensembl chr14:1,089,866...1,216,398
|
|
G |
Gal |
galanin and GMAP prepropeptide |
multiple interactions |
EXP |
[ferulic acid co-treated with Ascorbic Acid] inhibits the reaction [Isoproterenol results in increased activity of GAL protein] |
CTD |
PMID:17045618 |
|
NCBI chr 1:200,650,439...200,655,302
Ensembl chr 1:200,650,439...200,654,959
|
|
G |
Gamt |
guanidinoacetate N-methyltransferase |
affects expression |
ISO |
Ascorbic Acid affects the expression of GAMT protein |
CTD |
PMID:19224539 |
|
NCBI chr 7:9,448,590...9,451,413
Ensembl chr 7:9,448,628...9,451,778
|
|
G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
increases expression decreases expression multiple interactions |
ISO |
Ascorbic Acid results in increased expression of GAPDH protein Ascorbic Acid results in decreased expression of GAPDH mRNA; Ascorbic Acid results in decreased expression of GAPDH protein [Ascorbic Acid co-treated with Arsenic Trioxide] results in decreased expression of GAPDH protein; Arsenic Trioxide promotes the reaction [Ascorbic Acid results in decreased expression of GAPDH mRNA]; Ascorbic Acid promotes the reaction [Arsenic Trioxide results in decreased expression of GAPDH mRNA]; Ascorbic Acid promotes the reaction [Arsenic Trioxide results in decreased expression of GAPDH protein] |
CTD |
PMID:22139585 PMID:38160894 |
|
NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235
|
|
G |
Gars1 |
glycyl-tRNA synthetase 1 |
decreases expression |
ISO |
Ascorbic Acid results in decreased expression of GARS1 mRNA |
CTD |
PMID:19197388 |
|
NCBI chr 4:84,171,596...84,212,609
Ensembl chr 4:84,171,596...84,212,609
|
|
G |
Gas7 |
growth arrest specific 7 |
increases expression |
ISO |
Ascorbic Acid results in increased expression of GAS7 mRNA |
CTD |
PMID:15305145 |
|
NCBI chr10:52,152,718...52,383,283
Ensembl chr10:52,152,493...52,383,276
|
|
G |
Gata1 |
GATA binding protein 1 |
multiple interactions |
ISO |
[Tretinoin co-treated with Ascorbic Acid] results in increased expression of GATA1 mRNA |
CTD |
PMID:16443354 |
|
NCBI chr X:14,529,706...14,537,530
Ensembl chr X:14,529,702...14,537,530
|
|
G |
Gata4 |
GATA binding protein 4 |
increases expression |
ISO |
Ascorbic Acid results in increased expression of GATA4 mRNA |
CTD |
PMID:12668514 |
|
NCBI chr15:37,459,601...37,531,291
Ensembl chr15:37,459,601...37,505,636
|
|
G |
Gata6 |
GATA binding protein 6 |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GATA6 mRNA |
CTD |
PMID:34480604 |
|
NCBI chr18:2,188,121...2,219,532
Ensembl chr18:2,188,121...2,219,532
|
|
G |
Gbp2 |
guanylate binding protein 2 |
increases expression |
EXP |
Ascorbic Acid results in increased expression of GBP2 mRNA |
CTD |
PMID:15372504 |
|
NCBI chr 2:231,332,488...231,348,573
Ensembl chr 2:231,332,284...231,348,571
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions |
EXP |
[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of GCLC mRNA; Ascorbic Acid inhibits the reaction [Ethylene Chlorohydrin results in increased expression of GCLC mRNA]; Ascorbic Acid inhibits the reaction [Ethylene Chlorohydrin results in increased expression of GCLC protein]; Hydrogen Peroxide affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of GCLC mRNA]; Quercetin affects the reaction [Hydrogen Peroxide affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of GCLC mRNA]] |
CTD |
PMID:27028516 PMID:31585129 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GCLM mRNA |
CTD |
PMID:34480604 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gdf10 |
growth differentiation factor 10 |
multiple interactions |
EXP |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of GDF10 mRNA |
CTD |
PMID:15994055 |
|
NCBI chr16:9,237,182...9,250,537
Ensembl chr16:9,237,261...9,249,343
|
|
G |
Gdnf |
glial cell derived neurotrophic factor |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of E2F2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FOXM1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FZD10 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of GLI1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HES3 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HOXB1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of INHBE mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of LEF1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of TERT mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of CNTN1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of DLG4 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GABRA2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GFAP mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIA2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2A mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2B mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of MAP2 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SCN2A mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A6 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A7 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SYN mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SYN protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of TUBB3 protein |
CTD |
PMID:33713149 |
|
NCBI chr 2:56,894,022...56,919,935
Ensembl chr 2:56,895,010...56,917,209
|
|
G |
Gfap |
glial fibrillary acidic protein |
decreases expression multiple interactions |
EXP ISO |
Ascorbic Acid results in decreased expression of GFAP protein [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GFAP mRNA Ascorbic Acid inhibits the reaction [Vincristine results in increased expression of GFAP protein] |
CTD |
PMID:15372504 PMID:33713149 PMID:34286406 |
|
NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
|
|
G |
Gfra1 |
GDNF family receptor alpha 1 |
multiple interactions |
ISO |
[Tretinoin co-treated with Ascorbic Acid] results in increased expression of GFRA1 mRNA |
CTD |
PMID:16443354 |
|
NCBI chr 1:257,315,682...257,552,004
Ensembl chr 1:257,321,742...257,551,473
|
|
G |
Ggt1 |
gamma-glutamyltransferase 1 |
multiple interactions |
EXP |
Ascorbic Acid inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased activity of GGT1 protein] |
CTD |
PMID:16298753 |
|
NCBI chr20:13,074,695...13,104,095
Ensembl chr20:13,074,700...13,108,442
|
|
G |
Gh1 |
growth hormone 1 |
multiple interactions |
EXP |
Ascorbic Acid inhibits the reaction [chromium hexavalent ion results in decreased expression of GH1 protein] |
CTD |
PMID:18602937 |
|
NCBI chr10:91,228,102...91,230,079
Ensembl chr10:91,228,103...91,230,078
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
multiple interactions |
EXP ISO |
[Ascorbic Acid co-treated with Vitamin E] inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of GJA1 protein]; [Ascorbic Acid co-treated with Vitamin E] inhibits the reaction [mono-(2-ethylhexyl)phthalate results in decreased expression of GJA1 protein] Ascorbic Acid inhibits the reaction [Vincristine results in increased expression of GJA1 mRNA]; Ascorbic Acid inhibits the reaction [Vincristine results in increased expression of GJA1 protein] |
CTD |
PMID:29940330 PMID:34286406 |
|
NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582
|
|
G |
Gli1 |
GLI family zinc finger 1 |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of GLI1 mRNA |
CTD |
PMID:33713149 |
|
NCBI chr 7:63,156,926...63,169,579
Ensembl chr 7:63,156,926...63,169,251
|
|
G |
Glo1 |
glyoxalase 1 |
affects expression |
ISO |
Ascorbic Acid affects the expression of GLO1 protein |
CTD |
PMID:19224539 |
|
NCBI chr20:8,663,617...8,681,661
Ensembl chr20:8,662,801...8,681,649
|
|
G |
Glrx |
glutaredoxin |
multiple interactions |
EXP |
Ascorbic Acid inhibits the reaction [Potassium Dichromate results in decreased expression of GLRX mRNA] |
CTD |
PMID:23470461 |
|
NCBI chr 2:5,341,873...5,351,686
Ensembl chr 2:5,341,885...5,351,680
|
|
G |
Gls |
glutaminase |
multiple interactions |
ISO |
[Quercetin co-treated with Ascorbic Acid] results in decreased expression of GLS mRNA |
CTD |
PMID:17639512 |
|
NCBI chr 9:49,344,616...49,416,900
Ensembl chr 9:49,344,781...49,416,900
|
|
G |
Gng3 |
G protein subunit gamma 3 |
increases expression |
ISO |
Ascorbic Acid results in increased expression of GNG3 mRNA |
CTD |
PMID:15305145 |
|
NCBI chr 1:205,731,837...205,733,603
Ensembl chr 1:205,731,837...205,733,603
|
|
G |
Gng4 |
G protein subunit gamma 4 |
increases expression |
ISO |
Ascorbic Acid results in increased expression of GNG4 mRNA |
CTD |
PMID:15305145 |
|
NCBI chr17:86,448,708...86,497,560
Ensembl chr17:86,449,022...86,495,254
|
|
G |
Got1 |
glutamic-oxaloacetic transaminase 1 |
multiple interactions |
EXP |
Ascorbic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of GOT1 protein] |
CTD |
PMID:30676168 |
|
NCBI chr 1:242,357,293...242,381,535
Ensembl chr 1:242,357,306...242,380,633
|
|
G |
Gpat3 |
glycerol-3-phosphate acyltransferase 3 |
increases expression |
ISO |
Ascorbic Acid results in increased expression of GPAT3 mRNA |
CTD |
PMID:26198647 |
|
NCBI chr14:8,715,367...8,768,051
Ensembl chr14:8,714,373...8,766,490
|
|
G |
Gpc1 |
glypican 1 |
multiple interactions increases degradation increases expression |
ISO |
[Ascorbic Acid co-treated with Nitric Oxide] results in increased degradation of GPC1 protein modified form; Zinc promotes the reaction [[Ascorbic Acid co-treated with Nitric Oxide] results in increased degradation of GPC1 protein modified form] Ascorbic Acid results in increased degradation of GPC1 protein Ascorbic Acid results in increased expression of GPC1 mRNA |
CTD |
PMID:15677459 PMID:21642435 PMID:25555879 |
|
NCBI chr 9:93,396,234...93,424,047
Ensembl chr 9:93,396,234...93,424,047
|
|
G |
Gpc3 |
glypican 3 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of GPC3 mRNA; cadmium sulfate inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of GPC3 mRNA] |
CTD |
PMID:28189605 |
|
NCBI chr X:131,868,986...132,236,824
Ensembl chr X:131,868,990...132,236,798
|
|
G |
Gpd1 |
glycerol-3-phosphate dehydrogenase 1 |
multiple interactions |
EXP |
[Ascorbic Acid co-treated with INS1 protein] results in decreased expression of GPD1 mRNA |
CTD |
PMID:20400526 |
|
NCBI chr 7:130,842,526...130,851,530
Ensembl chr 7:130,844,138...130,851,529
|
|
G |
Gpn1 |
GPN-loop GTPase 1 |
multiple interactions decreases expression |
ISO |
[arsenic trioxide co-treated with Ascorbic Acid] results in decreased expression of GPN1 mRNA Ascorbic Acid results in decreased expression of GPN1 mRNA |
CTD |
PMID:25555879 |
|
NCBI chr 6:24,947,350...24,965,025
Ensembl chr 6:24,947,325...24,965,031
|
|
G |
Gpr183 |
G protein-coupled receptor 183 |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GPR183 mRNA |
CTD |
PMID:34480604 |
|
NCBI chr15:99,037,764...99,050,550
Ensembl chr15:99,036,367...99,050,559
|
|
G |
Gpr55 |
G protein-coupled receptor 55 |
multiple interactions |
ISO |
Ascorbic Acid inhibits the reaction [Hydrogen Peroxide results in increased expression of GPR55 protein] |
CTD |
PMID:28285367 |
|
NCBI chr 9:86,584,906...86,640,601
Ensembl chr 9:86,590,885...86,640,613
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP ISO |
Ascorbic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of GPT protein]; Ascorbic Acid inhibits the reaction [Cyclosporine results in increased activity of GPT protein]; Ascorbic Acid inhibits the reaction [Food Additives results in increased activity of GPT protein] Ascorbic Acid inhibits the reaction [Diquat results in increased expression of GPT protein] |
CTD |
PMID:16758767 PMID:19391111 PMID:30676168 PMID:33475796 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions increases expression |
ISO EXP |
[Ascorbic Acid co-treated with Vitamin E] results in increased expression of GPX1 mRNA; [Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of GPX1 mRNA; [Vitamin A co-treated with Ascorbic Acid co-treated with Vitamin E] results in increased expression of GPX1 protein; Ascorbic Acid inhibits the reaction [[lead acetate results in increased abundance of Lead] which results in decreased expression of GPX1 mRNA]; nutlin 3 inhibits the reaction [[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of GPX1 mRNA] [Ascorbic Acid co-treated with Vitamin E] inhibits the reaction [Diethylhexyl Phthalate results in increased expression of GPX1 protein]; Ascorbic Acid inhibits the reaction [Carbon Tetrachloride results in decreased activity of GPX1 protein]; Ascorbic Acid inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased activity of GPX1 protein] Ascorbic Acid results in increased expression of GPX1 mRNA |
CTD |
PMID:15372504 PMID:16248992 PMID:16298753 PMID:17179735 PMID:20530418 PMID:22207723 PMID:29663635 PMID:30676168 PMID:31576639 PMID:31610155 More...
|
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GPX2 mRNA; [Quercetin co-treated with Ascorbic Acid] results in increased expression of GPX2 mRNA; [Tretinoin co-treated with Ascorbic Acid] results in increased expression of GPX2 mRNA |
CTD |
PMID:16443354 PMID:17639512 PMID:34480604 |
|
NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877
|
|
G |
Gpx4 |
glutathione peroxidase 4 |
increases expression |
EXP |
Ascorbic Acid results in increased expression of GPX4 mRNA |
CTD |
PMID:15372504 |
|
NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982
|
|
G |
Gria1 |
glutamate ionotropic receptor AMPA type subunit 1 |
increases expression |
ISO |
Ascorbic Acid results in increased expression of GRIA1 protein |
CTD |
PMID:33872575 |
|
NCBI chr10:41,210,713...41,527,283
Ensembl chr10:41,210,713...41,527,283
|
|
G |
Gria2 |
glutamate ionotropic receptor AMPA type subunit 2 |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GRIA2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIA2 mRNA |
CTD |
PMID:33713149 PMID:34480604 |
|
NCBI chr 2:165,949,379...166,069,510
Ensembl chr 2:165,947,521...166,069,510
|
|
G |
Gria3 |
glutamate ionotropic receptor AMPA type subunit 3 |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GRIA3 mRNA |
CTD |
PMID:34480604 |
|
NCBI chr X:120,238,515...120,504,106
Ensembl chr X:120,238,534...120,504,096
|
|
G |
Grin1 |
glutamate ionotropic receptor NMDA type subunit 1 |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN1 mRNA |
CTD |
PMID:33713149 |
|
NCBI chr 3:8,103,680...8,130,603
Ensembl chr 3:8,103,680...8,130,603
|
|
G |
Grin2a |
glutamate ionotropic receptor NMDA type subunit 2A |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2A mRNA |
CTD |
PMID:33713149 |
|
NCBI chr10:5,629,683...6,053,262
Ensembl chr10:5,631,369...6,044,637
|
|
G |
Grin2b |
glutamate ionotropic receptor NMDA type subunit 2B |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2B mRNA |
CTD |
PMID:33713149 |
|
NCBI chr 4:168,580,824...169,044,110
Ensembl chr 4:168,599,546...169,042,279
|
|
G |
Grn |
granulin precursor |
increases expression multiple interactions |
ISO |
Ascorbic Acid results in increased expression of GRN mRNA [arsenic trioxide co-treated with Ascorbic Acid] results in increased expression of GRN mRNA |
CTD |
PMID:25555879 |
|
NCBI chr10:87,387,672...87,393,777
Ensembl chr10:87,387,638...87,393,775
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
decreases expression multiple interactions |
EXP |
Ascorbic Acid results in decreased expression of GSK3B mRNA Ascorbic Acid inhibits the reaction [Excitatory Amino Acid Agonists results in increased phosphorylation of GSK3B protein] |
CTD |
PMID:15372504 PMID:24675465 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
ISO EXP |
[Ascorbic Acid co-treated with GSR protein] affects the metabolism of Glucose; [juglone co-treated with Ascorbic Acid] results in decreased activity of GSR protein; Ascorbic Acid inhibits the reaction [Hydrogen Peroxide results in increased activity of GSR protein] [Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of GSR mRNA; Ascorbic Acid inhibits the reaction [arsenic trioxide results in decreased activity of GSR protein]; Ascorbic Acid inhibits the reaction [Cadmium Chloride results in decreased activity of GSR protein] Ascorbic Acid inhibits the reaction [[lead acetate results in increased abundance of Lead] which results in decreased activity of GSR protein]; Ascorbic Acid inhibits the reaction [bisphenol A results in decreased activity of GSR protein]; Ascorbic Acid inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased activity of GSR protein]; Ascorbic Acid inhibits the reaction [Cyclosporine results in decreased activity of GSR protein]; Ascorbic Acid inhibits the reaction [Potassium Dichromate results in decreased activity of GSR protein]; Ascorbic Acid inhibits the reaction [Potassium Dichromate results in decreased expression of GSR mRNA]; Ascorbic Acid inhibits the reaction [sodium arsenite results in decreased activity of GSR protein]; Ascorbic Acid inhibits the reaction [sodium arsenite results in decreased expression of GSR protein] |
CTD |
PMID:1901343 PMID:12767684 PMID:16248992 PMID:16298753 PMID:17917374 PMID:18548748 PMID:18715643 PMID:19391111 PMID:19429265 PMID:23194016 PMID:23470461 PMID:28285367 PMID:29992683 PMID:32407874 More...
|
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GSTA1 mRNA; [Quercetin co-treated with Ascorbic Acid] results in decreased expression of GSTA1 mRNA |
CTD |
PMID:17639512 PMID:34480604 |
|
NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121
|
|
G |
Gsta2 |
glutathione S-transferase alpha 2 |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GSTA2 mRNA |
CTD |
PMID:34480604 |
|
NCBI chr 8:79,184,535...79,196,827
Ensembl chr 8:79,184,322...79,196,798
|
|
G |
Gsta4 |
glutathione S-transferase alpha 4 |
multiple interactions |
EXP |
Ascorbic Acid inhibits the reaction [Potassium Dichromate results in decreased expression of GSTA4 mRNA] |
CTD |
PMID:23470461 |
|
NCBI chr 8:79,066,967...79,084,193
Ensembl chr 8:79,066,934...79,084,182
|
|
G |
Gsta5 |
glutathione S-transferase alpha 5 |
multiple interactions |
ISO |
Ascorbic Acid promotes the reaction [sodium arsenite results in increased expression of GSTA1 mRNA] |
CTD |
PMID:16517059 |
|
NCBI chr 8:79,105,561...79,117,472
Ensembl chr 8:79,105,661...79,117,472
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
affects response to substance multiple interactions |
ISO EXP |
GSTM1 affects the susceptibility to Ascorbic Acid deficiency GSTM1 gene polymorphism affects the susceptibility to [Ascorbic Acid co-treated with tocotrienol, alpha] Ascorbic Acid inhibits the reaction [chromium hexavalent ion results in decreased expression of GSTM1 mRNA]; Ascorbic Acid inhibits the reaction [Potassium Dichromate results in decreased expression of GSTM1 mRNA] |
CTD |
PMID:15668500 PMID:19710200 PMID:23470461 |
|
NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411
|
|
G |
Gstm2 |
glutathione S-transferase mu 2 |
multiple interactions increases expression |
EXP |
Ascorbic Acid inhibits the reaction [Potassium Dichromate results in decreased expression of GSTM2 mRNA] Ascorbic Acid results in increased expression of GSTM2 mRNA |
CTD |
PMID:15372504 PMID:23470461 |
|
NCBI chr 2:195,624,015...195,628,774
Ensembl chr 2:195,544,426...195,628,961
|
|
G |
Gsto1 |
glutathione S-transferase omega 1 |
increases expression multiple interactions |
ISO |
Ascorbic Acid results in increased expression of GSTO1 mRNA [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GSTO1 mRNA; Ascorbic Acid inhibits the reaction [[lead acetate results in increased abundance of Lead] which results in decreased expression of GSTO1 mRNA] |
CTD |
PMID:31610155 PMID:34480604 |
|
NCBI chr 1:246,721,089...246,731,228
Ensembl chr 1:246,721,221...246,731,468
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of GSTP1 mRNA; Ascorbic Acid inhibits the reaction [sodium arsenite results in decreased expression of GSTP1 protein]; Ascorbic Acid inhibits the reaction [sodium arsenite results in increased methylation of GSTP1 promoter] |
CTD |
PMID:33388378 PMID:34480604 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Gstt1 |
glutathione S-transferase theta 1 |
affects response to substance |
ISO |
GSTT1 affects the susceptibility to Ascorbic Acid deficiency |
CTD |
PMID:19710200 |
|
NCBI chr20:12,856,613...12,873,586
Ensembl chr20:12,856,669...12,873,585
|
|
G |
Gtf2h1 |
general transcription factor IIH subunit 1 |
multiple interactions |
ISO |
[Quercetin co-treated with Ascorbic Acid] results in decreased expression of GTF2H1 mRNA |
CTD |
PMID:17639512 |
|
NCBI chr 1:97,321,417...97,349,455
Ensembl chr 1:97,321,394...97,349,455
|
|
G |
Gucy1a1 |
guanylate cyclase 1 soluble subunit alpha 1 |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GUCY1A1 mRNA |
CTD |
PMID:34480604 |
|
NCBI chr 2:167,418,615...167,482,293
Ensembl chr 2:167,418,640...167,481,671
|
|
G |
Gucy1b1 |
guanylate cyclase 1 soluble subunit beta 1 |
multiple interactions |
EXP |
Ascorbic Acid inhibits the reaction [lead acetate results in decreased expression of GUCY1B1 protein] |
CTD |
PMID:11729227 |
|
NCBI chr 2:167,348,824...167,398,983
Ensembl chr 2:167,348,825...167,398,916
|
|
G |
Gusb |
glucuronidase, beta |
multiple interactions |
EXP |
[ferulic acid co-treated with Ascorbic Acid] inhibits the reaction [Isoproterenol results in increased activity of GUSB protein] |
CTD |
PMID:17045618 |
|
NCBI chr12:26,701,188...26,714,718
Ensembl chr12:26,697,951...26,726,905
|
|
G |
Gzmb |
granzyme B |
decreases expression |
ISO |
Ascorbic Acid deficiency results in decreased expression of GZMB mRNA |
CTD |
PMID:22306178 |
|
NCBI chr15:30,343,352...30,346,814
Ensembl chr15:30,173,603...30,346,814
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of H2AX mRNA; [Ascorbic Acid results in increased reduction of Vitamin K 3] which results in increased phosphorylation of H2AX protein |
CTD |
PMID:19482829 PMID:26424790 |
|
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
|
|
G |
Hadha |
hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha |
decreases expression |
EXP |
Ascorbic Acid results in decreased expression of HADHA mRNA |
CTD |
PMID:15372504 |
|
NCBI chr 6:26,187,969...26,227,605
Ensembl chr 6:26,187,956...26,227,869
|
|
G |
Hand2 |
heart and neural crest derivatives expressed 2 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of HAND2 mRNA; cadmium sulfate inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of HAND2 mRNA] [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HAND2 mRNA |
CTD |
PMID:28189605 PMID:34480604 |
|
NCBI chr16:32,917,448...32,920,791
Ensembl chr16:32,917,823...32,919,891
|
|
G |
Havcr1 |
hepatitis A virus cellular receptor 1 |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HAVCR1 mRNA |
CTD |
PMID:34480604 |
|
NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698
|
|
G |
Hcfc1 |
host cell factor C1 |
multiple interactions increases expression |
ISO |
[arsenic trioxide co-treated with Ascorbic Acid] results in increased expression of HCFC1 mRNA Ascorbic Acid results in increased expression of HCFC1 mRNA |
CTD |
PMID:25555879 |
|
NCBI chr X:151,687,779...151,712,688
Ensembl chr X:151,687,779...151,712,638
|
|
G |
Hells |
helicase, lymphoid specific |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of HELLS mRNA |
CTD |
PMID:26424790 |
|
NCBI chr 1:236,701,704...236,748,239
Ensembl chr 1:236,701,758...236,746,844
|
|
G |
Heph |
hephaestin |
multiple interactions |
ISO |
[Quercetin co-treated with Ascorbic Acid] results in decreased expression of HEPH mRNA |
CTD |
PMID:17639512 |
|
NCBI chr X:61,151,131...61,402,980
Ensembl chr X:61,296,345...61,402,980
|
|
G |
Herpud1 |
homocysteine inducible ER protein with ubiquitin like domain 1 |
decreases expression |
ISO |
Ascorbic Acid results in decreased expression of HERPUD1 mRNA |
CTD |
PMID:19197388 |
|
NCBI chr19:10,598,411...10,609,002
Ensembl chr19:10,598,417...10,618,424
|
|
G |
Hes1 |
hes family bHLH transcription factor 1 |
multiple interactions |
EXP |
[Ascorbic Acid co-treated with Vitamin E] inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of HES1 protein] |
CTD |
PMID:29663635 |
|
NCBI chr11:70,705,763...70,708,176
Ensembl chr11:70,705,764...70,708,192
|
|
G |
Hes3 |
hes family bHLH transcription factor 3 |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HES3 mRNA |
CTD |
PMID:33713149 |
|
NCBI chr 5:162,793,611...162,799,578
Ensembl chr 5:162,794,367...162,796,261
|
|
G |
Hes5 |
hes family bHLH transcription factor 5 |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of HES5 mRNA |
CTD |
PMID:34480604 |
|
NCBI chr 5:165,522,138...165,523,684
Ensembl chr 5:165,522,234...165,523,001
|
|
G |
Hgf |
hepatocyte growth factor |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ABCC1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ACTN2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ALDOA mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ASCL1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of CDC20 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of CYP24A1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of DCX mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ECSCR mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ELAVL3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ELAVL4 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of EMX2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ESRG mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FAH mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FLT1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FOXD3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FOXG1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of GSTP1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of H2BC14 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of HES5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of KEAP1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of LCK mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of MAFG mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of OLIG2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of OTX2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of POU5F1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SFRP2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SH3BP5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SOX1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SOX2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SPTSSB mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SRXN1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of STMN2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of A2M mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ACSL5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of AFP mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ALB mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of AMHR2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ANXA1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of APOA1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of BMP5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CDH10 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CEACAM6 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CIDEC mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of COL3A1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CRYAB mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CYP26B1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CYP3A5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DCC mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DCN mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DHRS9 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DNAJB1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of EBF3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of EGLN3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FABP1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FBXO32 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FGB mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FGF7 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FGG mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FLRT3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GADD45A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GATA6 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GCLM mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GPR183 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GPX2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GRIA2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GRIA3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GSTA1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GSTA2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GSTO1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GUCY1A1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HAND2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HAVCR1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HMGCS2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXA2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXB3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXD4 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXD8 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HSD3B1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of IGFBP7 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of IGHV3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of IL1R1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ISL1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of KRT6A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of LEF1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of LUM mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MLIP mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MMP1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MPZL1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MYL4 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of NQO1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of NR2F1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of NR2F2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of PDE1A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of PLN mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of RBM20 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of RRAD mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SCARB1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SCN2A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SEMA3C mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SERPINA1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SLCO2B1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SQSTM1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TBX2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TF mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TFAP2A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TM4SF4 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TTR mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TXNRD1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of UGT2A3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of VCAM1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of VGLL1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of VTN mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ZFAND2A mRNA |
CTD |
PMID:34480604 |
|
NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
increases degradation multiple interactions |
ISO EXP |
Ascorbic Acid results in increased degradation of HIF1A protein [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Ketoglutaric Acids co-treated with Ascorbic Acid co-treated with ferrous chloride] promotes the reaction [VHL protein binds to HIF1A protein]; Ascorbic Acid inhibits the reaction [chromium hexavalent ion results in increased stability of HIF1A protein]; Ascorbic Acid inhibits the reaction [cupric chloride results in decreased hydroxylation of HIF1A protein]; Ascorbic Acid inhibits the reaction [cupric chloride results in increased stability of HIF1A protein]; Ascorbic Acid inhibits the reaction [manganese chloride results in decreased hydroxylation of HIF1A protein]; Ascorbic Acid inhibits the reaction [manganese chloride results in increased stability of HIF1A protein]; Ascorbic Acid inhibits the reaction [nickel sulfate results in decreased hydroxylation of HIF1A protein]; Ascorbic Acid inhibits the reaction [nickel sulfate results in increased expression of HIF1A protein]; Ascorbic Acid inhibits the reaction [nickel sulfate results in increased stability of HIF1A protein]; Ascorbic Acid inhibits the reaction [potassium chromate(VI) results in increased stability of HIF1A protein]; Ascorbic Acid inhibits the reaction [Quercetin results in increased expression of HIF1A protein]; Ascorbic Acid inhibits the reaction [sodium arsenite results in decreased hydroxylation of HIF1A protein]; Ascorbic Acid inhibits the reaction [sodium arsenite results in increased expression of HIF1A protein]; Ascorbic Acid inhibits the reaction [sodium arsenite results in increased stability of HIF1A protein]; Ascorbic Acid inhibits the reaction [Vanadates results in decreased hydroxylation of HIF1A protein]; Ascorbic Acid inhibits the reaction [Vanadates results in increased stability of HIF1A protein]; manganese chloride inhibits the reaction [[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Ketoglutaric Acids co-treated with Ascorbic Acid co-treated with ferrous chloride] promotes the reaction [VHL protein binds to HIF1A protein]] Ascorbic Acid inhibits the reaction [AGT protein modified form results in decreased hydroxylation of HIF1A protein]; Ascorbic Acid inhibits the reaction [Hydrogen Peroxide results in decreased hydroxylation of HIF1A protein] |
CTD |
PMID:16288478 PMID:17364964 PMID:17382205 PMID:19074761 PMID:19263519 PMID:20881940 PMID:24188932 More...
|
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hist1h2bd |
histone cluster 1 H2B family member D |
multiple interactions |
ISO |
[Arsenic Trioxide co-treated with Ascorbic Acid] results in decreased expression of H2BC5 mRNA |
CTD |
PMID:25555879 |
|
NCBI chr17:42,792,887...42,793,268
|
|
G |
Hk1 |
hexokinase 1 |
multiple interactions decreases expression |
ISO |
[Ascorbic Acid co-treated with Arsenic Trioxide] results in decreased expression of HK1 protein; [Tretinoin co-treated with Ascorbic Acid] results in increased expression of HK1 mRNA; Arsenic Trioxide promotes the reaction [Ascorbic Acid results in decreased expression of HK1 mRNA]; Arsenic Trioxide promotes the reaction [Ascorbic Acid results in decreased expression of HK1 protein]; Ascorbic Acid promotes the reaction [Arsenic Trioxide results in decreased expression of HK1 mRNA]; Ascorbic Acid promotes the reaction [Arsenic Trioxide results in decreased expression of HK1 protein] Ascorbic Acid results in decreased expression of HK1 mRNA; Ascorbic Acid results in decreased expression of HK1 protein |
CTD |
PMID:16443354 PMID:38160894 |
|
NCBI chr20:30,230,488...30,332,099
Ensembl chr20:30,230,486...30,332,131
|
|
G |
Hlcs |
holocarboxylase synthetase |
decreases activity |
ISO |
Ascorbic Acid results in decreased activity of HLCS protein |
CTD |
PMID:26303405 |
|
NCBI chr11:33,455,806...33,635,197
Ensembl chr11:33,455,809...33,624,222
|
|
G |
Hmgb1 |
high mobility group box 1 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of HMGB1 mRNA |
CTD |
PMID:26424790 |
|
NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565 Ensembl chr16:5,901,586...5,978,565
|
|
G |
Hmgb2 |
high mobility group box 2 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of HMGB2 mRNA |
CTD |
PMID:26424790 |
|
NCBI chr16:32,710,651...32,713,230
Ensembl chr16:32,710,658...32,713,140
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
increases expression |
ISO |
Ascorbic Acid results in increased expression of HMGCR mRNA |
CTD |
PMID:32913121 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
increases expression |
ISO |
Ascorbic Acid results in increased expression of HMGCS1 mRNA |
CTD |
PMID:32913121 |
|
NCBI chr 2:51,649,368...51,667,100
Ensembl chr 2:51,649,497...51,667,100
|
|
G |
Hmgcs2 |
3-hydroxy-3-methylglutaryl-CoA synthase 2 |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HMGCS2 mRNA |
CTD |
PMID:34480604 |
|
NCBI chr 2:185,875,609...185,903,505
Ensembl chr 2:185,875,616...185,902,130
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression multiple interactions |
ISO EXP |
Ascorbic Acid results in increased expression of HMOX1 mRNA Ascorbic Acid inhibits the reaction [Cadmium Chloride results in increased expression of HMOX1 mRNA]; Ascorbic Acid inhibits the reaction [Cadmium results in increased expression of HMOX1 mRNA]; Ascorbic Acid inhibits the reaction [chromium hexavalent ion results in increased expression of HMOX1 mRNA]; Ascorbic Acid inhibits the reaction [Diquat results in decreased expression of HMOX1 protein]; Ascorbic Acid inhibits the reaction [Nelfinavir results in increased expression of HMOX1]; Ascorbic Acid promotes the reaction [sodium arsenite results in increased expression of HMOX1 mRNA] Ascorbic Acid results in increased expression of HMOX1 protein [Buthionine Sulfoximine co-treated with Ascorbic Acid] promotes the reaction [Copper Sulfate results in increased expression of HMOX1 mRNA]; Ascorbic Acid inhibits the reaction [[Vehicle Emissions results in increased abundance of Particulate Matter] which results in increased expression of HMOX1 mRNA]; Ascorbic Acid inhibits the reaction [benzo(a)pyrene-7,8-dione results in increased expression of HMOX1 protein]; Ascorbic Acid inhibits the reaction [HMOX1 protein results in increased expression of SOD2 mRNA]; Ascorbic Acid inhibits the reaction [Hydrogen Peroxide results in increased expression of HMOX1 protein]; Ascorbic Acid inhibits the reaction [Resveratrol results in increased expression of HMOX1 mRNA]; Ascorbic Acid inhibits the reaction [Resveratrol results in increased expression of HMOX1 protein]; Ascorbic Acid promotes the reaction [[lead acetate results in increased abundance of Lead] which results in increased expression of HMOX1 mRNA] Ascorbic Acid results in increased expression of HMOX1 mRNA; Ascorbic Acid results in increased expression of HMOX1 protein [Ascorbic Acid co-treated with Vitamin E] inhibits the reaction [Diethylhexyl Phthalate results in increased expression of HMOX1 protein]; [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of HMOX1 mRNA; [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of HMOX1 protein; Ascorbic Acid inhibits the reaction [Ethylene Chlorohydrin results in increased expression of HMOX1 mRNA]; Ascorbic Acid inhibits the reaction [Ethylene Chlorohydrin results in increased expression of HMOX1 protein]; Hydrogen Peroxide affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of HMOX1 mRNA]; Hydrogen Peroxide affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of HMOX1 protein]; Hydrogen Peroxide affects the reaction [Quercetin affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of HMOX1 mRNA]]; Hydrogen Peroxide affects the reaction [Quercetin affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of HMOX1 protein]]; Methamphetamine promotes the reaction [Ascorbic Acid results in increased expression of HMOX1 mRNA]; Methamphetamine promotes the reaction [Ascorbic Acid results in increased expression of HMOX1 protein]; Quercetin affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of HMOX1 mRNA]; Quercetin affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of HMOX1 protein]; Quercetin affects the reaction [Hydrogen Peroxide affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of HMOX1 protein]]; SB 203580 inhibits the reaction [Ascorbic Acid results in increased expression of HMOX1 protein] |
CTD |
PMID:8743975 PMID:10942521 PMID:15577407 PMID:16171798 PMID:16517059 PMID:19683516 PMID:21199573 PMID:22008531 PMID:22053912 PMID:23022510 PMID:27028516 PMID:28285367 PMID:29663635 PMID:29940330 PMID:31585129 PMID:31610155 PMID:32525552 PMID:33248029 PMID:33475796 More...
|
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hoxa2 |
homeobox A2 |
multiple interactions |
ISO |
Ascorbic Acid inhibits the reaction [Valproic Acid results in decreased expression of HOXA2 mRNA] [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXA2 mRNA |
CTD |
PMID:19655241 PMID:34480604 |
|
NCBI chr 4:81,262,668...81,266,970
Ensembl chr 4:81,262,768...81,265,044
|
|
G |
Hoxb1 |
homeo box B1 |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HOXB1 mRNA |
CTD |
PMID:33713149 |
|
NCBI chr10:81,331,507...81,332,928
Ensembl chr10:81,331,507...81,332,836
|
|
G |
Hoxb3 |
homeo box B3 |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXB3 mRNA |
CTD |
PMID:34480604 |
|
NCBI chr10:81,258,739...81,314,134
Ensembl chr10:81,299,357...81,313,107
|
|
G |
Hoxd4 |
homeo box D4 |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXD4 mRNA |
CTD |
PMID:34480604 |
|
NCBI chr 3:59,614,464...59,634,042
Ensembl chr 3:59,614,464...59,631,528
|
|
G |
Hoxd8 |
homeobox D8 |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXD8 mRNA |
CTD |
PMID:34480604 |
|
NCBI chr 3:59,607,793...59,610,359
Ensembl chr 3:59,607,996...59,610,361
|
|
G |
Hp |
haptoglobin |
affects activity multiple interactions affects response to substance |
ISO |
Ascorbic Acid affects the activity of HP protein polymorphism Ascorbic Acid inhibits the reaction [alpha-Tocopherol affects the activity of HP protein polymorphism] HP gene polymorphism affects the susceptibility to Ascorbic Acid deficiency |
CTD |
PMID:19769483 PMID:20926521 |
|
NCBI chr19:37,539,626...37,544,178
Ensembl chr19:37,539,627...37,544,523
|
|
G |
Hprt1 |
hypoxanthine phosphoribosyltransferase 1 |
multiple interactions |
EXP |
Ascorbic Acid inhibits the reaction [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased mutagenesis of HPRT1 gene] |
CTD |
PMID:12467141 |
|
NCBI chr X:132,736,175...132,768,149
Ensembl chr X:132,736,096...132,768,154
|
|
G |
Hsd17b1 |
hydroxysteroid (17-beta) dehydrogenase 1 |
multiple interactions |
EXP |
Ascorbic Acid inhibits the reaction [chromium hexavalent ion results in decreased expression of HSD17B1 mRNA] |
CTD |
PMID:18602937 |
|
NCBI chr10:86,009,728...86,011,928
Ensembl chr10:86,009,728...86,011,927
|
|
G |
Hsd17b2 |
hydroxysteroid (17-beta) dehydrogenase 2 |
multiple interactions |
EXP |
Ascorbic Acid inhibits the reaction [chromium hexavalent ion results in decreased expression of HSD17B2 mRNA] |
CTD |
PMID:18602937 |
|
NCBI chr19:45,753,576...45,825,203
Ensembl chr19:45,753,574...45,825,202
|
|
G |
Hsd17b3 |
hydroxysteroid (17-beta) dehydrogenase 3 |
multiple interactions |
EXP |
Ascorbic Acid inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of HSD17B3 mRNA] |
CTD |
PMID:17280759 |
|
NCBI chr17:1,027,229...1,058,554
Ensembl chr17:1,027,229...1,058,554
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
multiple interactions increases expression |
EXP ISO |
Ascorbic Acid inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of HSD3B1 mRNA] Ascorbic Acid results in increased expression of HSD3B1 mRNA [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HSD3B1 mRNA |
CTD |
PMID:17280759 PMID:17901237 PMID:34480604 |
|
NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999
|
|
G |
Hsp90ab1 |
heat shock protein 90 alpha family class B member 1 |
affects expression |
ISO |
Ascorbic Acid affects the expression of HSP90AB1 protein |
CTD |
PMID:19224539 |
|
NCBI chr 9:15,432,986...15,438,358
Ensembl chr 9:15,433,691...15,438,488
|
|
G |
Hspa1a |
heat shock protein family A (Hsp70) member 1A |
multiple interactions |
ISO |
[Quercetin co-treated with Ascorbic Acid] results in increased expression of HSPA1A mRNA |
CTD |
PMID:17639512 |
|
NCBI chr20:3,870,765...3,873,221
Ensembl chr20:3,856,006...3,873,227
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions decreases expression |
ISO |
Ascorbic Acid inhibits the reaction [Fenretinide results in increased expression of HSPA5 protein] Ascorbic Acid results in decreased expression of HSPA5 mRNA |
CTD |
PMID:17353921 PMID:19197388 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Hspa9 |
heat shock protein family A (Hsp70) member 9 |
decreases expression |
ISO |
Ascorbic Acid results in decreased expression of HSPA9 mRNA |
CTD |
PMID:19197388 |
|
NCBI chr18:26,536,131...26,554,294
Ensembl chr18:26,535,798...26,554,292
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
multiple interactions increases expression |
ISO EXP |
[Quercetin co-treated with Ascorbic Acid] results in increased expression of HSPB1 mRNA Ascorbic Acid results in increased expression of HSPB1 mRNA |
CTD |
PMID:15372504 PMID:17639512 |
|
NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743
|
|
G |
Hspe1 |
heat shock protein family E (Hsp10) member 1 |
multiple interactions |
ISO |
[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of HSPE1 mRNA |
CTD |
PMID:17917374 |
|
NCBI chr 9:56,589,912...56,593,000
Ensembl chr 9:56,589,789...56,593,089
|
|
G |
Iapp |
islet amyloid polypeptide |
multiple interactions |
EXP |
IAPP protein promotes the reaction [[Copper co-treated with Ascorbic Acid] results in increased abundance of Hydrogen Peroxide]; IAPP protein promotes the reaction [[Copper co-treated with Ascorbic Acid] results in increased abundance of Hydroxyl Radical] |
CTD |
PMID:23793354 |
|
NCBI chr 4:175,237,107...175,244,373
Ensembl chr 4:175,237,115...175,242,920
|
|
G |
Iars1 |
isoleucyl-tRNA synthetase 1 |
decreases expression |
ISO |
Ascorbic Acid results in decreased expression of IARS1 mRNA |
CTD |
PMID:19197388 |
|
NCBI chr17:14,940,919...14,987,277
Ensembl chr17:14,940,924...14,987,237
|
|
G |
Ibsp |
integrin-binding sialoprotein |
multiple interactions increases expression |
EXP ISO |
[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of IBSP mRNA; Hydrogen Peroxide affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of IBSP mRNA]; Quercetin affects the reaction [Hydrogen Peroxide affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of IBSP mRNA]] Ascorbic Acid results in increased expression of IBSP mRNA [Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of IBSP mRNA; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of IBSP mRNA] |
CTD |
PMID:26492236 PMID:27028516 PMID:28105418 |
|
NCBI chr14:5,439,825...5,452,570
Ensembl chr14:5,439,829...5,452,693
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with Lycopene co-treated with alpha-Tocopherol] inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]; Ascorbic Acid inhibits the reaction [2,3,5-trichloro-6-phenyl-(1,4)benzoquinone results in increased expression of ICAM1 protein]; Ascorbic Acid inhibits the reaction [Hydrogen Peroxide results in increased expression of ICAM1 mRNA]; Ascorbic Acid inhibits the reaction [Hydrogen Peroxide results in increased expression of ICAM1 protein]; Ascorbic Acid inhibits the reaction [Norepinephrine results in increased expression of ICAM1 mRNA]; Ascorbic Acid inhibits the reaction [TNF protein results in increased expression of ICAM1 protein] |
CTD |
PMID:12723939 PMID:23114885 PMID:25305479 PMID:25551565 PMID:35349355 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Ier3 |
immediate early response 3 |
multiple interactions |
ISO |
[Quercetin co-treated with Ascorbic Acid] results in increased expression of IER3 mRNA |
CTD |
PMID:17639512 |
|
NCBI chr20:2,928,378...2,929,582
Ensembl chr20:2,928,378...2,929,583
|
|
G |
Ifi27 |
interferon, alpha-inducible protein 27 |
increases expression |
EXP |
Ascorbic Acid results in increased expression of IFI27 mRNA |
CTD |
PMID:15372504 |
|
NCBI chr 6:122,590,461...122,596,996
Ensembl chr 6:122,590,472...122,779,294
|
|
G |
Ifng |
interferon gamma |
multiple interactions decreases expression |
ISO EXP |
IFNG protein promotes the reaction [Ascorbic Acid promotes the reaction [Quartz results in increased secretion of TNF protein]] Ascorbic Acid results in decreased expression of IFNG protein Ascorbic Acid inhibits the reaction [Formaldehyde results in increased expression of IFNG mRNA] |
CTD |
PMID:14624943 PMID:19298665 PMID:27020608 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Igf1r |
insulin-like growth factor 1 receptor |
increases expression |
ISO |
Ascorbic Acid results in increased expression of IGF1R protein |
CTD |
PMID:20530736 |
|
NCBI chr 1:121,549,831...121,838,548
Ensembl chr 1:121,550,743...121,831,777
|
|
G |
Igfbp5 |
insulin-like growth factor binding protein 5 |
multiple interactions |
ISO EXP |
[Tretinoin co-treated with Ascorbic Acid] results in decreased expression of IGFBP5 mRNA [alpha-Tocopherol co-treated with beta Carotene co-treated with Ascorbic Acid co-treated with Zinc co-treated with Sodium Selenite] results in decreased expression of IGFBP5 mRNA |
CTD |
PMID:16443354 PMID:23859036 |
|
NCBI chr 9:74,452,371...74,464,953
Ensembl chr 9:74,448,382...74,465,156
|
|
G |
Igfbp7 |
insulin-like growth factor binding protein 7 |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of IGFBP7 mRNA |
CTD |
PMID:34480604 |
|
NCBI chr14:30,737,414...30,797,317
Ensembl chr14:30,737,164...30,797,314
|
|
G |
Ihh |
Indian hedgehog signaling molecule |
increases expression |
ISO |
Ascorbic Acid results in increased expression of IHH mRNA |
CTD |
PMID:20530736 |
|
NCBI chr 9:76,504,315...76,510,532
Ensembl chr 9:76,504,315...76,510,532
|
|
G |
Ikzf1 |
IKAROS family zinc finger 1 |
multiple interactions decreases activity |
ISO |
2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole inhibits the reaction [Ascorbic Acid results in decreased activity of IKZF1 protein]; 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole-3',5'-monophosphorothioate inhibits the reaction [Ascorbic Acid results in decreased activity of IKZF1 protein] |
CTD |
PMID:17664058 |
|
NCBI chr14:86,255,065...86,340,839
Ensembl chr14:86,255,065...86,342,416
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO EXP |
[Ascorbic Acid co-treated with lycopene co-treated with alpha-Tocopherol] promotes the reaction [TNF protein results in increased expression of and results in increased secretion of IL10 protein]; Ascorbic Acid promotes the reaction [TNF protein results in increased expression of and results in increased secretion of IL10 protein] Ascorbic Acid inhibits the reaction [Formaldehyde promotes the reaction [Lipopolysaccharides results in increased expression of IL10 mRNA]] |
CTD |
PMID:25551565 PMID:27020608 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO EXP |
Ascorbic Acid inhibits the reaction [2,3,5-trichloro-6-phenyl-(1,4)benzoquinone results in increased expression of IL1B protein]; Ascorbic Acid inhibits the reaction [IL1B results in increased chemical synthesis of 8-epi-prostaglandin F2alpha]; Ascorbic Acid inhibits the reaction [IL1B results in increased chemical synthesis of Dinoprostone]; Ascorbic Acid promotes the reaction [Aspirin inhibits the reaction [IL1B results in increased chemical synthesis of 8-epi-prostaglandin F2alpha]]; Ascorbic Acid promotes the reaction [Aspirin inhibits the reaction [IL1B results in increased chemical synthesis of Dinoprostone]]; IL1B protein inhibits the reaction [[TGFB3 protein co-treated with Ascorbic Acid co-treated with Dexamethasone] results in decreased expression of MMP13 mRNA]; IL1B protein inhibits the reaction [[TGFB3 protein co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of ACAN mRNA]; IL1B protein inhibits the reaction [[TGFB3 protein co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of COL2A1 mRNA]; IL1B protein inhibits the reaction [[TGFB3 protein co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of SOX9 mRNA]; IL1B protein results in decreased susceptibility to [TGFB3 protein co-treated with Ascorbic Acid co-treated with Dexamethasone]; Resveratrol inhibits the reaction [IL1B protein inhibits the reaction [[TGFB3 protein co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of ACAN mRNA]]; Resveratrol inhibits the reaction [IL1B protein inhibits the reaction [[TGFB3 protein co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of COL2A1 mRNA]]; Resveratrol inhibits the reaction [IL1B protein inhibits the reaction [[TGFB3 protein co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of SOX9 mRNA]] Ascorbic Acid deficiency promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of IL1B protein]; Ascorbic Acid inhibits the reaction [lead acetate results in increased expression of IL1B protein]; Ascorbic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of IL1B protein]; Ascorbic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; Ascorbic Acid inhibits the reaction [Sodium Fluoride results in increased expression of IL1B protein] [Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of IL1B mRNA; [Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of IL1B protein; Ascorbic Acid inhibits the reaction [Silicon Dioxide analog promotes the reaction [Lipopolysaccharides results in increased expression of IL1B protein]]; Ascorbic Acid inhibits the reaction [Streptozocin results in increased expression of IL1B protein]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of IL1B mRNA]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of IL1B protein]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of IL1B mRNA]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of IL1B protein] |
CTD |
PMID:15612528 PMID:16529823 PMID:22728154 PMID:23692848 PMID:24685903 PMID:26526931 PMID:28259689 PMID:30606963 PMID:34089294 PMID:35349355 More...
|
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il1r1 |
interleukin 1 receptor type 1 |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of IL1R1 mRNA |
CTD |
PMID:34480604 |
|
NCBI chr 9:42,504,917...42,580,958
Ensembl chr 9:42,504,735...42,579,937
|
|
G |
Il4 |
interleukin 4 |
decreases expression |
ISO |
Ascorbic Acid results in decreased expression of IL4 protein |
CTD |
PMID:14624943 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP ISO |
Ascorbic Acid inhibits the reaction [Formaldehyde inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]]; Ascorbic Acid inhibits the reaction [lead acetate results in increased expression of IL6 protein]; Ascorbic Acid inhibits the reaction [Sodium Fluoride results in increased expression of IL6 protein] [Acetylcysteine co-treated with Ascorbic Acid] inhibits the reaction [Vehicle Emissions results in increased expression of IL6 mRNA]; Ascorbic Acid inhibits the reaction [2,3,5-trichloro-6-phenyl-(1,4)benzoquinone results in increased expression of IL6 protein] |
CTD |
PMID:22728154 PMID:27020608 PMID:32810504 PMID:34089294 PMID:35349355 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Inhba |
inhibin subunit beta A |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ABCC1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ACTN2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ALDOA mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ASCL1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of CDC20 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of CYP24A1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of DCX mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ECSCR mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ELAVL3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ELAVL4 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of EMX2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ESRG mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FAH mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FLT1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FOXD3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FOXG1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of GSTP1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of H2BC14 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of HES5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of KEAP1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of LCK mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of MAFG mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of OLIG2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of OTX2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of POU5F1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SFRP2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SH3BP5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SOX1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SOX2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SPTSSB mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SRXN1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of STMN2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of A2M mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ACSL5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of AFP mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ALB mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of AMHR2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ANXA1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of APOA1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of BMP5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CDH10 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CEACAM6 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CIDEC mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of COL3A1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CRYAB mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CYP26B1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CYP3A5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DCC mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DCN mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DHRS9 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DNAJB1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of EBF3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of EGLN3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FABP1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FBXO32 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FGB mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FGF7 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FGG mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FLRT3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GADD45A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GATA6 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GCLM mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GPR183 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GPX2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GRIA2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GRIA3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GSTA1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GSTA2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GSTO1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GUCY1A1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HAND2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HAVCR1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HMGCS2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXA2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXB3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXD4 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXD8 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HSD3B1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of IGFBP7 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of IGHV3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of IL1R1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ISL1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of KRT6A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of LEF1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of LUM mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MLIP mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MMP1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MPZL1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MYL4 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of NQO1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of NR2F1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of NR2F2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of PDE1A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of PLN mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of RBM20 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of RRAD mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SCARB1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SCN2A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SEMA3C mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SERPINA1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SLCO2B1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SQSTM1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TBX2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TF mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TFAP2A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TM4SF4 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TTR mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TXNRD1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of UGT2A3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of VCAM1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of VGLL1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of VTN mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ZFAND2A mRNA |
CTD |
PMID:34480604 |
|
NCBI chr17:49,091,635...49,111,573
Ensembl chr17:49,095,920...49,108,982
|
|
G |
Inhbe |
inhibin subunit beta E |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of INHBE mRNA |
CTD |
PMID:33713149 |
|
NCBI chr 7:63,176,221...63,179,209
Ensembl chr 7:63,176,219...63,179,172
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
ISO EXP |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with Firemaster 550] results in decreased expression of SP7 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with Firemaster 550] results in increased expression of FABP4 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with triphenyl phosphate] results in decreased expression of SP7 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with triphenyl phosphate] results in increased expression of FABP4 mRNA [Ascorbic Acid co-treated with INS1 protein] results in decreased expression of GPD1 mRNA; [Ascorbic Acid co-treated with INS1 protein] results in increased expression of CASP8 mRNA; [Ascorbic Acid co-treated with INS1 protein] results in increased expression of NAMPT mRNA; [Ascorbic Acid co-treated with Vitamin E] inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of INS1 protein]; [INS1 protein co-treated with Ascorbic Acid] results in increased expression of CDKN1A mRNA; [Lutein co-treated with Ascorbic Acid] results in decreased expression of INS1 protein; Ascorbic Acid inhibits the reaction [INS1 protein results in increased secretion of LEP protein] |
CTD |
PMID:12949374 PMID:20400526 PMID:21911000 PMID:25062436 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of ABCA1 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of CEBPA mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of DMP1 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of NR1H3 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PLIN1 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PPARG mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SREBF1 mRNA; [Bexarotene co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 protein; [Copper co-treated with Ascorbic Acid] results in increased oxidation of and affects the folding of INS protein; [diazepinylbenzoic acid co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in decreased expression of ABCA1 mRNA; [LG 100268 co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 mRNA; [Rosiglitazone co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 protein; [T0901317 co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 mRNA; [tributyltin co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 mRNA; [tributyltin co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 protein; Bexarotene inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; Bexarotene inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of DMP1 mRNA]; Bexarotene inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; Bexarotene promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of NR1H3 mRNA]; Bexarotene promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SREBF1 mRNA]; diazepinylbenzoic acid inhibits the reaction [[LG 100268 co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 mRNA]; diazepinylbenzoic acid inhibits the reaction [[tributyltin co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 mRNA]; Rosiglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; Rosiglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of DMP1 mRNA]; Rosiglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; Rosiglitazone promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of NR1H3 mRNA]; Rosiglitazone promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SREBF1 mRNA]; tributyltin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; tributyltin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of DMP1 mRNA]; tributyltin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; tributyltin promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of NR1H3 mRNA]; tributyltin promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SREBF1 mRNA]; Trientine inhibits the reaction [[Copper co-treated with Ascorbic Acid] results in increased oxidation of and affects the folding of INS protein] [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PLIN1 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PPARG mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of RUNX2 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA; Allethrins inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; Allethrins inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; d,d-T80-prallethrin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; d,d-T80-prallethrin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; d,d-T80-prallethrin promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA]; Pioglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; Pioglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; Pioglitazone promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA]; Pioglitazone promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PLIN1 mRNA]; quinoxyfen inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; quinoxyfen inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; Rosiglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; Rosiglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of RUNX2 mRNA]; Rosiglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; Rosiglitazone promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA]; Rosiglitazone promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PLIN1 mRNA]; Rosiglitazone promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PPARG mRNA]; tetrabromobisphenol A inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; tetrabromobisphenol A promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA]; tetrabromobisphenol A promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PLIN1 mRNA]; Tretinoin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; Tretinoin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PLIN1 mRNA]; Tretinoin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PPARG mRNA]; Tretinoin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; triphenyltin hydroxide inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; triphenyltin hydroxide inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; triphenyltin hydroxide promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA]; triphenyltin hydroxide promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PLIN1 mRNA] |
CTD |
PMID:23403016 PMID:25932594 PMID:32473317 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Insr |
insulin receptor |
multiple interactions |
EXP |
[Ascorbic Acid co-treated with Vitamin E] inhibits the reaction [Diethylhexyl Phthalate results in increased expression of INSR mRNA] |
CTD |
PMID:21911000 |
|
NCBI chr12:1,193,193...1,330,976
Ensembl chr12:1,197,100...1,330,883
|
|
G |
Ireb2 |
iron responsive element binding protein 2 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with CAT protein] inhibits the reaction [Zinc deficiency results in increased expression of IREB2 protein] |
CTD |
PMID:18073202 |
|
NCBI chr 8:55,228,080...55,311,613
Ensembl chr 8:55,228,085...55,311,611
|
|
G |
Irs1 |
insulin receptor substrate 1 |
multiple interactions |
EXP |
[Ascorbic Acid co-treated with Vitamin E] inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of IRS1 protein]; [Ascorbic Acid co-treated with Vitamin E] inhibits the reaction [Diethylhexyl Phthalate results in decreased phosphorylation of IRS1 protein] |
CTD |
PMID:21911000 |
|
NCBI chr 9:83,552,964...83,605,797
Ensembl chr 9:83,548,944...83,606,122
|
|
G |
Isl1 |
ISL LIM homeobox 1 |
increases expression multiple interactions |
ISO |
Ascorbic Acid results in increased expression of ISL1 mRNA [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ISL1 mRNA |
CTD |
PMID:15305145 PMID:34480604 |
|
NCBI chr 2:48,079,412...48,090,704
Ensembl chr 2:48,080,522...48,095,584
|
|
G |
Jag1 |
jagged canonical Notch ligand 1 |
decreases expression |
ISO |
Ascorbic Acid results in decreased expression of JAG1 mRNA |
CTD |
PMID:15305145 |
|
NCBI chr 3:124,406,783...124,442,220
Ensembl chr 3:124,406,794...124,442,209
|
|
G |
Kcnb1 |
potassium voltage-gated channel subfamily B member 1 |
multiple interactions |
ISO |
[Tretinoin co-treated with Ascorbic Acid] results in increased expression of KCNB1 mRNA |
CTD |
PMID:16443354 |
|
NCBI chr 3:155,820,255...155,913,383
Ensembl chr 3:155,822,963...155,916,194
|
|
G |
Kdm3a |
lysine demethylase 3A |
multiple interactions |
ISO |
Ascorbic Acid inhibits the reaction [nickel chloride results in increased expression of KDM3A mRNA]; Ascorbic Acid inhibits the reaction [nickel chloride results in increased expression of KDM3A protein] |
CTD |
PMID:22318714 |
|
NCBI chr 4:103,630,907...103,675,073
Ensembl chr 4:103,630,908...103,675,073
|
|
G |
Kdr |
kinase insert domain receptor |
decreases expression |
ISO |
Ascorbic Acid results in decreased expression of KDR mRNA |
CTD |
PMID:21919647 |
|
NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
decreases expression multiple interactions |
ISO |
Ascorbic Acid results in decreased expression of KEAP1 protein [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of KEAP1 mRNA; Ascorbic Acid inhibits the reaction [[lead acetate results in increased abundance of Lead] which results in increased expression of KEAP1 protein]; Ascorbic Acid inhibits the reaction [Hydrogen Peroxide results in decreased expression of KEAP1 protein] |
CTD |
PMID:28285367 PMID:31610155 PMID:34480604 |
|
NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862
|
|
G |
Kidins220 |
kinase D-interacting substrate 220 |
decreases expression |
EXP |
Ascorbic Acid results in decreased expression of KIDINS220 mRNA |
CTD |
PMID:15372504 |
|
NCBI chr 6:41,618,207...41,706,990
Ensembl chr 6:41,618,294...41,703,256
|
|
G |
Kif1b |
kinesin family member 1B |
decreases expression |
EXP |
Ascorbic Acid results in decreased expression of KIF1B mRNA |
CTD |
PMID:15372504 |
|
NCBI chr 5:159,607,697...159,742,778
Ensembl chr 5:159,561,271...159,742,778
|
|
G |
Kif1c |
kinesin family member 1C |
decreases expression |
EXP |
Ascorbic Acid results in decreased expression of KIF1C mRNA |
CTD |
PMID:15372504 |
|
NCBI chr10:55,414,412...55,444,587
Ensembl chr10:55,415,900...55,443,545
|
|
G |
Kif23 |
kinesin family member 23 |
multiple interactions |
ISO |
[Quercetin co-treated with Ascorbic Acid] results in increased expression of KIF23 mRNA |
CTD |
PMID:17639512 |
|
NCBI chr 8:62,397,908...62,425,162
Ensembl chr 8:62,397,948...62,425,072
|
|
G |
Klrk1 |
killer cell lectin like receptor K1 |
decreases expression |
ISO |
Ascorbic Acid deficiency results in decreased expression of KLRK1 protein |
CTD |
PMID:22306178 |
|
NCBI chr 4:163,079,887...163,092,434
Ensembl chr 4:163,081,927...163,092,459
|
|
G |
Lck |
LCK proto-oncogene, Src family tyrosine kinase |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of LCK mRNA; Ascorbic Acid inhibits the reaction [bis(2-hydroxy-2-ethylbutanoato)oxochromate(V) results in increased phosphorylation of LCK protein]; Ascorbic Acid inhibits the reaction [Potassium Dichromate results in increased phosphorylation of LCK protein] |
CTD |
PMID:14572611 PMID:34480604 |
|
NCBI chr 5:141,888,318...141,916,945
Ensembl chr 5:141,888,326...141,903,794
|
|
G |
Ldha |
lactate dehydrogenase A |
multiple interactions decreases expression |
ISO |
[Ascorbic Acid co-treated with alpha-Tocopherol co-treated with ferulic acid] inhibits the reaction [[Ozone co-treated with Oxygen] results in increased secretion of LDHA protein]; [Ascorbic Acid co-treated with Arsenic Trioxide] results in decreased expression of LDHA protein; Arsenic Trioxide promotes the reaction [Ascorbic Acid results in decreased expression of LDHA mRNA]; Arsenic Trioxide promotes the reaction [Ascorbic Acid results in decreased expression of LDHA protein]; Ascorbic Acid promotes the reaction [Arsenic Trioxide results in decreased expression of LDHA mRNA]; Ascorbic Acid promotes the reaction [Arsenic Trioxide results in decreased expression of LDHA protein] Ascorbic Acid results in decreased expression of LDHA mRNA; Ascorbic Acid results in decreased expression of LDHA protein |
CTD |
PMID:26270818 PMID:38160894 |
|
NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472
|
|
G |
Ldlr |
low density lipoprotein receptor |
multiple interactions increases expression |
ISO |
Ascorbic Acid inhibits the reaction [Dactinomycin results in decreased expression of LDLR mRNA]; FOXO3 protein affects the reaction [Ascorbic Acid results in increased expression of LDLR protein]; SREBF2 protein affects the reaction [Ascorbic Acid results in increased expression of LDLR mRNA]; SREBF2 protein affects the reaction [Ascorbic Acid results in increased expression of LDLR protein] Ascorbic Acid results in increased expression of LDLR mRNA; Ascorbic Acid results in increased expression of LDLR protein Ascorbic Acid affects the reaction [GULO protein affects the expression of LDLR protein] |
CTD |
PMID:32913121 |
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Lef1 |
lymphoid enhancer binding factor 1 |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of LEF1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of LEF1 mRNA |
CTD |
PMID:33713149 PMID:34480604 |
|
NCBI chr 2:219,666,549...219,779,815
Ensembl chr 2:219,666,592...219,779,794
|
|
G |
Lep |
leptin |
decreases secretion multiple interactions |
EXP |
Ascorbic Acid results in decreased secretion of LEP protein Ascorbic Acid inhibits the reaction [INS1 protein results in increased secretion of LEP protein] |
CTD |
PMID:20400526 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lgals1 |
galectin 1 |
multiple interactions |
ISO |
[Quercetin co-treated with Ascorbic Acid] results in increased expression of LGALS1 mRNA |
CTD |
PMID:17639512 |
|
NCBI chr 7:110,485,239...110,488,345
Ensembl chr 7:110,481,392...110,488,345
|
|
G |
Lgals3 |
galectin 3 |
increases expression |
EXP |
Ascorbic Acid results in increased expression of LGALS3 mRNA |
CTD |
PMID:15372504 |
|
NCBI chr15:20,620,083...20,632,019
Ensembl chr15:20,607,692...20,632,025
|
|
G |
Lhb |
luteinizing hormone subunit beta |
multiple interactions |
EXP |
Ascorbic Acid inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of LHB protein] |
CTD |
PMID:16248992 PMID:16298753 PMID:17280759 |
|
NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
|
|
G |
Lhcgr |
luteinizing hormone/choriogonadotropin receptor |
multiple interactions |
EXP |
Ascorbic Acid inhibits the reaction [chromium hexavalent ion results in decreased expression of LHCGR mRNA] |
CTD |
PMID:18602937 |
|
NCBI chr 6:5,661,871...5,728,109
Ensembl chr 6:5,661,871...5,724,521
|
|
G |
Loxl2 |
lysyl oxidase-like 2 |
decreases expression |
ISO |
Ascorbic Acid results in decreased expression of LOXL2 mRNA |
CTD |
PMID:19197388 |
|
NCBI chr15:44,683,449...44,773,067
Ensembl chr15:44,683,880...44,773,067
|
|
G |
Lpar2 |
lysophosphatidic acid receptor 2 |
multiple interactions |
ISO |
Ascorbic Acid inhibits the reaction [Benzo(a)pyrene results in decreased methylation of LPAR2 promoter]; Ascorbic Acid inhibits the reaction [Benzo(a)pyrene results in increased expression of LPAR2 mRNA] |
CTD |
PMID:27901495 |
|
NCBI chr16:19,592,067...19,599,998
Ensembl chr16:19,595,655...19,599,998
|
|
G |
Lum |
lumican |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of LUM mRNA |
CTD |
PMID:34480604 |
|
NCBI chr 7:32,358,990...32,365,794
Ensembl chr 7:32,358,614...32,365,793
|
|
G |
Lxn |
latexin |
increases expression |
ISO |
Ascorbic Acid results in increased expression of LXN mRNA; Ascorbic Acid results in increased expression of LXN protein |
CTD |
PMID:22139585 |
|
NCBI chr 2:151,727,556...151,733,426
Ensembl chr 2:151,727,102...151,733,460
|
|
G |
Lyn |
LYN proto-oncogene, Src family tyrosine kinase |
multiple interactions |
ISO |
Ascorbic Acid inhibits the reaction [bis(2-hydroxy-2-ethylbutanoato)oxochromate(V) results in increased phosphorylation of LYN protein]; Ascorbic Acid inhibits the reaction [Potassium Dichromate results in increased phosphorylation of LYN protein] |
CTD |
PMID:14572611 |
|
NCBI chr 5:16,639,512...16,755,501
Ensembl chr 5:16,639,466...16,756,868
|
|
G |
Maff |
MAF bZIP transcription factor F |
multiple interactions |
ISO |
[Quercetin co-treated with Ascorbic Acid] results in increased expression of MAFF mRNA |
CTD |
PMID:17639512 |
|
NCBI chr 7:110,912,367...110,923,711
Ensembl chr 7:110,912,499...110,923,851
|
|
G |
Mafg |
MAF bZIP transcription factor G |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of MAFG mRNA |
CTD |
PMID:34480604 |
|
NCBI chr10:105,903,307...105,911,808
Ensembl chr10:105,903,237...105,912,026
|
|
G |
Magi2 |
membrane associated guanylate kinase, WW and PDZ domain containing 2 |
increases expression |
ISO |
Ascorbic Acid results in increased expression of MAGI2 mRNA |
CTD |
PMID:15305145 |
|
NCBI chr 4:14,386,389...15,870,036
Ensembl chr 4:14,386,399...15,870,240
|
|
G |
Malt1 |
MALT1 paracaspase |
multiple interactions |
ISO |
[Quercetin co-treated with Ascorbic Acid] results in increased expression of MALT1 mRNA |
CTD |
PMID:17639512 |
|
NCBI chr18:58,942,282...58,996,318
Ensembl chr18:58,942,299...58,994,260
|
|
G |
Map2 |
microtubule-associated protein 2 |
decreases expression multiple interactions |
EXP ISO |
Ascorbic Acid results in decreased expression of MAP2 protein [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of MAP2 protein |
CTD |
PMID:15372504 PMID:33713149 |
|
NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809
|
|
G |
Map2k3 |
mitogen activated protein kinase kinase 3 |
multiple interactions |
ISO |
Ascorbic Acid inhibits the reaction [Fenretinide results in increased phosphorylation of MAP2K3 protein] |
CTD |
PMID:16407847 |
|
NCBI chr10:45,608,145...45,629,492
Ensembl chr10:45,607,163...45,629,492
|
|
G |
Map2k6 |
mitogen-activated protein kinase kinase 6 |
multiple interactions |
ISO |
Ascorbic Acid inhibits the reaction [Fenretinide results in increased phosphorylation of MAP2K6 protein] |
CTD |
PMID:16407847 |
|
NCBI chr10:95,373,304...95,490,406
Ensembl chr10:95,373,204...95,488,293
|
|
G |
Map3k5 |
mitogen-activated protein kinase kinase kinase 5 |
multiple interactions |
ISO |
Ascorbic Acid inhibits the reaction [Plant Extracts results in increased phosphorylation of MAP3K5 protein] |
CTD |
PMID:20206247 |
|
NCBI chr 1:14,685,776...14,904,935
Ensembl chr 1:14,685,492...14,904,800
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO EXP |
U 0126 inhibits the reaction [Ascorbic Acid results in increased phosphorylation of MAPK1 protein] Ascorbic Acid inhibits the reaction [Ethylene Chlorohydrin results in increased phosphorylation of MAPK1 protein]; Ascorbic Acid inhibits the reaction [lead acetate results in increased phosphorylation of MAPK1 protein]; Ascorbic Acid inhibits the reaction [Potassium Dichromate affects the localization of MAPK1 protein modified form] [juglone co-treated with Ascorbic Acid] results in decreased phosphorylation of MAPK1 protein |
CTD |
PMID:20530736 PMID:21262251 PMID:22728154 PMID:29992683 PMID:31585129 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions |
ISO |
Ascorbic Acid inhibits the reaction [Fenretinide results in increased phosphorylation of MAPK14 protein] |
CTD |
PMID:16407847 |
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO EXP |
U 0126 inhibits the reaction [Ascorbic Acid results in increased phosphorylation of MAPK3 protein] Ascorbic Acid inhibits the reaction [Ethylene Chlorohydrin results in increased phosphorylation of MAPK3 protein]; Ascorbic Acid inhibits the reaction [lead acetate results in increased phosphorylation of MAPK3 protein]; Ascorbic Acid inhibits the reaction [Potassium Dichromate affects the localization of MAPK3 protein modified form] [juglone co-treated with Ascorbic Acid] results in decreased phosphorylation of MAPK3 protein |
CTD |
PMID:20530736 PMID:21262251 PMID:22728154 PMID:29992683 PMID:31585129 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with Eosine I Bluish] results in increased phosphorylation of MAPK8 protein; Ascorbic Acid inhibits the reaction [Plant Extracts results in increased phosphorylation of MAPK8 protein]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with Eosine I Bluish] results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:20206247 PMID:24488945 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with Eosine I Bluish] results in increased phosphorylation of MAPK9 protein; Ascorbic Acid inhibits the reaction [Plant Extracts results in increased phosphorylation of MAPK9 protein]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with Eosine I Bluish] results in increased phosphorylation of MAPK9 protein] |
CTD |
PMID:20206247 PMID:24488945 |
|
NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178
|
|
G |
Mapt |
microtubule-associated protein tau |
multiple interactions |
EXP |
Ascorbic Acid inhibits the reaction [cyanoginosin LR results in increased phosphorylation of MAPT protein] |
CTD |
PMID:24142891 |
|
NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129
|
|
G |
Mcm4 |
minichromosome maintenance complex component 4 |
multiple interactions |
ISO |
[Quercetin co-treated with Ascorbic Acid] results in increased expression of MCM4 mRNA |
CTD |
PMID:17639512 |
|
NCBI chr11:85,258,443...85,272,144
Ensembl chr11:85,258,443...85,272,144
|
|
G |
Mdk |
midkine |
increases expression |
EXP |
Ascorbic Acid results in increased expression of MDK mRNA |
CTD |
PMID:15372504 |
|
NCBI chr 3:77,901,134...77,903,997
Ensembl chr 3:77,901,158...77,903,130
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
multiple interactions |
EXP |
Ascorbic Acid inhibits the reaction [Potassium Dichromate results in decreased expression of MDM2 protein] |
CTD |
PMID:21262251 |
|
NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915
|
|
G |
Mep1a |
meprin A subunit alpha |
multiple interactions |
ISO |
[Quercetin co-treated with Ascorbic Acid] results in decreased expression of MEP1A mRNA |
CTD |
PMID:17639512 |
|
NCBI chr 9:17,474,634...17,504,147
Ensembl chr 9:17,474,619...17,504,147
|
|
G |
Met |
MET proto-oncogene, receptor tyrosine kinase |
decreases expression |
ISO |
Ascorbic Acid results in decreased expression of MET mRNA |
CTD |
PMID:21919647 |
|
NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876
|
|
G |
Mgmt |
O-6-methylguanine-DNA methyltransferase |
multiple interactions |
EXP |
Ascorbic Acid inhibits the reaction [[kojic acid co-treated with Diethylnitrosamine] results in increased expression of MGMT mRNA] |
CTD |
PMID:18544905 |
|
NCBI chr 1:191,710,980...191,937,760
Ensembl chr 1:191,710,930...191,937,756
|
|
G |
Mgst1 |
microsomal glutathione S-transferase 1 |
increases expression |
EXP |
Ascorbic Acid results in increased expression of MGST1 mRNA |
CTD |
PMID:15372504 |
|
NCBI chr 4:171,029,666...171,044,893
Ensembl chr 4:171,029,630...171,044,892
|
|
G |
Mir93 |
microRNA 93 |
multiple interactions |
EXP ISO |
Ascorbic Acid inhibits the reaction [Estradiol results in increased expression of MIR93 mRNA] |
CTD |
PMID:23492819 |
|
NCBI chr12:17,043,135...17,043,221
Ensembl chr12:17,043,135...17,043,221
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
multiple interactions decreases expression |
ISO EXP |
[Quercetin co-treated with Ascorbic Acid] results in increased expression of MKI67 mRNA; Arsenic Trioxide promotes the reaction [Ascorbic Acid results in decreased expression of MKI67 protein]; Ascorbic Acid promotes the reaction [Arsenic Trioxide results in decreased expression of MKI67 protein] [alpha-Tocopherol co-treated with beta Carotene co-treated with Ascorbic Acid co-treated with Zinc co-treated with Sodium Selenite] results in decreased expression of MKI67 mRNA |
CTD |
PMID:17639512 PMID:23859036 PMID:38160894 |
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Mlh1 |
mutL homolog 1 |
multiple interactions |
ISO |
Ascorbic Acid promotes the reaction [MLH1 gene mutant form results in decreased susceptibility to chromium hexavalent ion]; MLH1 protein promotes the reaction [Ascorbic Acid results in increased susceptibility to chromium hexavalent ion]; MLH1 protein results in increased susceptibility to [chromium hexavalent ion co-treated with Ascorbic Acid] |
CTD |
PMID:15831465 PMID:17169990 PMID:17301063 |
|
NCBI chr 8:111,196,468...111,233,721
Ensembl chr 8:111,196,468...111,233,617
|
|
G |
Mlip |
muscular LMNA-interacting protein |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MLIP mRNA |
CTD |
PMID:34480604 |
|
NCBI chr 8:77,935,087...78,204,725
Ensembl chr 8:77,935,079...78,204,254
|
|
G |
Mme |
membrane metallo-endopeptidase |
decreases activity |
EXP |
Ascorbic acid decreases activity of Mme protein in osteoblasts |
RGD |
PMID:15908023 |
RGD:1581744 |
NCBI chr 2:147,686,913...147,803,808
Ensembl chr 2:147,722,086...147,803,792
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MMP1 mRNA; Ascorbic Acid inhibits the reaction [Tobacco Smoke Pollution results in increased expression of MMP1 mRNA] |
CTD |
PMID:10836612 PMID:34480604 |
|
NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of MMP13 mRNA; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of MMP13 mRNA]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of MMP13 protein]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of MMP13 mRNA]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of MMP13 protein] [TGFB3 protein co-treated with Ascorbic Acid co-treated with Dexamethasone] results in decreased expression of MMP13 mRNA; IL1B protein inhibits the reaction [[TGFB3 protein co-treated with Ascorbic Acid co-treated with Dexamethasone] results in decreased expression of MMP13 mRNA] |
CTD |
PMID:23692848 PMID:26526931 |
|
NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
EXP ISO |
Ascorbic Acid inhibits the reaction [Cyclosporine results in increased expression of MMP2 protein] [juglone co-treated with Ascorbic Acid] affects the expression of MMP2 mRNA |
CTD |
PMID:19391111 PMID:29992683 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp7 |
matrix metallopeptidase 7 |
multiple interactions |
ISO |
[Quercetin co-treated with Ascorbic Acid] results in increased expression of MMP7 mRNA |
CTD |
PMID:17639512 |
|
NCBI chr 8:4,848,186...4,855,908
Ensembl chr 8:4,848,186...4,855,902
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
[juglone co-treated with Ascorbic Acid] results in decreased expression of MMP9 mRNA |
CTD |
PMID:29992683 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP ISO |
[Ascorbic Acid co-treated with beta Carotene co-treated with alpha-Tocopherol co-treated with Sodium Selenite] inhibits the reaction [Galactosamine results in increased activity of MPO protein]; Ascorbic Acid inhibits the reaction [Fluorouracil results in increased activity of MPO protein]; Ascorbic Acid inhibits the reaction [Formaldehyde inhibits the reaction [Lipopolysaccharides results in increased expression of MPO protein]]; Ascorbic Acid inhibits the reaction [Indomethacin results in increased activity of MPO protein] Ascorbic Acid inhibits the reaction [[MPO protein co-treated with Hydrogen Peroxide] results in increased oxidation of Albuterol]; Ascorbic Acid inhibits the reaction [[MPO protein co-treated with Hydrogen Peroxide] results in increased oxidation of Fenoterol] |
CTD |
PMID:18726076 PMID:19462961 PMID:26921358 PMID:27020608 PMID:31022331 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mpzl1 |
myelin protein zero-like 1 |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MPZL1 mRNA |
CTD |
PMID:34480604 |
|
NCBI chr13:77,852,467...77,889,305
Ensembl chr13:77,852,467...77,896,616
|
|
G |
Msh2 |
mutS homolog 2 |
multiple interactions |
ISO |
MSH2 protein promotes the reaction [Ascorbic Acid results in increased susceptibility to chromium hexavalent ion]; MSH2 protein results in increased susceptibility to [chromium hexavalent ion co-treated with Ascorbic Acid] |
CTD |
PMID:17169990 PMID:17301063 |
|
NCBI chr 6:6,813,793...6,872,960
Ensembl chr 6:6,813,795...6,872,938
|
|
G |
Mst1 |
macrophage stimulating 1 |
multiple interactions |
ISO |
[Quercetin co-treated with Ascorbic Acid] results in decreased expression of MST1 mRNA |
CTD |
PMID:17639512 |
|
NCBI chr 8:108,767,886...108,773,425
Ensembl chr 8:108,768,839...108,773,416
|
|
G |
Msx2 |
msh homeobox 2 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of MSX2 mRNA; cadmium sulfate inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of MSX2 mRNA] |
CTD |
PMID:28189605 |
|
NCBI chr17:11,097,214...11,102,879
Ensembl chr17:11,097,103...11,102,879
|
|
G |
Mt1 |
metallothionein 1 |
increases expression |
EXP |
Ascorbic Acid results in increased expression of MT1A mRNA |
CTD |
PMID:15372504 |
|
NCBI chr19:10,826,032...10,827,048
Ensembl chr19:10,826,032...10,827,049 Ensembl chr17:10,826,032...10,827,049
|
|
G |
Mt3 |
metallothionein 3 |
increases expression multiple interactions |
EXP ISO |
Ascorbic Acid results in increased expression of MT3 mRNA [[MT3 protein binds to Zinc] which co-treated with Ascorbic Acid] inhibits the reaction [Copper results in increased chemical synthesis of Hydroxyl Radical] |
CTD |
PMID:15372504 PMID:17389590 |
|
NCBI chr19:10,848,754...10,850,158
Ensembl chr19:10,848,755...10,850,158
|
|
G |
Mthfd2 |
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase |
decreases expression |
ISO |
Ascorbic Acid results in decreased expression of MTHFD2 mRNA |
CTD |
PMID:19197388 |
|
NCBI chr 4:115,811,135...115,822,663
Ensembl chr 4:115,811,139...115,822,608
|
|
G |
Myb |
MYB proto-oncogene, transcription factor |
multiple interactions |
EXP |
[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of MYB protein |
CTD |
PMID:7593635 |
|
NCBI chr 1:15,939,771...15,973,367
Ensembl chr 1:15,939,761...15,973,057
|
|
G |
Mybl2 |
MYB proto-oncogene like 2 |
multiple interactions |
ISO |
[Quercetin co-treated with Ascorbic Acid] results in increased expression of MYBL2 mRNA |
CTD |
PMID:17639512 |
|
NCBI chr 3:151,705,254...151,733,714
Ensembl chr 3:151,705,288...151,733,708
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions |
ISO |
Ascorbic Acid inhibits the reaction [phenylhydrazine results in decreased expression of MYC mRNA] |
CTD |
PMID:30140404 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Myh11 |
myosin heavy chain 11 |
increases expression |
EXP |
Ascorbic Acid results in increased expression of MYH11 protein |
CTD |
PMID:14639096 |
|
NCBI chr10:743,364...838,459
Ensembl chr10:743,685...838,459
|
|
G |
Myh6 |
myosin heavy chain 6 |
increases expression |
ISO |
Ascorbic Acid results in increased expression of MYH6 mRNA |
CTD |
PMID:12668514 |
|
NCBI chr15:28,418,120...28,442,316
Ensembl chr15:28,417,616...28,441,720
|
|
G |
Myh7 |
myosin heavy chain 7 |
increases expression |
ISO |
Ascorbic Acid results in increased expression of MYH7 mRNA |
CTD |
PMID:12668514 PMID:21570463 |
|
NCBI chr15:28,446,550...28,469,888
Ensembl chr15:28,446,550...28,468,217
|
|
G |
Myl2 |
myosin light chain 2 |
increases expression |
ISO |
Ascorbic Acid results in increased expression of MYL2 mRNA |
CTD |
PMID:21570463 |
|
NCBI chr12:34,454,223...34,468,554
Ensembl chr12:34,454,218...34,468,983
|
|
G |
Myl4 |
myosin, light chain 4 |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MYL4 mRNA |
CTD |
PMID:34480604 |
|
NCBI chr10:89,449,456...89,485,365
Ensembl chr10:89,449,443...89,485,363
|
|
G |
Myo1a |
myosin IA |
multiple interactions |
ISO |
[Quercetin co-treated with Ascorbic Acid] results in decreased expression of MYO1A mRNA |
CTD |
PMID:17639512 |
|
NCBI chr 7:63,542,988...63,557,944
Ensembl chr 7:63,542,988...63,557,944
|
|
G |
Myo1e |
myosin IE |
decreases expression |
EXP |
Ascorbic Acid results in decreased expression of MYO1E mRNA |
CTD |
PMID:15372504 |
|
NCBI chr 8:70,887,934...71,080,180
Ensembl chr 8:70,887,870...71,080,169
|
|
G |
Nampt |
nicotinamide phosphoribosyltransferase |
multiple interactions |
EXP |
[Ascorbic Acid co-treated with INS1 protein] results in increased expression of NAMPT mRNA |
CTD |
PMID:20400526 |
|
NCBI chr 6:49,425,316...49,462,109
Ensembl chr 6:49,424,332...49,462,100
|
|
G |
Nars1 |
asparaginyl-tRNA synthetase 1 |
decreases expression |
ISO |
Ascorbic Acid results in decreased expression of NARS1 mRNA |
CTD |
PMID:19197388 |
|
NCBI chr18:57,989,308...58,005,584
Ensembl chr18:57,989,308...58,005,622
|
|
G |
Ncald |
neurocalcin delta |
increases expression |
ISO |
Ascorbic Acid results in increased expression of NCALD mRNA |
CTD |
PMID:15305145 |
|
NCBI chr 7:68,532,671...68,964,740
Ensembl chr 7:68,534,421...68,964,496
|
|
G |
Ndrg1 |
N-myc downstream regulated 1 |
multiple interactions |
ISO |
Ascorbic Acid inhibits the reaction [nickel sulfate results in increased expression of NDRG1 protein] |
CTD |
PMID:16288478 |
|
NCBI chr 7:98,684,487...98,725,869
Ensembl chr 7:98,684,487...98,725,880
|
|
G |
Ndrg2 |
NDRG family member 2 |
increases expression |
EXP |
Ascorbic Acid results in increased expression of NDRG2 mRNA |
CTD |
PMID:15372504 |
|
NCBI chr15:24,600,981...24,609,621
Ensembl chr15:24,600,982...24,609,626
|
|
G |
Nes |
nestin |
decreases expression |
EXP |
Ascorbic Acid results in decreased expression of NES protein |
CTD |
PMID:15372504 |
|
NCBI chr 2:173,437,867...173,447,777
Ensembl chr 2:173,438,734...173,447,777
|
|
G |
Nfe2l1 |
NFE2 like bZIP transcription factor 1 |
increases expression |
ISO |
Ascorbic Acid results in increased expression of NFE2L1 mRNA; Ascorbic Acid results in increased expression of NFE2L1 protein |
CTD |
PMID:25130429 |
|
NCBI chr10:81,796,055...81,812,926
Ensembl chr10:81,800,366...81,832,318
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions affects localization increases expression |
ISO EXP |
[Ascorbic Acid co-treated with alpha-Tocopherol co-treated with ferulic acid] promotes the reaction [[Ozone co-treated with Oxygen] results in increased localization of NFE2L2 protein]; [lead acetate results in increased abundance of Lead] inhibits the reaction [Ascorbic Acid results in increased expression of NFE2L2 protein]; Ascorbic Acid inhibits the reaction [Estradiol results in decreased expression of NFE2L2 mRNA]; Ascorbic Acid inhibits the reaction [Estradiol results in decreased expression of NFE2L2 protein]; Ascorbic Acid inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of NFE2L2 protein]; Ascorbic Acid inhibits the reaction [Resveratrol results in increased activity of NFE2L2 promoter]; Ascorbic Acid promotes the reaction [[lead acetate results in increased abundance of Lead] which results in increased expression of NFE2L2 mRNA] Ascorbic Acid affects the localization of NFE2L2 protein [Ascorbic Acid co-treated with Vitamin E] inhibits the reaction [Diethylhexyl Phthalate results in increased expression of NFE2L2 protein]; Ascorbic Acid inhibits the reaction [Arsenic Trioxide results in decreased expression of NFE2L2 mRNA]; Ascorbic Acid inhibits the reaction [Estradiol affects the localization of NFE2L2 protein]; Ascorbic Acid inhibits the reaction [Estradiol inhibits the reaction [NFE2L2 protein binds to SOD3 promoter]]; Ascorbic Acid inhibits the reaction [Estradiol results in decreased expression of NFE2L2 mRNA]; Ascorbic Acid inhibits the reaction [Estradiol results in decreased expression of NFE2L2 protein]; Ascorbic Acid inhibits the reaction [Ethylene Chlorohydrin results in increased expression of NFE2L2 mRNA]; Ascorbic Acid inhibits the reaction [Ethylene Chlorohydrin results in increased expression of NFE2L2 protein]; Ascorbic Acid promotes the reaction [Cadmium results in increased expression of NFE2L2 protein]; Ascorbic Acid promotes the reaction [Fluorouracil affects the localization of NFE2L2 protein] Ascorbic Acid results in increased expression of NFE2L2 mRNA; Ascorbic Acid results in increased expression of NFE2L2 protein Ascorbic Acid inhibits the reaction [Diquat results in decreased expression of NFE2L2 protein] |
CTD |
PMID:21199573 PMID:22008531 PMID:23027624 PMID:23492819 PMID:25130429 PMID:26270818 PMID:26921358 PMID:28285367 PMID:29297235 PMID:29663635 PMID:29940330 PMID:31585129 PMID:31610155 PMID:33475796 More...
|
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfe2l3 |
NFE2 like bZIP transcription factor 3 |
decreases expression |
ISO |
Ascorbic Acid results in decreased expression of NFE2L3 mRNA; Ascorbic Acid results in decreased expression of NFE2L3 protein |
CTD |
PMID:25130429 |
|
NCBI chr 4:80,506,756...80,534,629
Ensembl chr 4:80,506,756...80,534,629
|
|
G |
Nfib |
nuclear factor I/B |
increases expression |
ISO |
Ascorbic Acid results in increased expression of NFIB mRNA |
CTD |
PMID:15305145 |
|
NCBI chr 5:96,759,208...96,974,001
Ensembl chr 5:96,764,653...96,975,479
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO EXP |
[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of [NFKB1 protein binds to RELA protein]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of [NFKB1 protein binds to RELA protein]]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of [NFKB1 protein binds to RELA protein]] [Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of NFKB1 protein; [Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of NFKB1 protein]; Ascorbic Acid inhibits the reaction [Norepinephrine affects the localization of NFKB1 protein] Ascorbic Acid inhibits the reaction [Fluorouracil affects the localization of NFKB1 protein] |
CTD |
PMID:17879260 PMID:23114885 PMID:23692848 PMID:26921358 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with ferrous sulfate] results in decreased expression of NFKBIA protein; [Ascorbic Acid co-treated with lycopene co-treated with alpha-Tocopherol] inhibits the reaction [TNF protein results in increased expression of NFKBIA mRNA]; [Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in decreased expression of NFKBIA protein]; Ascorbic Acid inhibits the reaction [Hydrogen Peroxide results in increased degradation of NFKBIA protein]; Ascorbic Acid inhibits the reaction [TNF protein results in increased expression of NFKBIA mRNA] |
CTD |
PMID:17879260 PMID:25305479 PMID:25551565 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nfya |
nuclear transcription factor Y subunit alpha |
multiple interactions |
ISO |
[Tretinoin co-treated with Ascorbic Acid] results in decreased expression of NFYA mRNA |
CTD |
PMID:16443354 |
|
NCBI chr 9:12,587,437...12,613,911
Ensembl chr 9:12,586,259...12,613,898
|
|
G |
Ninj1 |
ninjurin 1 |
multiple interactions |
ISO |
[Tretinoin co-treated with Ascorbic Acid] results in decreased expression of NINJ1 mRNA |
CTD |
PMID:16443354 |
|
NCBI chr17:15,452,804...15,461,684
Ensembl chr17:15,452,813...15,461,704
|
|
G |
Nkx2-1 |
NK2 homeobox 1 |
multiple interactions |
ISO EXP |
Ascorbic Acid inhibits the reaction [nitrofen results in decreased expression of NKX2-1 mRNA]; Ascorbic Acid inhibits the reaction [nitrofen results in decreased expression of NKX2-1 protein] |
CTD |
PMID:15083329 PMID:16863852 |
|
NCBI chr 6:73,996,601...74,001,483
Ensembl chr 6:73,996,601...73,999,791
|
|
G |
Nkx2-5 |
NK2 homeobox 5 |
increases expression |
ISO |
Ascorbic Acid results in increased expression of NKX2-5 mRNA |
CTD |
PMID:12668514 |
|
NCBI chr10:16,340,428...16,347,004
Ensembl chr10:16,344,159...16,346,934
|
|
G |
Nme1 |
NME/NM23 nucleoside diphosphate kinase 1 |
multiple interactions |
ISO |
[Tretinoin co-treated with Ascorbic Acid] results in decreased expression of NME1 mRNA |
CTD |
PMID:16443354 |
|
NCBI chr10:78,907,036...78,929,659
Ensembl chr10:78,906,083...78,916,408
|
|
G |
Nnat |
neuronatin |
increases expression |
ISO |
Ascorbic Acid results in increased expression of NNAT mRNA |
CTD |
PMID:15305145 |
|
NCBI chr 3:146,225,941...146,228,868
Ensembl chr 3:146,226,407...146,228,834
|
|
G |
Nog |
noggin |
multiple interactions |
EXP |
NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 protein]]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMPR1A protein]]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 protein]]] |
CTD |
PMID:27387537 |
|
NCBI chr10:74,128,712...74,130,339
Ensembl chr10:74,128,712...74,130,339
|
|
G |
Nos2 |
nitric oxide synthase 2 |
increases activity multiple interactions decreases expression |
ISO EXP |
Ascorbic Acid results in increased activity of NOS2 protein Ascorbic Acid inhibits the reaction [Aspirin results in increased expression of NOS2 protein] [Ascorbic Acid co-treated with Formaldehyde] results in decreased expression of NOS2 mRNA; [Ascorbic Acid co-treated with Vitamin E co-treated with beta Carotene co-treated with Copper] inhibits the reaction [Streptozocin results in increased expression of NOS2 mRNA]; Ascorbic Acid inhibits the reaction [Cyclosporine results in increased expression of NOS2 protein]; Ascorbic Acid inhibits the reaction [endotoxin, Escherichia coli results in increased expression of NOS2 protein]; Ascorbic Acid inhibits the reaction [Isoproterenol results in increased expression of NOS2 protein]; Ascorbic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; Ascorbic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; Ascorbic Acid inhibits the reaction [nickel sulfate results in increased activity of NOS2 protein] Ascorbic Acid results in decreased expression of NOS2 [Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of NOS2 mRNA; [Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of NOS2 protein; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of NOS2 mRNA]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of NOS2 protein]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of NOS2 mRNA]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of NOS2 protein] |
CTD |
PMID:15612528 PMID:17218764 PMID:17637181 PMID:18779489 PMID:19391111 PMID:19466570 PMID:19494560 PMID:20179380 PMID:23463385 PMID:23692848 PMID:27020608 More...
|
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions increases phosphorylation increases activity |
ISO EXP |
[Isosorbide Dinitrate co-treated with Ascorbic Acid] affects the expression of NOS3 mRNA Ascorbic Acid results in increased phosphorylation of NOS3 protein [Vitamin E co-treated with Ascorbic Acid] inhibits the reaction [Dexamethasone results in decreased expression of NOS3 protein]; Ascorbic Acid inhibits the reaction [Formaldehyde results in decreased expression of NOS3 mRNA]; Ascorbic Acid inhibits the reaction [lead acetate results in increased expression of NOS3 protein] Ascorbic Acid results in increased activity of NOS3 protein |
CTD |
PMID:11243424 PMID:11729227 PMID:15719745 PMID:20068362 PMID:21570463 PMID:27020608 More...
|
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Nox1 |
NADPH oxidase 1 |
increases expression |
ISO |
Ascorbic Acid results in increased expression of NOX1 protein |
CTD |
PMID:21570463 |
|
NCBI chr X:97,279,058...97,332,291
Ensembl chr X:97,279,056...97,302,236
|
|
G |
Nox4 |
NADPH oxidase 4 |
increases expression multiple interactions |
ISO |
Ascorbic Acid results in increased expression of NOX4 mRNA; Ascorbic Acid results in increased expression of NOX4 protein Ascorbic Acid inhibits the reaction [Hydrogen Peroxide results in increased expression of NOX4 mRNA]; Ascorbic Acid inhibits the reaction [Hydrogen Peroxide results in increased expression of NOX4 protein] |
CTD |
PMID:21570463 PMID:25305479 |
|
NCBI chr 1:140,900,886...141,078,844
Ensembl chr 1:140,901,097...141,077,406
|
|
G |
Npm1 |
nucleophosmin 1 |
increases expression |
ISO |
Ascorbic Acid results in increased expression of NPM1 mRNA |
CTD |
PMID:22139585 |
|
NCBI chr10:17,741,512...17,751,626
Ensembl chr10:17,739,941...17,751,645
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions increases expression |
ISO EXP |
Ascorbic Acid inhibits the reaction [Diquat results in decreased expression of NQO1 protein]; Ascorbic Acid promotes the reaction [sodium arsenite results in increased expression of NQO1 mRNA] [Ascorbic Acid co-treated with Vitamin E] inhibits the reaction [Diethylhexyl Phthalate results in increased expression of NQO1 protein]; Ascorbic Acid promotes the reaction [Cadmium results in increased expression of NQO1 protein] Ascorbic Acid results in increased expression of NQO1 protein [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of NQO1 mRNA; Ascorbic Acid inhibits the reaction [[lead acetate results in increased abundance of Lead] which results in decreased expression of NQO1 mRNA]; Ascorbic Acid inhibits the reaction [[Vehicle Emissions results in increased abundance of Particulate Matter] which results in increased expression of NQO1 mRNA]; Ascorbic Acid inhibits the reaction [Estradiol results in decreased expression of NQO1 mRNA]; Ascorbic Acid inhibits the reaction [Estradiol results in decreased expression of NQO1 protein] |
CTD |
PMID:16517059 PMID:22008531 PMID:25130429 PMID:29663635 PMID:31610155 PMID:32525552 PMID:33475796 PMID:34480604 More...
|
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of NR1H3 mRNA; bexarotene promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of NR1H3 mRNA]; rosiglitazone promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of NR1H3 mRNA]; tributyltin promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of NR1H3 mRNA] |
CTD |
PMID:25932594 |
|
NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722
|
|
G |
Nr2f1 |
nuclear receptor subfamily 2, group F, member 1 |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of NR2F1 mRNA |
CTD |
PMID:34480604 |
|
NCBI chr 2:8,040,375...8,050,123
Ensembl chr 2:8,040,377...8,050,123
|
|
G |
Nr2f2 |
nuclear receptor subfamily 2, group F, member 2 |
multiple interactions |
ISO |
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of NR2F2 mRNA |
CTD |
PMID:34480604 |
|
NCBI chr 1:124,008,282...124,022,521
Ensembl chr 1:124,009,181...124,022,031
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
multiple interactions |
ISO |
[Tretinoin co-treated with Ascorbic Acid] results in increased expression of NR3C1 mRNA |
CTD |
PMID:16443354 |
|
NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375
|
|
G |
Nr4a2 |
nuclear receptor subfamily 4, group A, member 2 |
increases expression multiple interactions |
EXP |
Ascorbic Acid results in increased expression of NR4A2 protein [Ascorbic Acid co-treated with Vitamin E] results in increased expression of NR4A2 protein |
CTD |
PMID:18772553 |
|
NCBI chr 3:41,689,847...41,707,036
Ensembl chr 3:41,689,851...41,697,877
|
|
G |
Nr4a3 |
nuclear receptor subfamily 4, group A, member 3 |
multiple interactions |
ISO |
[Tretinoin co-treated with Ascorbic Acid] results in increased expression of NR4A3 mRNA |
CTD |
PMID:16443354 |
|
NCBI chr 5:62,361,588...62,401,489
Ensembl chr 5:62,361,822...62,402,733
|
|
G |
Nr5a1 |
nuclear receptor subfamily 5, group A, member 1 |
multiple interactions |
EXP |
Ascorbic Acid inhibits the reaction [chromium hexavalent ion results in decreased expression of NR5A1 mRNA] |
CTD |
PMID:18602937 |
|
NCBI chr  |